[{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Pimicotinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0.60999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Abbisko Therapeutics \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Thrive Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.59999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Isomorphic Labs \/ Thrive Capital","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Thrive Capital"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"KER-065","moa":"Myostatin\/Activin A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||HER-2","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"OST31-154","moa":"HER-2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Endoglin","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"AdjuTec Pharma","sponsor":"Venus Remedies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"APC-148","moa":"||MBL","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AdjuTec Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AdjuTec Pharma \/ Venus Remedies","highestDevelopmentStatusID":"4","companyTruncated":"AdjuTec Pharma \/ Venus Remedies"},{"orgOrder":0,"company":"PinCell","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"PC111","moa":"FasL","graph1":"Immunology","graph2":"Preclinical","graph3":"PinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PinCell \/ Scinai Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PinCell \/ Scinai Immunotherapeutics"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Yosemite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Yosemite Capital","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Yosemite Capital"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Deerfield Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Deerfield Management Company"},{"orgOrder":0,"company":"Yoda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"YA-101","moa":"GluN1\/NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Yoda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Yoda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yoda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ICP-248","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177Lu-vipivotide Tetraxetan","moa":"||PSMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Fitusiran","moa":"AT mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Jerome Stevens Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Acquisition","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Azurity Pharma \/ Jerome Stevens Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Jerome Stevens Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2025","type":"Licensing Agreement","leadProduct":"Mecasermin","moa":"IGF-1R","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eton Pharmaceuticals \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG302","moa":"Synapses","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MC4R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"NeuroNOS","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Nitric oxide","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroNOS","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroNOS \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NeuroNOS \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"LaunXP Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vebreltinib","moa":"||c-MET","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Apollomics Inc \/ LaunXP Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics Inc \/ LaunXP Biomedical"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Becaplermin","moa":"PDGFR","graph1":"Podiatry","graph2":"Approved FDF","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Aqemia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Aqemia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Tazarotene","moa":"RAR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Steroid","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Vectura Ltd"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Sydnexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sydnexis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha\/gamma\/delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin A receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Organon"},{"orgOrder":0,"company":"Airna","sponsor":"Venrock Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"AIR-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Airna","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Airna \/ Venrock Healthcare Capital","highestDevelopmentStatusID":"4","companyTruncated":"Airna \/ Venrock Healthcare Capital"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Tr1X Bio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Sibeprenlimab","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"ARV-102","moa":"LRRK2","graph1":"Neurology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Renascience Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Phenazon","moa":"||COX-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Renascience Pharma","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Otic Solution","sponsorNew":"Renascience Pharma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Renascience Pharma \/ Lupin Ltd"},{"orgOrder":0,"company":"RayThera","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"RayThera","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"RayThera \/ Foresite Capital","highestDevelopmentStatusID":"4","companyTruncated":"RayThera \/ Foresite Capital"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ociperlimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Skyepharma","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"Skyepharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Skyepharma \/ MaaT Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Skyepharma \/ MaaT Pharma"},{"orgOrder":0,"company":"Trace Neuroscience","sponsor":"Unlearn","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"UNC13A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Trace Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trace Neuroscience \/ Unlearn","highestDevelopmentStatusID":"5","companyTruncated":"Trace Neuroscience \/ Unlearn"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Marubeni Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Antibiotic","year":"2025","type":"Acquisition","leadProduct":"Meropenem","moa":"PBP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.29999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma \/ Marubeni Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Marubeni Corporation"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Tazarotene","moa":"RAR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Allakos","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allakos \/ Concentra Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Concentra Biosciences"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Bain Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Bain Capital","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Bain Capital"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.56999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Multiomic Health","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery","graph3":"Multiomic Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multiomic Health \/ Alloy Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Multiomic Health \/ Alloy Therapeutics"},{"orgOrder":0,"company":"ABL Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"ABL Bio","amount2":2.73,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":2.73,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"ABL Bio \/ GSK"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Navepegritide","moa":"FGFR 3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2a\/5-HT2c\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor\/microtubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"APR-1051","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BCDA-02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine\/Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||RAS-PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vividion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"7MW3711","moa":"||B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"SIGMAR1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Navigo Proteins","sponsor":"SCK CEN","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Navigo Proteins","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navigo Proteins \/ SCK CEN","highestDevelopmentStatusID":"4","companyTruncated":"Navigo Proteins \/ SCK CEN"},{"orgOrder":0,"company":"Savara","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2025","type":"Financing","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Savara \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Hercules Capital"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Tetrodotoxin","moa":"Sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Maxim Group"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Large Molecule","year":"2025","type":"Financing","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0.31,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0.31,"dosageForm":"Topical Patch","sponsorNew":"DBV Technologies \/ MPM BioImpact","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ MPM BioImpact"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Private Placement","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Subdermal Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Golimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor\/microtubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ALY-101","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Alys Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alys Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GLP1\/GIP\/GCG receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GLP1\/GIP\/GCG receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"Neltependocel","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Alcon inc","highestDevelopmentStatusID":"8","companyTruncated":"Aurion Biotech \/ Alcon inc"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"LX9851","moa":"ACSL5","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexicon pharmaceuticals","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lexicon pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131 Group","sponsor":"CURIUM US LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Radiolabelled Compounds","year":"2025","type":"Acquisition","leadProduct":"Lu-177 PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Eczac\u0131ba\u015f\u0131 Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC","highestDevelopmentStatusID":"10","companyTruncated":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SPY003","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CRB-913","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4\/13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||HER-2\/NEU receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BNT327","moa":"||PD-L1\/VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Yale University"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ WallachBeth Capital","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ WallachBeth Capital"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ WallachBeth Capital","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ WallachBeth Capital"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Acuta Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Avoro Capital","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Avoro Capital"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Eoc Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Eoc Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Eoc Pharma"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Foundation Medicine"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pennsylvania University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Pennsylvania University","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Pennsylvania University"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Pancrelipase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Series C Financing","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ RA Capital Management"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Famar","sponsor":"Medicom Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"HPAPI","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Famar \/ Medicom Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Famar \/ Medicom Healthcare"},{"orgOrder":0,"company":"Medicom Healthcare","sponsor":"Famar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Medicom Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Medicom Healthcare \/ Famar","highestDevelopmentStatusID":"15","companyTruncated":"Medicom Healthcare \/ Famar"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Series A Financing","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Gho Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Divestment","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Gho Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Gho Capital"},{"orgOrder":0,"company":"Nicox SA","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Private Placement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ HBM Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ HBM Healthcare Investments"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Private Placement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Kreos Capital"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Private Placement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aequus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aequus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aequus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Laboratoires Thea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoires Thea \/ Inapplicable"},{"orgOrder":0,"company":"Viwit Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Viwit Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Viwit Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viwit Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"OMERS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Glecaprevir","moa":"||HCV NS5A\/HCV NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enanta Pharmaceuticals \/ OMERS Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Enanta Pharmaceuticals \/ OMERS Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Mr. Doug Janzen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2023","type":"Financing","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aequus Pharmaceuticals \/ Mr. Doug Janzen","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Mr. Doug Janzen"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"D-Ala-D-Ala moiety of NAM\/NAG peptide subunits of peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"PDL BioPharma","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PDL BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDL BioPharma \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"PDL BioPharma \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0.14999999999999999,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accord BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Accord BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Relief Therapeutics \/ Acer Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Zevra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Acer Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Christopher Schelling","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Christopher Schelling","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Christopher Schelling"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Zevra Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Zevra Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Marathon Asset Management"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Aytu BioPharma \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Amneal Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Serenity LLC","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Serenity LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Serenity LLC \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serenity LLC \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Serenity Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Serenity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Serenity Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serenity Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acrotech Biopharma \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Xi'an Guokang Ruijin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Agreement","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Undisclosed \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Adalvo"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Termination","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ US WorldMeds"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Deerfield Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Deerfield Partners","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Deerfield Partners"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Sterling Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Sterling Pharma Solutions"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Owl Rock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Owl Rock","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Owl Rock"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"Overland ADCT BioPharma","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Overland ADCT BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Overland ADCT BioPharma \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Overland ADCT BioPharma \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SST2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SST2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SST2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SST2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SST2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"AGEPHA Pharma US","sponsor":"Caristo Diagnostics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Collaboration","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AGEPHA Pharma US","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AGEPHA Pharma US \/ Caristo Diagnostics","highestDevelopmentStatusID":"15","companyTruncated":"AGEPHA Pharma US \/ Caristo Diagnostics"},{"orgOrder":0,"company":"AGEPHA Pharma US","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AGEPHA Pharma US","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AGEPHA Pharma US \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AGEPHA Pharma US \/ Inapplicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Acquisition","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Insud Pharma"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Merger","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Insud Pharma"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Public Offering","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"vitaCare Prescription Services","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ vitaCare Prescription Services","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ vitaCare Prescription Services"},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"Agile Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Afaxys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Afaxys Pharma \/ Agile Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Afaxys Pharma \/ Agile Therapeutics"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Hematology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Hematology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centogene \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centogene \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Private Placement","leadProduct":"AKTX-101","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Akari Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Akebia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"US Renal Care","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akebia Therapeutics \/ US Renal Care","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ US Renal Care"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Hermann-Texas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Hermann-Texas Medical Center","highestDevelopmentStatusID":"5","companyTruncated":"Akebia Therapeutics \/ Hermann-Texas Medical Center"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Medice Arzneimittel P\u00fctter GmbH&Co.KG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"US Renal Care","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ US Renal Care","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ US Renal Care"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Erkim","sponsor":"MEDICE Health Family","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Erkim \/ MEDICE Health Family","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ MEDICE Health Family"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AK138D1","moa":"HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Tropical Infectious Diseases Research and Education Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tropical Infectious Diseases Research and Education Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Tropical Infectious Diseases Research and Education Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tropical Infectious Diseases Research and Education Center \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Alcon Inc"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Oxford Finance"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Netarsudil","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Netarsudil","moa":"ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Netarsudil","moa":"ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Aerie Pharmaceuticals","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aerie Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerie Pharmaceuticals \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Aerie Pharmaceuticals \/ Alcon Inc"},{"orgOrder":0,"company":"Aerie Pharmaceuticals","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aerie Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerie Pharmaceuticals \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Aerie Pharmaceuticals \/ Alcon Inc"},{"orgOrder":0,"company":"Aerie Pharmaceuticals","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aerie Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerie Pharmaceuticals \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Aerie Pharmaceuticals \/ Alcon Inc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Brinzolamide","moa":"||CA2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alcon Inc"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OMERS Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Antibody","year":"2023","type":"Divestment","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"OMERS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OMERS Life Sciences \/ Xencor","highestDevelopmentStatusID":"15","companyTruncated":"OMERS Life Sciences \/ Xencor"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"SIFI","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ SIFI","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ SIFI"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Horus Pharma \/ Alimera Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Horus Pharma \/ Alimera Sciences"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2025","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"ANI Pharmaceuticals Inc \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Divestment","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Alimera Sciences","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Alimera Sciences"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Otonomy","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Otonomy \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"Otonomy \/ ALK"},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Otonomy"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allecra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allecra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allecra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allecra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acino Pharma","sponsor":"Allecra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Cefepime","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Acino Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acino Pharma \/ Allecra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acino Pharma \/ Allecra Therapeutics"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Advanz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Cefepime","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orchid Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchid Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Orchid Pharma \/ Cipla"},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orchid Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchid Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchid Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zyla Life Sciences","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Gabapentin","moa":"CaV channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zyla Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zyla Life Sciences \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Zyla Life Sciences \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Almirall"},{"orgOrder":0,"company":"Athenex","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ PharmaEssentia"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Partnership","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Gen Pharmaceuticals and Health Products","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Gen Pharmaceuticals and Health Products","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Gen Pharmaceuticals and Health Products"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Taiba Healthcare"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin III","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin III","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Dicerna Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PANTHERx Rare Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Expanded Collaboration","leadProduct":"Givosiran Sodium","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ The Benchmark Company","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ The Benchmark Company"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Titan Partners Group LLC","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ DKSH"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Cipla","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Cipla"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Alvotech","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Private Placement","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HLS Therapeutics \/ Amarin","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therapeutics \/ Amarin"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Edding Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Edding Pharm"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"MedStar Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ MedStar Health Research Institute","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ MedStar Health Research Institute"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edding Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Edding Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Edding Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Edding Pharm"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edding Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Edding Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ HLS Therapeutics"},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaiser Permanente Washington Health Research \/ Amarin","highestDevelopmentStatusID":"11","companyTruncated":"Kaiser Permanente Washington Health Research \/ Amarin"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ American Regent"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChemoCentryx","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ChemoCentryx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChemoCentryx \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"ChemoCentryx \/ Amgen Inc"},{"orgOrder":0,"company":"ChemoCentryx","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ChemoCentryx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChemoCentryx \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"ChemoCentryx \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"CSL","sponsor":"ChemoCentryx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ ChemoCentryx","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ ChemoCentryx"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"4P Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sorrento Therapeutics \/ 4P Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ 4P Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BeiGene \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carmot Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Carmot Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NYU Grossman School of Medicine \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"NYU Grossman School of Medicine \/ Amgen Inc"},{"orgOrder":0,"company":"Labcorp","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Labcorp \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Amgen Inc"},{"orgOrder":0,"company":"Qiagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qiagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Qiagen \/ Inapplicable"},{"orgOrder":0,"company":"Qiagen","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qiagen \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Qiagen \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Panitumumab","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"||PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Global Coalition for Adaptive Research \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Amgen Inc"},{"orgOrder":0,"company":"Vifor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Vifor Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vifor Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vifor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Denosumab","moa":"RANK","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BeiGene \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Erenumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Erenumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Erenumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Amgen Inc"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"ARYA Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ ARYA Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ ARYA Sciences"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Amicus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Amicus Therapeutics"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Mabxience","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Zentiva"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bial","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bial \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bial \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Recipharm AB \/ Bial","highestDevelopmentStatusID":"15","companyTruncated":"Recipharm AB \/ Bial"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Private Placement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Amring Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pierre Fabre \/ Amring Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Amring Pharma"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Amring Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Amring Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Amring Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Anastrozole","moa":"Aromatase","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AstraZeneca \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Juvise Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"OrphanDC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pint Pharma \/ OrphanDC","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ OrphanDC"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Hydroxylapatite","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"EA Pharma \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"EA Pharma \/ Eisai"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Riluzole","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"MARATHON PHARMS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ MARATHON PHARMS","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ MARATHON PHARMS"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"ATNAHS PHARMA UK LIMITED","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ ATNAHS PHARMA UK LIMITED","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ ATNAHS PHARMA UK LIMITED"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Montreal Heart Institute \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","highestDevelopmentStatusID":"15","companyTruncated":"Montreal Heart Institute \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"PK MED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"||Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"PK MED","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intra-articular Injection, Prolonged Release","sponsorNew":"PK MED \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PK MED \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Funding","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Immunology","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ SLR Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ SLR Capital Partners"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ SLR Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ SLR Capital Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Ardelyx","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"||NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kyowa Kirin \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Medison Pharma"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Argenx"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elektrofi \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Elektrofi \/ Argenx"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Argenx"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Neurology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Financing","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Teijin Pharma"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.A.E","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vector Pharma \/ Ascendis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ Ascendis Pharma"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Specialised Therapeutics \/ Ascendis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Ascendis Pharma"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Conjugated Estrogens","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Pharmacare Holdings \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Avion Pharmaceuticals"},{"orgOrder":0,"company":"Asahi Kasei Finechem","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Finechem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asahi Kasei Finechem \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Finechem \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Knight Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Micafungin","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Kotobuki Pharmaceutical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Kotobuki Pharmaceutical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"IVERIC bio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ IVERIC bio","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ IVERIC bio"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Financing","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Hercules Capital"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Astellas Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Avir Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Avir Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Avir Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Blood and Marrow Transplant Clinical Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Blood and Marrow Transplant Clinical Trials Network","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Blood and Marrow Transplant Clinical Trials Network"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"Avacincaptad Pegol","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ DelSiTech","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ DelSiTech"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MANA RBM","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"MANA RBM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MANA RBM \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MANA RBM \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Mankind Pharma"},{"orgOrder":0,"company":"Honeywell","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Partnership","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Honeywell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"Honeywell \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Honeywell \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Foundation Medicine"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"IDMC","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"IDMC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IDMC \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"IDMC \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Guardant Health","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Guardant Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Guardant Health \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Guardant Health \/ Blueprint Medicines"},{"orgOrder":0,"company":"Biocartis","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biocartis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biocartis \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Biocartis \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Hutchmed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"||IL-5-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"||IL-5-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Saint Luke's Health System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Saint Luke's Health System","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Saint Luke's Health System"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Grunenthal"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Grunenthal"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Acerta Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Acerta Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Chugai Pharmaceutical \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"NIHR","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ NIHR","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ NIHR"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Alvogen"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cap Alter Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cap Alter Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cap Alter Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ DCH Auriga","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ DCH Auriga"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distribution Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distribution Solutions"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distriphil","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distriphil"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ ICI Pakistan Limited","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ ICI Pakistan Limited"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Zuellig Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Sabal Therapeutics","sponsor":"Athena Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Clonidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sabal Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Sabal Therapeutics \/ Athena Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Sabal Therapeutics \/ Athena Bioscience"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Athena Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Aucta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ RTW Investments"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGF1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGF1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Hercules Capital"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Hercules Capital"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Hercules Capital"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ LG Chem","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ LG Chem"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Eusa Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Eusa Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Eusa Pharma"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tivozanib","moa":"||VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGF1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGF1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2025","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Grunenthal \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Grunenthal \/ Apotex Inc"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Grunenthal"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carmustine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carmustine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Divestment","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Zolpidem Tartrate","moa":"GABAA-alpha-1\/beta-1\/gamma-2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Aytu BioScience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Aytu BioScience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine Methylsulfate","moa":"||Cholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Arbor Pharmaceuticals \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Arbor Pharmaceuticals \/ Azurity Pharma"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Brand Institute \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Azurity Pharma"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Verapamil Hydrochloride","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Societal CDMO \/ Lannett Company, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ Lannett Company, Inc."},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hasten Biopharmaceutic \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ CBC Group"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Mannkind","sponsor":"Vertice Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"THR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mannkind \/ Vertice Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Vertice Pharma"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Banner Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Banner Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Banner Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Banner Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Banner Life Sciences \/ Cycle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Banner Life Sciences \/ Cycle Pharmaceuticals"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Shenzhen China Resources Gosun Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Shenzhen China Resources Gosun Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Shenzhen China Resources Gosun Pharmaceuticals"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Nordic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Nordic Capital","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Nordic Capital"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Innoviva Specialty Therapeutics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Innoviva Specialty Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva Specialty Therapeutics \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Innoviva Specialty Therapeutics \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Premier","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Premier \/ Baudax Bio","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Baudax Bio"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ JMP Securities","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ JMP Securities"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ JMP Securities"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Vizient"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazarotene","moa":"RAR-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Boston University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boston University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boston University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boston University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Kedalion Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kedalion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kedalion Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Kedalion Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Financing","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Soleus Capital","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Soleus Capital"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"ACh receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Arctic Vision","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Arctic Vision"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Clearside Biomedical"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch Health \/ Clearside Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Clearside Biomedical"},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Solaris Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Solaris Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Solaris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"CYP450-3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Ingenus Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"CYP450-3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ingenus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ingenus Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Ingenus Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"CYP450-3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Ifosfamide","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NanoAlvand \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Inapplicable"},{"orgOrder":0,"company":"NMDP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CYP450-3A4","graph1":"Oncology","graph2":"Phase II","graph3":"NMDP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NMDP \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMDP \/ Inapplicable"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"CYP450-3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NanoAlvand \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sorafenib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sorafenib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Nifurtimox","moa":"Nitroreductases","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Neurology","graph2":"Preclinical","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"4","companyTruncated":"Partner Therapeutics \/ University of Colorado"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Larotrectinib","moa":"Neurotrophic TYK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"TYK","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Coalition for Adaptive Research \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Coalition for Adaptive Research \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CPC Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ CPC Clinical Research","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ CPC Clinical Research"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Collaboration","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Thermo Fisher Scientific \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Larotrectinib","moa":"Neurotrophic TYK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3K p110-alpha-subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3K p110-alpha-subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3K p110-alpha-subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Larotrectinib","moa":"Neurotrophic TYK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"IQWiG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"IQWiG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IQWiG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IQWiG \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Bayer AG"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Agreement","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Agreement","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"American Association of Kidney Patients","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ American Association of Kidney Patients","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ American Association of Kidney Patients"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Partner Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ BARDA"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Mirati Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Mirati Therapeutics"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glenmark Pharmaceuticals \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ BeiGene"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"The Max Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ The Max Foundation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ The Max Foundation"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunityBio \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ BeiGene"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Medison Pharma"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Benuvia","sponsor":"Avernus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Benuvia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Benuvia \/ Avernus Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Benuvia \/ Avernus Pharma"},{"orgOrder":0,"company":"Benuvia","sponsor":"Medra Brasil Medicamentos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Benuvia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benuvia \/ Medra Brasil Medicamentos","highestDevelopmentStatusID":"15","companyTruncated":"Benuvia \/ Medra Brasil Medicamentos"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"VA CSRD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benuvia Therapeutics \/ VA CSRD","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ VA CSRD"},{"orgOrder":0,"company":"Biocodex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biocodex \/ Inapplicable"},{"orgOrder":0,"company":"Biocodex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biocodex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ Inapplicable"},{"orgOrder":0,"company":"Biocodex","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Stiripentol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biocodex \/ PANTHERx Rare Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ PANTHERx Rare Pharmacy"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Erkim","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"TURKEY","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erkim \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Pint Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Pint Pharma"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Swixx BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Swixx BioPharma"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCryst Pharmaceuticals \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCryst Pharmaceuticals \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCryst Pharmaceuticals \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ US Government"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Alvogen"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Endo Pharm"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioDelivery Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Wellcome Trust","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Wellcome Trust"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurimmune \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurimmune \/ Inapplicable"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurimmune \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Neurimmune \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta-aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin-alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin-alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin-alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Diroximel fumarate","moa":"nACh-alpha-10 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Beta-1A","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Alcyone Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Alcyone Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children\u2019s Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"CXCR-4 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ St. Jude Children\u2019s Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children\u2019s Research Hospital"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"},{"orgOrder":0,"company":"BioLineRx","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Highbridge Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Highbridge Capital Management"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Ayrmid","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Ayrmid","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Ayrmid"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Blackrock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Blackrock","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Blackrock"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Gloria Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Gloria Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Gloria Biosciences"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Divestment","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioXcel Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Oaktree Capital"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Bluebird Bio","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Bluebird Bio"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Blueprint Medicines"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Royalty Pharma"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Blueprint Medicines"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Blueprint Medicines"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Sixth Street","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Sixth Street"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Blueprint Medicines"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFA receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Optime Care","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Optime Care","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optime Care \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Optime Care \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint Medicines \/ Genentech"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Ecog-Acrin Cancer Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"ErbB4","graph1":"Oncology","graph2":"Phase II","graph3":"Ecog-Acrin Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ecog-Acrin Cancer Research Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ecog-Acrin Cancer Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Quallent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"||ErbB4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGF receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGF receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Duke Clinical Research Institute \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clinical Research Institute \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"||M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Icahn School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGF receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Braeburn","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Braeburn","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Braeburn"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Altruix"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Qiagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Qiagen","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Qiagen"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"PicnicHealth","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PicnicHealth","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PicnicHealth \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"PicnicHealth \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ MyoKardia","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ MyoKardia"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ MyoKardia","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ MyoKardia"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"New York Heart Association","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ New York Heart Association","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ New York Heart Association"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zai Lab \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celgene Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Turning Point Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Turning Point Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Abatacept","moa":"||GMP-AMP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Cambridge Biomedical Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cambridge Biomedical Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cambridge Biomedical Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cambridge Biomedical Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"||GMP-AMP synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||IDH","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||IDH","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Romidepsin","moa":"HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Melanoma Research Alliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Melanoma Research Alliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melanoma Research Alliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Melanoma Research Alliance \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fedratinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fedratinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Personalis","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Personalis \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Personalis \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAHO Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Orally Dissolving Thin Film","sponsorNew":"TAHO Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Orally Dissolving Thin Film","sponsorNew":"TAHO Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Aztreonam","moa":"Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Advanz Pharma"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Neurology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"15","companyTruncated":"BTG Specialty Pharmaceuticals \/ Serb"},{"orgOrder":0,"company":"Eicos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Eicos Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eicos Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eicos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Tsukuba Research Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Tsukuba Research Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Tsukuba Research Laboratories"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Dydo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Dydo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Dydo Pharma"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Dydo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Dydo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Dydo Pharma"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Dydo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Dydo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Dydo Pharma"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"KYE Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KYE Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"KYE Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"KYE Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KYE Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KYE Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Sperogenix Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sperogenix Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ASTE","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ASTE","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ASTE"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"GENESIS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ GENESIS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ GENESIS Pharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Financing","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Private Placement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Financing","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Suspension","sponsorNew":"Idorsia Pharmaceuticals \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Clinigen Group"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Hematology","graph2":"Approved FDF","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celltrion \/ Rani Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion \/ Rani Therapeutics"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ GSK"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MorphoSys \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Royalty Pharma"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Janssen Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Janssen Biotech"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Amivantamab","moa":"EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"||FGFR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"||FGFR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"||IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"||IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"||TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ AbbVie Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Janssen-Cilag \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Centocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centocor \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ GSK"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OmniAb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"OmniAb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OmniAb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"OmniAb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Genmab","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ GSK"},{"orgOrder":0,"company":"Genmab","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Janssen Biotech"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"European Hematology Association","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Phase III","graph3":"European Hematology Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"European Hematology Association \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"European Hematology Association \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Genmab"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"European Myeloma Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ European Myeloma Network","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ European Myeloma Network"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Veracyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veracyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veracyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veracyte \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Aragon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"University of South Australia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","graph1":"Oncology","graph2":"Preclinical","graph3":"University of South Australia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of South Australia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of South Australia \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Financing","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Phebra","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Phebra"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Medsenic"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Gestys Sant\u00e9 Biotech","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Gestys Sant\u00e9 Biotech"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"},{"orgOrder":0,"company":"Orsenix","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Orsenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orsenix \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Orsenix \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Australasian Leukaemia And Lymphoma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Australasian Leukaemia And Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Neurology","graph2":"Preclinical","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Chlordiazepoxide","moa":"||Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica"},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Fexofenadine Hydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adelia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adelia Therapeutics \/ Cybin","highestDevelopmentStatusID":"15","companyTruncated":"Adelia Therapeutics \/ Cybin"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Velmanase Alpha","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Psagot Investment House","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Financing","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Psagot Investment House","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Psagot Investment House"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Amryt Pharma"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Jefferies"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zileuton","moa":"||5-LOX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novateur Ventures \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novateur Ventures \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Chiesi Group"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Chiesi Group"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Episalvan","moa":"Keratinocyte","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Medison Pharma"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cangrelor","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CHIESI USA INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CHIESI USA INC \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"IL-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Divestment","leadProduct":"Aldesleukin","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Aldesleukin","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Ajinomoto Company","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Ajinomoto Company"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Eisai"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Eisai"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Funding","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ New Jersey Economic Development Authority"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"TenX Keane Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Oncology \/ TenX Keane Acquisition","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ TenX Keane Acquisition"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Dexrazoxane","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ CNX Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ CNX Therapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexrazoxane","moa":"Topoisomerase II","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"MC1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"MC1 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"MC1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"MC1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"MC1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Cav1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Leo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Leo Pharma"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Hong Kong King-Friend Industrial Co. Ltd","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Divestment","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Superior Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Superior Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Superior Biologics \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Superior Biologics \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Divestment","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Coherus Biosciences \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Junshi Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"TopAlliance Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"TopAlliance Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"KemPharm \/ Corium","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Corium"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"CorMedix","sponsor":"ARC Dialysis, LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ ARC Dialysis, LLC","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ ARC Dialysis, LLC"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Suntrust Robinson Humphrey","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Suntrust Robinson Humphrey","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Suntrust Robinson Humphrey"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Taurolidine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ New Jersey Economic Development Authority"},{"orgOrder":0,"company":"Undisclosed","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ CorMedix"},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ RBC Capital Markets"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Amlodipine","moa":"||L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Cosette Pharma"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Prasugrel Hydrochloride","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Prasugrel Hydrochloride","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Covis Pharma"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Covis Pharma"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Patiromer Sorbitex Calcium","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"CSL \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"WraSer Pharmaceuticals","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Levoamlodipine","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"WraSer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"WraSer Pharmaceuticals \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"WraSer Pharmaceuticals \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Tedizolid","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nabriva Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tedizolid","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nabriva Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Daptomycin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Granisetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kyowa Kirin \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Granisetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ibuprofen","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Currax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Currax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Currax \/ Inapplicable"},{"orgOrder":0,"company":"Currax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Currax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"HPDD","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roche Diagnostics GmbH \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Roche Diagnostics GmbH \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Alteogen","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alteogen \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"Alteogen \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Natera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Natera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GREECE","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GENESIS Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GENESIS Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medison Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hepatic Injection","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Series E Financing","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Zyla Life Sciences","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Diclofenac Potassium","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zyla Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zyla Life Sciences \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Zyla Life Sciences \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Organon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Inapplicable"},{"orgOrder":0,"company":"Organon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Innovaderm","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Innovaderm"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Marathon Asset Management"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Cenegermin","moa":"TRKA receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"FarmaMondo \/ Dompe Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"FarmaMondo \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Cenegermin","moa":"TRKA receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tanner Pharma \/ Dompe Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eton Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Pennsylvania \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"University of Pennsylvania \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"||TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"SymBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Eagle Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"VFMCRP","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ VFMCRP","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ VFMCRP"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Termination","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Vifor Pharma"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"C2N Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ C2N Diagnostics","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ C2N Diagnostics"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"CareMed","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"CareMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareMed \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"CareMed \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eribulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Agilent Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Agilent Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Agilent Technologies"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"VEGF2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Financing","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Pharmakon Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Pharmakon Advisors"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"||TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Shilpa Medicare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Shilpa Medicare","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Shilpa Medicare"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ErbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Pfizer Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ErbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Pfizer Inc"},{"orgOrder":0,"company":"Flatiron Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab","moa":"ErbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Flatiron Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flatiron Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Flatiron Health \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lupin Ltd"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ National Institutes of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ National Institutes of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eli Lilly"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Eli Lilly"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"EGYPT","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Dexcom","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Dexcom","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dexcom \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Dexcom \/ Eli Lilly"},{"orgOrder":0,"company":"Cipla","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cipla \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Hims","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hims","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hims \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hims \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Zuellig Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Erythromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"||TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ildong Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Ildong Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ AffaMed Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ AffaMed Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Organon"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Organon \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Eli Lilly"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Focal Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focal Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Focal Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Focal Medical \/ Inapplicable"},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Funding","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced Chemotherapy Technologies \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Chemotherapy Technologies \/ National Institutes of Health"},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced Chemotherapy Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Chemotherapy Technologies \/ Khosla Ventures"},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series A Financing","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced Chemotherapy Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Chemotherapy Technologies \/ Khosla Ventures"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Columbia University"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Paulson Investment Company"},{"orgOrder":0,"company":"RenovoRx","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Titan Partners Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intra-articular Injection","sponsorNew":"RenovoRx \/ Titan Partners Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Sonire therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Sonire therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonire therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonire therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Ramucirumab","moa":"VEGF2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Innovent Biologics"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Merck Group","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Merck Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck Group","sponsor":"4D Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ 4D Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ 4D Pharma"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Merck & Co"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Pfizer Inc"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Pfizer Inc"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ EMD Serono","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ EMD Serono"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Queen Mary University of London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ Inapplicable"},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prime Therapeutics \/ EMD Serono","highestDevelopmentStatusID":"15","companyTruncated":"Prime Therapeutics \/ EMD Serono"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chord Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Merck Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Asembia","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Asembia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Asembia \/ Emmaus Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Asembia \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2025","type":"Merger","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Endo International \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"BioSpecifics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"BioSpecifics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"BioSpecifics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"BioSpecifics \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Pharmakon Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Pharmakon Advisors"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Epizyme","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Epizyme"},{"orgOrder":0,"company":"Eisai","sponsor":"National Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ National Cancer Center","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ National Cancer Center"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Jefferies"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tolmar","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tolmar \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ EffRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ EffRx Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Evive Biotech","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo Pharma Limited \/ Evive Biotech"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Adjuvant Capital"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Aditxt","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Aditxt"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Keystone Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Keystone Capital Partners"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Piper Sandler"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Piper Sandler"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Windtree Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Exeltis \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Divestment","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Evofem Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Evofem Biosciences"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Ceek Womens Health","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ceek Womens Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Ceek Womens Health \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Ceek Womens Health \/ Lupin Ltd"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Eversana"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Eversana"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Leerink Partners"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"Cholinesterase","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Pharma Sciences, LLC.","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Exela Pharma Sciences, LLC."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Licensing Agreement","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Exelixis","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ National Institutes of Health"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2021","type":"Divestment","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Royalty Pharma"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Merck & Co"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Chardan Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Chardan Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Chardan Healthcare"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Journey Medical Corporation \/ Fortress Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Fortress Biotech"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Genentech"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Vemurafenib","moa":"Serine\/threonine-protein kinase BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Kechow Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Entero Healthcare Solutions","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Entero Healthcare Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entero Healthcare Solutions \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Entero Healthcare Solutions \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Ceftriaxone","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Fabre-Kramer Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fabre-Kramer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Fabre-Kramer Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fabre-Kramer Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Menotropins","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Menotropins","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Antares Pharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Antares Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Antares Pharma"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Oxiconazole Nitrate","moa":"Ergosterol biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Sandoz B2B \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Premier"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius SE & Co. KGaA \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Formycon"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Carrick Therapeutics \/ Arvinas","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Arvinas"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Beimei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Agreement","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Beimei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Beimei Pharma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"MagnaPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ MagnaPharm","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ MagnaPharm"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"SEARCHLIGHT PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ SEARCHLIGHT PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ SEARCHLIGHT PHARMA"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"||Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd"},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"GALDERMA LABS LP","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"GALDERMA LABS LP \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GALDERMA LABS LP \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Perrigo Company plc \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Galderma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Jefferies"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fortovia Therapeutics","sponsor":"Galt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Miconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fortovia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fortovia Therapeutics \/ Galt Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Fortovia Therapeutics \/ Galt Pharmaceuticals"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"KabaFusion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ KabaFusion","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ KabaFusion"},{"orgOrder":0,"company":"Soleo Health","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ GC Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ GC Biopharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genentech"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Frontier Science Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Frontier Science Foundation","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Frontier Science Foundation"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCLA Jonsson Comprehensive Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Immunicom","sponsor":"Acibadem University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunicom","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunicom \/ Acibadem University","highestDevelopmentStatusID":"15","companyTruncated":"Immunicom \/ Acibadem University"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImaginAb","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImaginAb \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Entrectinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genentech"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genentech"},{"orgOrder":0,"company":"Oncocyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncocyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncocyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncocyte \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"||IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Canadian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Canadian Government","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Canadian Government"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"||IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NaviFUS \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NaviFUS \/ Inapplicable"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NaviFUS \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NaviFUS \/ Inapplicable"},{"orgOrder":0,"company":"iCAD","sponsor":"Xoft Brain","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Phase II","graph3":"iCAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"iCAD \/ Xoft Brain","highestDevelopmentStatusID":"8","companyTruncated":"iCAD \/ Xoft Brain"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute for Health Research","sponsor":"Manchester University NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute for Health Research \/ Manchester University NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"National Institute for Health Research \/ Manchester University NHS Foundation Trust"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||EGFR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||EGFR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Shionogi"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Nippon Shinyaku"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Lenalidomide","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Biogen"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Spinal Muscular Atrophy Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Spinal Muscular Atrophy Foundation","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Spinal Muscular Atrophy Foundation"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azathioprine","moa":"||IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Brigham and Women\u2019s Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brigham and Women\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brigham and Women\u2019s Hospital \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Brigham and Women\u2019s Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Astellas Pharma"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Glofitamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Genentech"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"XOMA \/ Blue Owl Capital","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Blue Owl Capital"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"ZENOAQ","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"ZENOAQ","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZENOAQ \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"ZENOAQ \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Natera","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Natera \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Natera \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Gensco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Gensco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Gensco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gensco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Royalty Pharma"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Public Offering","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Stifel","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Stifel"},{"orgOrder":0,"company":"Geron","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ TD Cowen"},{"orgOrder":0,"company":"Geron","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Geron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Partnership","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Onco360 \/ Geron","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Geron"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imetelstat","moa":"||TERT","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Hercules Capital"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Imetelstat","moa":"TERT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ European Commission"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"The European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ The European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ The European Commission"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ World Health Organization","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ World Health Organization"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"US Army Medical Research And Development Command","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ US Army Medical Research And Development Command","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ US Army Medical Research And Development Command"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Flamma SpA","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Flamma SpA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flamma SpA \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Flamma SpA \/ Gilead Sciences"},{"orgOrder":0,"company":"Almac Group","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Almac Group \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"15","companyTruncated":"Almac Group \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"CHAI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ CHAI","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ CHAI"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Emcure Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Emcure Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Emcure Pharmaceuticals"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Eva Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Eva Pharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Ferozsons Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Ferozsons Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Ferozsons Laboratories"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hetero Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Hetero Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Hetero Biopharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Viatris"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"||PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Seladelpar Lysine","moa":"||PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Gilead Sciences"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Seladelpar Lysine","moa":"PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PANTHERx Rare Pharmacy \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"||PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"||PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PIK3CD","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Celanese","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Celanese","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Celanese"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Celanese","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Celanese","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Celanese \/ Glaukos","highestDevelopmentStatusID":"10","companyTruncated":"Celanese \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biopharma","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UKRAINE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biopharma \/ Global Blood Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biopharma \/ Global Blood Therapeutics"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vilanterol Trifenatate","moa":"||Adrenergic-beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"AnaptysBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ AnaptysBio","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ AnaptysBio"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Divestment","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnaptysBio \/ DRI Healthcare Trust","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Collaboration","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ivy Brain Tumor Center \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Measles, Mumps and Rubella Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ GSK"},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Belantamab Mafodotin","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Tesaro","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AnaptysBio \/ Tesaro","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Tesaro"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ J.P. Morgan"},{"orgOrder":0,"company":"Zai Lab","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Public Offering","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ J.P. Morgan"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Divestment","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Theravance Biopharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ Royalty Pharma"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docosanol","moa":"Viral fusion","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosette Pharma \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Sage Chemical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Sage Chemical","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Sage Chemical"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Harm Reduction Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RareStone Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"RareStone Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Inapplicable"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bioprojet Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioprojet Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Citrine Medicine"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Harrow \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Apotex Inc"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Lupin Ltd \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Nicox SA"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Moxifloxacin Hydrochloride","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nepafenac","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Nepafenac","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Harrow \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Essential Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Essential Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"Adrenergic-alpha receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Essential Pharma"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Harrow \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Undisclosed"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"Adrenergic-alpha receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Essential Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Essential Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"Adrenergic-alpha receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Harrow"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Harrow"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Chugai Pharma Europe","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Netupitant","moa":"||NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"FarmaMondo \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"FarmaMondo \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Esteve Quimica","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Netupitant","moa":"||NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Esteve Quimica","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Esteve Quimica"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ QED Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ QED Therapeutics"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ BridgeBio Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Juniper Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Juniper Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Juniper Biologics"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Immedica Pharma"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Acquisition","leadProduct":"Levalbuterol Hydrochloride","moa":"Adrenergic-beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Lupin Ltd"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NEW ZEALAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AFT Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AFT Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine reducer","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine reducer","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ University of Michigan"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Teprotumumab","moa":"||IGF-1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Horizon Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme Therapeutics \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EirGen Pharma","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EirGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EirGen Pharma \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EirGen Pharma \/ Horizon Therapeutics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AGC Biologics \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vizient \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Vizient \/ Pfizer Inc"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum Leap Healthcare \/ Athenex","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Athenex"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apotex Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kexing Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Smerud Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncology Venture \/ Smerud Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncology Venture \/ Smerud Medical Research"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Merck & Co"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"IND Enabling","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transmucosal Patch","sponsorNew":"Privo Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Privo Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boston Scientific \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Fulgent Pharma","sponsor":"Fulgent Genetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Fulgent Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fulgent Pharma \/ Fulgent Genetics","highestDevelopmentStatusID":"6","companyTruncated":"Fulgent Pharma \/ Fulgent Genetics"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Fidia Farmaceutici Spa \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fidia Farmaceutici Spa \/ Inapplicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Boryeong","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Boryeong","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Boryeong"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Inceptua Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inceptua Group \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Inceptua Group \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Catalyst Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Catalyst Health Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Catalyst Health Ventures"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ US Biotest","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ US Biotest"},{"orgOrder":0,"company":"Surmodics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Abbott Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Inapplicable"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Huons CO., LTD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Huons CO., LTD","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Huons CO., LTD"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Esteve Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Steroid","year":"2024","type":"Divestment","leadProduct":"Metyrapone","moa":"CYP450","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"HRA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"HRA Pharma \/ Esteve Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"HRA Pharma \/ Esteve Healthcare"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Hugel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Inapplicable"},{"orgOrder":0,"company":"Hugel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Inapplicable"},{"orgOrder":0,"company":"Hugel","sponsor":"Sihuan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Sihuan Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Hugel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hugel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"IBSA Institut Biochimique","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Diclofenac Epolamine","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Pfizer Inc \/ IBSA Institut Biochimique","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ IBSA Institut Biochimique"},{"orgOrder":0,"company":"Eversana","sponsor":"Yaral Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Diclofenac Epolamine","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Eversana \/ Yaral Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eversana \/ Yaral Pharma"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"THR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IBSA Institut Biochimique \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"15","companyTruncated":"IBSA Institut Biochimique \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"THR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IBSA Institut Biochimique \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IBSA Institut Biochimique \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Janssen Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Janssen Biotech"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nxera Pharma","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Nxera Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Nxera Pharma \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Nxera Pharma \/ Shionogi"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Heptares \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Nxera Pharma","sponsor":"Holling Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Nxera Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Nxera Pharma \/ Holling Bio-Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Nxera Pharma \/ Holling Bio-Pharma"},{"orgOrder":0,"company":"Nxera Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Nxera Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Nxera Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nxera Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Jefferies"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AdHER2DC","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CAR-NK","moa":"||IL-15-alpha receptor","graph1":"Hematology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Agreement","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"ImmunityBio \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Serum Institute of India"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"IL-15-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Nant Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Nant Capital","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Nant Capital"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ NantKwest"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Oberland Capital Management"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Piper Sandler"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Private Placement","leadProduct":"Durvalumab","moa":"||GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunocore \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ RTW Investments"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||GP100","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Immunocore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Immunocore","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Immunocore"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Medison Pharma"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Blackrock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Series C Financing","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Blackrock","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Blackrock"},{"orgOrder":0,"company":"Immunocore","sponsor":"EORTC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ EORTC","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ EORTC"},{"orgOrder":0,"company":"Immunocore","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Public Offering","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Medison Pharma"},{"orgOrder":0,"company":"Immunogen","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Immunogen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Pharmakon Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Pharmakon Advisors"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Everest Medicines"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Financing","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Abingworth","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Abingworth"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Immunomedics","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Immunomedics"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Everest Medicines \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Merck & Co"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Strata Oncology \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Strata Oncology \/ Gilead Sciences"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Janchor Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Janchor Partners","highestDevelopmentStatusID":"1","companyTruncated":"Everest Medicines \/ Janchor Partners"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Cowen"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Cowen"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Dla Piper","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Dla Piper","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Dla Piper"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Gilead Sciences"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Gilead Sciences"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Gilead Sciences"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Immunomedics","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Immunomedics"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Specialised Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Incyte Corporation"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Maruho"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ONCOtherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ONCOtherapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cellenkos \/ Incyte Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"CMS","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ CMS","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ CMS"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Alar Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Advanz Pharma"},{"orgOrder":0,"company":"Alliancerx Walgreens Prime","sponsor":"Duquesne University School of Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Alliancerx Walgreens Prime","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alliancerx Walgreens Prime \/ Duquesne University School of Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Alliancerx Walgreens Prime \/ Duquesne University School of Pharmacy"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Advanz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Advanz Pharma"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Alfasigma"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Alfasigma"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Levacetylleucine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Johnson & Johnson"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Merrimack Pharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medison Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Jadeite Medicines","sponsor":"Albireo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Jadeite Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jadeite Medicines \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Jadeite Medicines \/ Albireo Pharma"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Genpharm"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Genfit","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Genfit"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Jadeite Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jadeite Medicines"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jefferies"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Ispen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ispen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ispen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ispen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Allergan Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Galderma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"ITF Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PANTHERx Rare Pharmacy \/ ITF Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ ITF Therapeutics"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Medis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Medis","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Medis"},{"orgOrder":0,"company":"MEDUNIK CANADA","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"MEDUNIK CANADA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MEDUNIK CANADA \/ Jacobus Pharmaceutical Company, Inc","highestDevelopmentStatusID":"15","companyTruncated":"MEDUNIK CANADA \/ Jacobus Pharmaceutical Company, Inc"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Daunorubicin","moa":"||DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Daunorubicin","moa":"||DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Stand Up To Cancer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2021","type":"Collaboration","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Stand Up To Cancer","highestDevelopmentStatusID":"1","companyTruncated":"Jazz Pharmaceuticals \/ Stand Up To Cancer"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Immedica Pharma","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Immedica Pharma"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Partnership","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Eczac\u0131ba\u015f\u0131 Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Eczac\u0131ba\u015f\u0131 Group","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Eczac\u0131ba\u015f\u0131 Group"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Megapharm","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Megapharm"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Greenwich Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Cutia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Foamix Pharmaceuticals \/ Cutia Therapeutics"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Journey Medical Corporation"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Eli Lilly \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Eli Lilly \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Maruho"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ Janssen Biotech"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darunavir","moa":"||HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ketamine Wellness Center","sponsor":"Delic Corp","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ketamine Wellness Center","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ketamine Wellness Center \/ Delic Corp","highestDevelopmentStatusID":"15","companyTruncated":"Ketamine Wellness Center \/ Delic Corp"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mundipharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"American Heart Association","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American Heart Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"American Heart Association \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"American Heart Association \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"||NNRT","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"||NNRT","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Darunavir","moa":"HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Darunavir","moa":"||HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Adium Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Adium Pharma"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2022","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ STADA Arzneimittel"},{"orgOrder":0,"company":"PharmaMar","sponsor":"TOYO Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ TOYO Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ TOYO Pharmaceutical"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Undisclosed \/ Bionxt Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ Bionxt Solutions"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Undisclosed \/ Bionxt Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Undisclosed \/ Bionxt Solutions"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Key Oncologics"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Onko Kocsel Pharmaceuticals"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Bismuth Potassium Citrate","moa":"||Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juvise Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Juvise Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Juvise Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Series C Financing","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Antengene","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Hansoh Pharma"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"European Myeloma Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ European Myeloma Network","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ European Myeloma Network"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Filgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv BioSciences"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"Kashiv BioSciences \/ Brand Institute"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv BioSciences"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Filgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv BioSciences"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"Transferrin-1 receptor","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"Transferrin-1 receptor","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Profounda Pharmaceuticals","sponsor":"Knight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Miltefosine","moa":"Cytochrome-C oxidase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Profounda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Profounda Pharmaceuticals \/ Knight Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Profounda Pharmaceuticals \/ Knight Therapeutics"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miltefosine","moa":"Cytochrome-C oxidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"World Health Organization \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"World Health Organization \/ Inapplicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"||COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kowa Pharmaceuticals America \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Divestment","leadProduct":"Burosumab","moa":"FGF23","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Burosumab","moa":"FGF23","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ DKSH"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Angiotensin II type-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Innoviva"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Angiotensin II type-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Innoviva"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"PAION UK LTD","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Angiotensin II","moa":"Angiotensin II type-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ PAION UK LTD","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ PAION UK LTD"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"||IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ESG401","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Escugen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Levena Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Escugen Biotechnology \/ Levena Biopharma"},{"orgOrder":0,"company":"Oqory","sponsor":"Vincerx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Termination","leadProduct":"ESG401","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Oqory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oqory \/ Vincerx Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Oqory \/ Vincerx Pharma"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Loxo Oncology Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Innovent Biologics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Sunovion Pharmaceuticals \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Lupin Ltd"},{"orgOrder":0,"company":"Sedor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosphenytoin Sodium","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sedor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"TerSera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ TerSera Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ TerSera Therapeutics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Hercules Credit Facility","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Hercules Credit Facility","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Hercules Credit Facility"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ MAIA Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron Pharmaceuticals \/ MAIA Biotechnology"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bivalirudin","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Bivalirudin","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ MAIA Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ MAIA Biotechnology"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Basal Insulin","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mankind Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FINLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Orion Corporation \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Marinus Pharmaceuticals"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ SVB Securities","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ SVB Securities"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Tenacia Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Tenacia Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Orion Corporation \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Marinus Pharmaceuticals"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Immedica Pharma"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Smartway Pharmaceuticals","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2023","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Smartway Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Smartway Pharmaceuticals \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Smartway Pharmaceuticals \/ Marinus Pharmaceuticals"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Gameday Men\u2019s Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Numan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Numan","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Numan"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Duke University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"USSM","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ USSM","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ USSM"},{"orgOrder":0,"company":"nuBioAge","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"nuBioAge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"nuBioAge \/ Marius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"nuBioAge \/ Marius Pharmaceuticals"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"OLIC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Drospirenone","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ OLIC","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ OLIC"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Drospirenone","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Drospirenone","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Drospirenone","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Nurx","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Nurx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Nurx \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Nurx \/ TherapeuticsMD"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Inapplicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Rubric Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Financing","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Rubric Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Rubric Capital Management"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Population Council","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Duchesnay \/ Population Council","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Population Council"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0.42999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.42999999999999999,"dosageForm":"Vaginal Insert","sponsorNew":"Mayne Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Public Offering","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Mayne Pharma","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Mayne Pharma"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Mayne Pharma \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ TherapeuticsMD"},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ TherapeuticsMD"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Novan","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Novan"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Public Offering","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Almirall"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Endo Pharm"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Hyphens Pharma"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Haloperidol Decanoate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Essential Pharma"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Zambon Switzerland \/ Newron Pharmaceuticals"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"MAO-B","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Newron Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Zambon Group SpA"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"CSL","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Pharmanovia"},{"orgOrder":0,"company":"Medicines360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Medicines360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Medicines360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medicines360 \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban","moa":"||Integrin-alpha-2b\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban","moa":"||Integrin-alpha-2b\/beta-3","graph1":"Hematology","graph2":"Phase II","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"PolyMedics Innovations","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"PolyMedics Innovations","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PolyMedics Innovations \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"PolyMedics Innovations \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Ghassan Aboud Group","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Ghassan Aboud Group"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ US Department of Defense"},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"CVC Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Duchesnay \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Inapplicable"},{"orgOrder":0,"company":"SYSNAV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"SYSNAV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"SYSNAV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SYSNAV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"Megalith Pharmaceuticals \/ Radiance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Megalith Pharmaceuticals \/ Radiance Biopharma"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan precursor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Melinta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Delafloxacin","moa":"Topoisomerse IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melinta Therapeutics \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Delafloxacin","moa":"Topoisomerse IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melinta Therapeutics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Reflexion Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Reflexion Medical","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Reflexion Medical"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"||DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Letermovir","moa":"||DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"AiCuris","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AiCuris \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AiCuris \/ Royalty Pharma"},{"orgOrder":0,"company":"Codexis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Codexis \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Codexis \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roche Diagnostics GmbH \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Roche Diagnostics GmbH \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Japan Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Japan Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Japan Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Personalis","sponsor":"Olink Proteomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Personalis \/ Olink Proteomics","highestDevelopmentStatusID":"15","companyTruncated":"Personalis \/ Olink Proteomics"},{"orgOrder":0,"company":"University of Central florida","sponsor":"Ludwig Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Central florida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Central florida \/ Ludwig Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"University of Central florida \/ Ludwig Enterprises"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/ Merck & Co"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bayer AG"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bayer AG"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Merck & Co"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fox Chase Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fox Chase Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Seagen"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Activin signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon-alpha\/beta-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"||mAChR","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ ASPR"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||mAChR","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0.13,"dosageForm":"Intramuscular Injection","sponsorNew":"Kindeva Drug Delivery \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Teijin Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teijin Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Esteve Quimica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Esteve Quimica \/ Acorda Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Quimica \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Catalent Pharma Solutions \/ Acorda Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biopas Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Biopas Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Biopas Laboratories"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Chance Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Chance Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Chance Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Vensica Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"ACh receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Vensica Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vensica Medical \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vensica Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"ISRAEL","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase III","graph3":"Vensica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Vensica Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Vensica Medical","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2024","type":"Funding","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase I","graph3":"Vensica Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Medical \/ Israel Biotech Fund","highestDevelopmentStatusID":"6","companyTruncated":"Vensica Medical \/ Israel Biotech Fund"},{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Urokinase","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Microbix Biosystems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Microbix Biosystems \/ Sequel Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Microbix Biosystems \/ Sequel Pharma"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Satiogen","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Satiogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Satiogen \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Satiogen \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"GC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ GC Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ GC Pharma"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Cholic Acid","moa":"Bile acid synthesis","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Travere Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Abacus Medicine","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Abacus Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Abacus Medicine"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Brand Institute"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Mobius","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Mobius","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Mobius \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mobius \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"9","companyTruncated":"MorphoSys \/ Incyte Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Incyte Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"Xencor \/ MorphoSys"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ InnoCare Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ InnoCare Pharma"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"ADCE-T02","moa":"Tissue factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multitude Therapeutics \/ Adcendo","highestDevelopmentStatusID":"5","companyTruncated":"Multitude Therapeutics \/ Adcendo"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADCE-T02","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Napp Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Mycovia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Mycovia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Hengrui Medicine \/ Mycovia Pharmaceuticals"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Sinovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Sinovant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Sinovant Sciences"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Lefamulin Acetate","moa":"Peptidyl transferase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Erkim"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sinovant Sciences","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sinovant Sciences \/ Nabriva Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sinovant Sciences \/ Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"WEP Clinical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ WEP Clinical","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ WEP Clinical"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"50S ribosomal subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Iliad Research And Trading","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Iliad Research And Trading","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Iliad Research And Trading"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo EU","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo EU","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo EU"},{"orgOrder":0,"company":"Napo EU","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Oasis Capital","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Oasis Capital"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Quadri Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Napo EU \/ Quadri Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Quadri Pharmaceuticals"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Oasis Capital","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Oasis Capital"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napo EU \/ Jaguar Health","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Jaguar Health"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napo Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"6","companyTruncated":"Napo Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Napo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Neos Therapeutics \/ Aytu BioPharma"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Lupin Pharma Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aytu BioPharma \/ Lupin Pharma Canada","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Lupin Pharma Canada"},{"orgOrder":0,"company":"Neurelis","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Series D Financing","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Cormorant Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Neurelis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aculys Pharma \/ Neurelis","highestDevelopmentStatusID":"15","companyTruncated":"Aculys Pharma \/ Neurelis"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aculys Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Phase IV","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"New American Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Metoprolol Succinate","moa":"Adrenergic-beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"New American Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"New American Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"New American Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Medison Pharma"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Option Care Health","sponsor":"NS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Option Care Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Option Care Health \/ NS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Option Care Health \/ NS Pharma"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon-53","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Almirall"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"||IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"||IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta-receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NHS England \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Natera","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natera \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alpelisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alpelisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"SOLTI Innovative Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ SOLTI Innovative Cancer Research","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ SOLTI Innovative Cancer Research"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Translational Research In Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Translational Research In Oncology"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||IL-1-beta-receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||IL-1-beta-receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta-receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta-receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Inclisiran","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"NHS England \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"EnPlusOne Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"EnPlusOne Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EnPlusOne Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Aucta Pharmaceuticals \/ Oakrum Pharma, LLC","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Oakrum Pharma, LLC"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Artemether","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Siponimod fumarate","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Siponimod fumarate","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Saol therapeutics \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Saol therapeutics \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3K-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta-receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Endocyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2020","type":"Agreement","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotope Technologies Munich \/ Endocyte","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ Endocyte"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"||Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Endocyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Endocyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endocyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endocyte \/ Inapplicable"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Collaboration","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ABX Advanced Biochemical Compounds","sponsor":"Endocyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"ABX Advanced Biochemical Compounds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ABX Advanced Biochemical Compounds \/ Endocyte","highestDevelopmentStatusID":"15","companyTruncated":"ABX Advanced Biochemical Compounds \/ Endocyte"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta-receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta-receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NICE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NICE","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NICE \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NICE \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Brolucizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Pyxis Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pyxis Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Emisphere Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Emisphere Technologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Emisphere Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Emisphere Technologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Biomm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Biomm","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Biomm"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ Inapplicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ Novo Nordisk"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Somapacitan","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Somapacitan","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Somapacitan","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Gilead Sciences"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Parathyroid Hormone","moa":"Calcium","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"AffaMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"AffaMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ AffaMed Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ AffaMed Therapeutics"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Ocular Therapeutix"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"AffaMed Therapeutics \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Lannett Company, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Target Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blue Water Vaccines \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Vaccines \/ IQVIA"},{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Onconetix \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Optinose","amount2":0.33000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"15","companyTruncated":"KALEO INC \/ Optinose"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Subgingival Dry Powder","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Bausch Health"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Subgingival Dry Powder","sponsorNew":"ORAPHARMA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Orasis Pharmaceuticals \/ Arboretum Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Arboretum Ventures"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Orasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Orasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Optus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Pilocarpine Hydrochloride","moa":"M1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orasis Pharmaceuticals \/ Optus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Optus Pharmaceuticals"},{"orgOrder":0,"company":"Orexo","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Accord healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Orexo \/ Accord healthcare"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Perrigo Company plc \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Organon"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Douglas CDMO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Douglas CDMO","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Douglas CDMO"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Divestment","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Brand Institute \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"Alora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Millmount Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"V2 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Millmount Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Millmount Healthcare"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Oncology \/ National Cancer Institute"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka America Pharmaceutical, Inc.","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka America Pharmaceutical, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"H. Lundbeck AS \/ Otsuka Holdings","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Holdings"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Holdings \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Holdings \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Viatris"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Viatris"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Depuy Synthes Sales","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Depuy Synthes Sales","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Depuy Synthes Sales"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Hk Tainuo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ Hk Tainuo","highestDevelopmentStatusID":"15","companyTruncated":"Flexion Therapeutics \/ Hk Tainuo"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ Pacira BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Flexion Therapeutics \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Premier"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension, Liposomal","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Funding","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Zai Lab"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axplora","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axplora \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Axplora \/ Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Partnership","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Auxilium Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hims & Hers Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Hims & Hers Health","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Hims & Hers Health"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Neurotrope","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Neurotrope"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Pierre Fabre"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Talazoparib","moa":"PARP-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Swanielle Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Collaboration","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Swanielle Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Swanielle Inc"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafamidis","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafamidis Meglumine","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tafamidis Meglumine","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arena Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Everest Medicines"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dacomitinib","moa":"ErbB1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1P receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ HealthCare Royalty"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ TFS Trial Form Support","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP-2","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Astellas Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Amlodipine","moa":"||L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Viatris"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quinapril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quinapril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Divestment","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ National Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ National Cancer Institute"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EORTC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ EORTC","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ EORTC"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Genpharm"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Medison Pharma"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bioshin","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Bioshin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Bioshin \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bioshin \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Cove","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cove","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cove \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cove \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Royalty Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Pint Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Pint Pharma"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pint Pharma \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"PANTHERx Rare Pharmacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Mankind Pharma"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Park West Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Park West Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Park West Asset Management"},{"orgOrder":0,"company":"Protega Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Protega Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protega Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protega Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Monoamine oxidase","graph1":"Hematology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"American Regent \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Acentrus Specialty","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Acentrus Specialty","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Acentrus Specialty"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Athyrium Capital"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Bixink Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Bixink Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Bixink Therapeutics"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Pierre Fabre"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The National Comprehensive Cancer Network \/ Puma Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"The National Comprehensive Cancer Network \/ Puma Biotechnology"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Adlon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adlon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adlon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Burke Therapeutics","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Amlodipine Besylate","moa":"||Cav1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Burke Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burke Therapeutics \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Burke Therapeutics \/ Coeptis Pharmaceuticals"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pyros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pyros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pyros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pyros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyros Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pyros Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Clionix"},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ isoSolutions"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Inapplicable"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Optum Frontier Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Partnership","leadProduct":"Sacrosidase","moa":"Sucrase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Optum Frontier Therapies","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Optum Frontier Therapies"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Inapplicable"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Abiogen Pharma S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Alendronate Sodium","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Radius Health","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Radius Health"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Theramex"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ Rayner Surgical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner Surgical Group Limited"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betaine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carglumic Acid","moa":"CPS1","graph1":"Hematology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"CYP450-11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Technologies","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Rifamycin","moa":"DdRP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosmo Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Technologies \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Technologies \/ RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Entera Health"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Gaelan Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Gaelan Medical","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Gaelan Medical"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Phil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Phil","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Phil"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DdRP","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GENESIS Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GENESIS Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atoltivimab","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"UNC School of Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"UNC School of Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UNC School of Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"UNC School of Medicine \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cemdisiran","moa":"||C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atoltivimab","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Alirocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Alirocumab","moa":"PCSK9","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Barclays","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Barclays"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Athyrium Capital"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sisram Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sisram Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sisram Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sisram Medical \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.92000000000000004,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0.92000000000000004,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Syneos Health"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Syneos Health"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xinvento","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Xinvento","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xinvento \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xinvento \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Genpharm"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"RareStone Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ RareStone Group","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ RareStone Group"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Termination","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"RareStone Group \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Medison Pharma"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Funding","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Drogsan Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rockwell Medical \/ Drogsan Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Drogsan Pharmaceuticals"},{"orgOrder":0,"company":"Drogsan Pharmaceuticals","sponsor":"Rockwell Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Drogsan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Drogsan Pharmaceuticals \/ Rockwell Medical","highestDevelopmentStatusID":"15","companyTruncated":"Drogsan Pharmaceuticals \/ Rockwell Medical"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"||Transferrin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.A.E","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ R-Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ R-Pharm"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"RVL Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"RVL Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Revision Skincare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Revision Skincare \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Revision Skincare \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Omeprazole","moa":"||K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Carlin Consumer Health","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Carlin Consumer Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bausch Health \/ Salix Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Salix Pharmaceuticals"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"||RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Noramco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Noramco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Noramco \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noramco \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Samsung Bioepis"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Merck & Co"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Sandoz B2B"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Sandoz B2B"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Johnson & Johnson"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Samsung Bioepis"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Societal CDMO \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"InfectoPharm Drugs and Consilium \/ Societal CDMO","highestDevelopmentStatusID":"15","companyTruncated":"InfectoPharm Drugs and Consilium \/ Societal CDMO"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Nelarabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Bioeq IP AG","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Bioeq IP AG"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Brand Institute"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bioeq IP AG \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Bioeq IP AG \/ Coherus Biosciences"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bioeq IP AG \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Bioeq IP AG \/ Formycon"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin-alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin-alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin-alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Polpharma Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Polpharma Biologics"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin-alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Polpharma","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Polpharma"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Eversana","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Nelarabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Eversana"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Nelarabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Sandoz B2B"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Sandoz B2B"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Recordati"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Wellbeam Consumer Health","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Arnica Montana","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Wellbeam Consumer Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Wellbeam Consumer Health \/ Carlin Consumer Health","highestDevelopmentStatusID":"15","companyTruncated":"Wellbeam Consumer Health \/ Carlin Consumer Health"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Corticotropin","moa":"MC2 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Kadmon","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kadmon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kadmon \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Kadmon \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Meiji Seika Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Plerixafor","moa":"CXCR-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"4P-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"4P-Pharma \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"4P-Pharma \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eliglustat","moa":"Glucosylceramide synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Kadmon","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kadmon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kadmon \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Kadmon \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai ADM Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Hyundai ADM Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hyundai ADM Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hyundai ADM Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"OncoTEX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Oxaliplatin Pt(Iv) Prodrug","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sterling Pharma Solutions \/ OncoTEX","highestDevelopmentStatusID":"4","companyTruncated":"Sterling Pharma Solutions \/ OncoTEX"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"OncoTEX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Oxaliplatin Pt(Iv) Prodrug","moa":"||Mutated p53","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoTEX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoTEX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoTEX \/ Inapplicable"},{"orgOrder":0,"company":"OncoTEX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Oxaliplatin Pt(Iv) Prodrug","moa":"||Mutated p53","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoTEX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoTEX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoTEX \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Corticotropin","moa":"MC2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Zolpidem Tartrate","moa":"GABAA-alpha-1\/beta-1\/gamma-2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Cosette Pharma"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved FDF","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"AmbioPharm \/ Upsher-Smith Laboratories"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Kesin Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kesin Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Kesin Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kesin Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Torsemide","moa":"NKCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sarfez Pharmaceuticals \/ Novo Integrated Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Novo Integrated Sciences"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ YA II PN","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ YA II PN"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Avion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Avion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"RxOMEG Therapeutics \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RxOMEG Therapeutics \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Romeg Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Licensing Agreement","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Romeg Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Romeg Therapeutics \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Romeg Therapeutics \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Ethypharm"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Collegium Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Undisclosed \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp I","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"ACEA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ ACEA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ ACEA Therapeutics"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Devart Middle East","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Devart Middle East","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Devart Middle East"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Farouk, Maamoun Tamer & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Farouk, Maamoun Tamer & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Farouk, Maamoun Tamer & Co."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"CH Trading Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ CH Trading Group","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ CH Trading Group"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.13,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Brand Institute"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ SVB Securities","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ SVB Securities"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Nephrology","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ FDA","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ FDA"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hercules Capital"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tucatinib","moa":"ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tucatinib","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BioNova Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sutro Biopharma \/ BioNova Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ BioNova Pharmaceuticals"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Seagen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Pfizer Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Pfizer Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Baillie Gifford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Baillie Gifford","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Baillie Gifford"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"ErbB2","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Genmab"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seagen \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Genmab"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3K delta\/gamma","graph1":"Oncology","graph2":"Approved FDF","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Secura Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Secura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3K delta\/gamma","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Secura Bio"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3K delta\/gamma","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Secura Bio"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3K delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BostonGene","sponsor":"The Weinstock Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Duvelisib","moa":"PI3K delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BostonGene \/ The Weinstock Laboratory","highestDevelopmentStatusID":"8","companyTruncated":"BostonGene \/ The Weinstock Laboratory"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3K delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Secura Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Secura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Servier"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Mission Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Mission Bio","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Mission Bio"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Servier"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shionogi \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Clinton Health Access Initiative"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Therakind","sponsor":"Shorla Oncology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Acquisition","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Therakind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Therakind \/ Shorla Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Therakind \/ Shorla Oncology"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Thiotepa","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"NIHR","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NIHR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NIHR \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NIHR \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ University of Oxford"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ JPEO-CBRND"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meridian Medical Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meridian Medical Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"ASEAN","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ ASEAN","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ ASEAN"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Meridian Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Meridian Medical Technologies","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Meridian Medical Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Patheon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Patheon","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Patheon"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ US Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ US Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"AllianceRx Walgreens","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Leadiant Biosciences \/ AllianceRx Walgreens","highestDevelopmentStatusID":"15","companyTruncated":"Leadiant Biosciences \/ AllianceRx Walgreens"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Arvelle Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ Angelini Pharma"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Angelini Pharma"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Series A Financing","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ NovaQuest Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Life Science \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SK Life Science \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Cytel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Sigma-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cytel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytel \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytel \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"||G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"G-CSF receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||G-CSF receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||G-CSF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Assertio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assertio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||G-CSF receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Children\u2019s Oncology Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Children\u2019s Oncology Group","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Children\u2019s Oncology Group"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Seagen"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Sprout Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Flibanserin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sprout Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sprout Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sprout Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nippon Shinyaku \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Nippon Shinyaku \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Belimumab","moa":"BLyS","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Nippon Medac"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Nippon Medac"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Acquisition","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Medac","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medac \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Eisai"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elite Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elite Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Jefferies"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Gedeon Richter"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Myovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Myovant Sciences"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Accord healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Accord healthcare"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Sumitomo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Brand Institute \/ Myovant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Myovant Sciences"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Myovant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Myovant Sciences"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Bial","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Bial"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Marathon Asset Management"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ 3S Bio Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ 3S Bio Inc"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyphens Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyundai Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyundai Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyundai Pharm"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Cassiopea","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Cassiopea"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Curia","sponsor":"Cassiopea","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Curia \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Curia \/ Cassiopea"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonidegib Phosphate","moa":"Homolog","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Phenobarbital Sodium","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Phenobarbital Sodium","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Angelini Pharma \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Angelini Pharma \/ Sunovion Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"HPDD","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Hellenic Institute for the Study of Sepsis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||JAK2\/FLT3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||JAK2\/FLT3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"The Lundquist Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"The Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Lundquist Institute \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"The Lundquist Institute \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"CTI BioPharma Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onco360 \/ CTI BioPharma Corp","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ CTI BioPharma Corp"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Palivizumab","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Servier"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"FoundationOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"FoundationOne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"FoundationOne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FoundationOne \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Hutchison China MediTech \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hutchmed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hutchmed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"SHIRE LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ SHIRE LLC","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ SHIRE LLC"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Innovent Biologics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Innovent Biologics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ HengRui","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ HengRui"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"University of Maryland","sponsor":"NICO Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Pioglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"University of Maryland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Maryland \/ NICO Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland \/ NICO Corporation"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"||Integrin-alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ramelteon","moa":"MTN1A receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Link Healthcare Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Pharma USA \/ Link Healthcare Group","highestDevelopmentStatusID":"15","companyTruncated":"Teikoku Pharma USA \/ Link Healthcare Group"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Gozetotide","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"TerSera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ TerSera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ TerSera Therapeutics"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TerSera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TerSera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Canada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"TerSera Canada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"TerSera Canada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Canada \/ Inapplicable"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"La Jolla Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Pharma Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Pharma Group \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Pharma Group \/ Everest Medicines"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Armistice Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Armistice Capital","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Armistice Capital"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Assia Chemical Industries Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assia Chemical Industries Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Assia Chemical Industries Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Jiangsu Nhwa Pharmaceutical","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Jiangsu Nhwa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Kinimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"MHC-II","graph1":"Oncology","graph2":"Phase I","graph3":"Kinimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kinimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinimmune \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ublituximab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Rhizen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Rhizen Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Rhizen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Rhizen Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Thea Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thea Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Prasco Laboratories","sponsor":"Thea Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Prasco Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Prasco Laboratories \/ Thea Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Prasco Laboratories \/ Thea Pharma"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Akorn Pharmaceuticals \/ Laboratoires Thea","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Laboratoires Thea"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Th\u00e9a Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Akorn Pharmaceuticals \/ Th\u00e9a Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Th\u00e9a Pharma"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Thea Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thea Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Thea Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thea Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Tafluprost","moa":"||FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Tafluprost","moa":"||FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"TheracosBio","sponsor":"BAMCO Africa","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ BAMCO Africa","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ BAMCO Africa"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Inapplicable"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Inapplicable"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Inapplicable"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Independent Pharmacy Cooperative","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Independent Pharmacy Cooperative","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Independent Pharmacy Cooperative"},{"orgOrder":0,"company":"TheracosBio","sponsor":"SmithRx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ SmithRx","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ SmithRx"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"AcedrA BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"TaiMed Biologics \/ AcedrA BioPharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ AcedrA BioPharmaceuticals"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Marathon Asset Management"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"World Orphan Drug Alliance","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ World Orphan Drug Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ World Orphan Drug Alliance"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Italian Medicines Agency","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Italian Medicines Agency"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Phoenix Biotech Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Pyrimethamine","moa":"DHFR","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vyera Pharmaceuticals \/ Phoenix Biotech Acquisition Corp","highestDevelopmentStatusID":"15","companyTruncated":"Vyera Pharmaceuticals \/ Phoenix Biotech Acquisition Corp"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Tilde Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Acquisition","leadProduct":"Pyrimethamine","moa":"DHFR","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vyera Pharmaceuticals \/ Tilde Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Vyera Pharmaceuticals \/ Tilde Sciences"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Pyrimethamine","moa":"DHFR","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Tolmar","sponsor":"UpScriptHealth","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tolmar \/ UpScriptHealth","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ UpScriptHealth"},{"orgOrder":0,"company":"Blue Water Acquisition Corporation","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Merger","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Blue Water Acquisition Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blue Water Acquisition Corporation \/ Clarus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Acquisition Corporation \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Tolmar"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Renalys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Renalys Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Renalys Pharma"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Alcami","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alcami","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alcami \/ Trevena","highestDevelopmentStatusID":"15","companyTruncated":"Alcami \/ Trevena"},{"orgOrder":0,"company":"Premier","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Trevena","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Trevena"},{"orgOrder":0,"company":"Trevena","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ CBC Group"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Jiangsu Nhwa Pharmaceutical"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Pediatrix Therapeutics"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Perigon Pharmacy 360","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Perigon Pharmacy 360","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Perigon Pharmacy 360"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"ALMATICA PHARMA INC","sponsor":"TWi Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Lisinopril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ALMATICA PHARMA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals"},{"orgOrder":0,"company":"Alvogen","sponsor":"AZTIQ PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Lisinopril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alvogen \/ AZTIQ PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Alvogen \/ AZTIQ PHARMA"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xbrane Biopharma \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Biogen"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Highmark","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Highmark \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2\/sigma-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ CBC Group"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Anlotinib HCl","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"SteinCares","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ SteinCares","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ SteinCares"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"WARPNINE","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ WARPNINE","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ WARPNINE"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Vidutolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Acquisition","leadProduct":"Carboplatin","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Biotheus","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Romidepsin","moa":"HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series D Financing","leadProduct":"EIK1001","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Eikon Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Eikon Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"9","companyTruncated":"Eikon Therapeutics \/ Lux Capital"},{"orgOrder":0,"company":"Akeso","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Cisplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Sichuan Kelun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Sichuan Kelun Pharmaceutical"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiauranib","moa":"||VEGF receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Orphelia Pharma","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Orphelia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orphelia Pharma \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Orphelia Pharma \/ Ethypharm"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Public Offering","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Lake Street Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Public Offering","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Lake Street Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Innovent Biologics \/ Hutchmed","highestDevelopmentStatusID":"9","companyTruncated":"Innovent Biologics \/ Hutchmed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Ascentage Pharma"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR\/LGR5","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirror Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"AlloStim","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mirror Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mirror Biologics \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Mirror Biologics \/ Merck Group"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE251","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMC-R117C","moa":"PIWIL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SB-007","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SpliceBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliceBio \/ Inapplicable"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SB-007","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SpliceBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliceBio \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ IQVIA"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorinab","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olorinab","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Theramex"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Durbin","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Durbin","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Durbin"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"SIFI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Avanzanite Bioscience \/ SIFI","highestDevelopmentStatusID":"10","companyTruncated":"Avanzanite Bioscience \/ SIFI"},{"orgOrder":0,"company":"SIFI","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ University of California"},{"orgOrder":0,"company":"Aspen API","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Aspen API","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen API \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aspen API \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ RA Capital Management"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Deep Track Capital"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"FrostPharma AB","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ FrostPharma AB","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ FrostPharma AB"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"15","companyTruncated":"Avanzanite Bioscience \/ Advicenne"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"15","companyTruncated":"Avanzanite Bioscience \/ Advicenne"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Non-Beta-Lactam Antibiotic","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"2","companyTruncated":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"APL-2301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Douglas CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Douglas CDMO","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Douglas CDMO"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Mayne Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Mayne Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Mayne Pharma"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Alethea Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"GDD3898","moa":"SCD1","graph1":"Dermatology","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Lipidio Pharmaceuticals \/ Alethea Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Alethea Capital"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"EB005","moa":"Gut microbiome","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Eligo Bioscience \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ GSK"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"EB005","moa":"Gut microbiome","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Eligo Bioscience \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HT-003","moa":"Toll-like-2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"HT-003","moa":"Toll-like-2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Weill Cornell Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Altaris Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Adapalene","moa":"RAR-beta","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Altaris Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Altaris Capital Partners"},{"orgOrder":0,"company":"Certara","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Certara \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Certara \/ Galderma"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adapalene","moa":"||RAR-beta","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adapalene","moa":"||RAR-beta","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nogra Pharma","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"PPA-gamma receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Nogra Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nogra Pharma \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nogra Pharma \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BX001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BX001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"SeegPharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Cosette Pharma \/ SeegPharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ SeegPharm"},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Solaris Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Solaris Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Solaris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vyome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"VB-1953","moa":"Toll-like receptor\/MD2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Vyome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vyome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ortho Dermatologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alchemee","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alchemee","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Alchemee \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alchemee \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TVB-3567","moa":"FASN","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zinc Hyaluronate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Origimm Biotechnology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"ORI-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Origimm Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Origimm Biotechnology \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Origimm Biotechnology \/ Sanofi"},{"orgOrder":0,"company":"INJA Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glutathione","moa":"Glutathione peroxidase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"INJA Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INJA Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"INJA Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OQL025","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lutris Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lutris Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sandoz B2B \/ Aspen Pharmacare Holdings","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Aspen Pharmacare Holdings"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"||SST receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-23 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Adage Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Adage Capital Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Sanwa Kagaku Kenkyusho","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Sanwa Kagaku Kenkyusho","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Sanwa Kagaku Kenkyusho"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"PeptiDream","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"AZP-3813","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ PeptiDream","highestDevelopmentStatusID":"6","companyTruncated":"Amolyt Pharma \/ PeptiDream"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"MAR002","moa":"GHS receptor","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marea Therapeutics \/ ProBioGen","highestDevelopmentStatusID":"5","companyTruncated":"Marea Therapeutics \/ ProBioGen"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Genomic Biopharma","sponsor":"POIC e dintorni","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Genomic Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genomic Biopharma \/ POIC e dintorni","highestDevelopmentStatusID":"2","companyTruncated":"Genomic Biopharma \/ POIC e dintorni"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRL-4","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Drugs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hetero Drugs \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Drugs \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Merck & Co"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Cyclarity Therapeutics","sponsor":"Monash University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cyclodextrin","moa":"Toxic oxidized cholesterol","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Cyclarity Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cyclarity Therapeutics \/ Monash University","highestDevelopmentStatusID":"5","companyTruncated":"Cyclarity Therapeutics \/ Monash University"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eptifibatide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tirofiban","moa":"Integrin-alpha-2b\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Berenberg"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Berenberg"},{"orgOrder":0,"company":"Rhoshan Pharmaceuticals","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Rhoshan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rhoshan Pharmaceuticals \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Rhoshan Pharmaceuticals \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vicagrel","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Inapplicable"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Qu\u00e9bec Government","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Qu\u00e9bec Government","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Qu\u00e9bec Government"},{"orgOrder":0,"company":"University Medical Center Utrecht","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Medical Center Utrecht","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University Medical Center Utrecht \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Utrecht \/ Inapplicable"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eptifibatide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Provention Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Provention Bio \/ Inapplicable"},{"orgOrder":0,"company":"KBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"EV68-228-N","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"KBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBio \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"KBio \/ National Institutes of Health"},{"orgOrder":0,"company":"Yaqrit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"Ammonia","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Yaqrit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Yaqrit \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yaqrit \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Mitem Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Rev1 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"DTRI-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basking Biosciences \/ Rev1 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Basking Biosciences \/ Rev1 Ventures"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Toll-like-4 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Toll-like-4 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"c-Met receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"c-Met receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"c-Met receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CalciMedica \/ Deerfield Management","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Deerfield Management"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"University of Calgary","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ University of Calgary","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ University of Calgary"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CER-001","moa":"||APOA-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CER-001","moa":"||APOA-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Cowen"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"Rex Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Nephrology","graph2":"Phase II","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rediscovery Life Sciences \/ Rex Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Rediscovery Life Sciences \/ Rex Health Ventures"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"AM-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Agreement","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KBI Biopharma \/ AM-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"KBI Biopharma \/ AM-Pharma"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Juniper Point","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Stannic Protoporfin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Juniper Point","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Juniper Point"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Stannic Protoporfin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RVL-HV02","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Talphera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2 S","graph1":"Nephrology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"REVTx-300","moa":"Toll-like-4 receptor","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nephraegis Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NPH-022","moa":"Epoxyeicosatrienoic acid","graph1":"Nephrology","graph2":"Preclinical","graph3":"Nephraegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nephraegis Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Nephraegis Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Telara Pharma","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Preclinical","graph3":"Telara Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telara Pharma \/ Arch Biopartners","highestDevelopmentStatusID":"4","companyTruncated":"Telara Pharma \/ Arch Biopartners"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"USP-30","graph1":"Nephrology","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mission Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Kantum Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB-1801","moa":"P2Y14 receptor","graph1":"Nephrology","graph2":"Preclinical","graph3":"Kantum Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kantum Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kantum Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExCellThera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ExCellThera \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LOX","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Liquid","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Altasciences Company Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dociparstat Sodium","moa":"HMGB1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"The Virginia Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ The Virginia Catalyst","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ The Virginia Catalyst"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"TRV027","moa":"AT1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Trevena","highestDevelopmentStatusID":"6","companyTruncated":"Imperial College London \/ Trevena"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanetics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ National Institutes of Health"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"PIP-2","moa":"NOX2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peroxitech Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech Therapeutics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Financing","leadProduct":"PIP-2","moa":"NOX2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peroxitech Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Amplicore","sponsor":"Photon Fund","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"AM3101","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amplicore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amplicore \/ Photon Fund","highestDevelopmentStatusID":"4","companyTruncated":"Amplicore \/ Photon Fund"},{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Undisclosed"},{"orgOrder":0,"company":"Kaizen Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"||K-ATPase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Kaizen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaizen Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kaizen Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DPPC","moa":"||Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novus Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KUR-101","moa":"MOR","graph1":"Neurology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CG001419","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullgen \/ Inapplicable"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Elysium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"O2P Hydrocodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elysium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elysium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAXONA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAXONA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Park Therapeutics","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Park Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Park Therapeutics \/ Tris Pharma Inc","highestDevelopmentStatusID":"8","companyTruncated":"Park Therapeutics \/ Tris Pharma Inc"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Chromocell Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Neurology","graph2":"Phase I","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Benuvia Therapeutics \/ Chromocell Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Benuvia Therapeutics \/ Chromocell Corporation"},{"orgOrder":0,"company":"iX Biopharma","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"iX Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Wafer","sponsorNew":"iX Biopharma \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"iX Biopharma \/ Seelos Therapeutics"},{"orgOrder":0,"company":"Yaral Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Yaral Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Yaral Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yaral Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SiteOne Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Fermion Oy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FZ008-145","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Fermion Oy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fermion Oy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fermion Oy \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ODM-111","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SCI-160","moa":"CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Nimesulide","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Angelini Pharma"},{"orgOrder":0,"company":"Xgene Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pregabalin","moa":"||Alpha-2-beta-subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Xgene Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xgene Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xgene Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"TRN-261","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ Tris Pharma Inc","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ Tris Pharma Inc"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cessatech","sponsor":"Proveca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cessatech \/ Proveca","highestDevelopmentStatusID":"9","companyTruncated":"Cessatech \/ Proveca"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Partnership","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ National Institutes of Health"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ReAlta Life Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ US Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ US Department of Defense"},{"orgOrder":0,"company":"Synedgen","sponsor":"JWMRP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"MIIST305","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synedgen \/ JWMRP","highestDevelopmentStatusID":"4","companyTruncated":"Synedgen \/ JWMRP"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Tivic Health Systems","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"Entolimod","moa":"Toll-like-5 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Statera Biopharma \/ Tivic Health Systems","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ Tivic Health Systems"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institutes of Health"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Divestment","leadProduct":"Cefuroxime Axetil","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Sandoz B2B"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.19,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"},{"orgOrder":0,"company":"Versantis","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Genfit","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Genfit"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Aceso Life Science Holding","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"HepaStem","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Promethera Biosciences \/ Aceso Life Science Holding","highestDevelopmentStatusID":"8","companyTruncated":"Promethera Biosciences \/ Aceso Life Science Holding"},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HepaStem","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Promethera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promethera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.20000000000000001,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Starton Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Starton Therapeutics \/ Love Pharma"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fludrocortisone Acetate","moa":"Mineralocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fludrocortisone Acetate","moa":"Mineralocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"CT-0508","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sesen Bio \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio \/ Carisma Therapeutics"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BA3182","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Dimesna","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Reprocell","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Reprocell"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||PAR1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ZKN-013","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eloxx Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REC-4881","moa":"MEK1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"REC-4881","moa":"MEK1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ CPRIT"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"One-Two Therapeutics Assets Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ One-Two Therapeutics Assets Limited","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ One-Two Therapeutics Assets Limited"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OTL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ J.P. Morgan"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Kite Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Kite Pharma"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RZL 012","moa":"Cell membrane synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ingenu","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ingenu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ingenu \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Ingenu \/ Psyence"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Cantheon Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Cantheon Capital","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Cantheon Capital"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Newcourt Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Newcourt Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Newcourt Acquisition Corp"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence Biomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence Biomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Seaver Autism Center for Research and Treatment","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Seaver Autism Center for Research and Treatment","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seaver Autism Center for Research and Treatment \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaver Autism Center for Research and Treatment \/ Inapplicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OR-449","moa":"SF-1\/NR5A1","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OR-449","moa":"SF-1\/NR5A1","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BBP-631","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BBP-631","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"EffRx Pharmaceuticals \/ Diurnal Group","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Diurnal Group"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"OMass Therapeutics \/ GV","highestDevelopmentStatusID":"2","companyTruncated":"OMass Therapeutics \/ GV"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"OMass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"OMass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ 5Am Ventures"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Omega Funds"},{"orgOrder":0,"company":"HBM Alpha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"HAT001","moa":"CRH","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"HBM Alpha Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"HBM Alpha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"HBM Alpha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Crossject","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Crossject"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Norwegian Cancer Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"CY-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Norwegian Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Norwegian Cancer Society"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Radionetics Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radionetics Oncology \/ GordonMD Global Investments","highestDevelopmentStatusID":"2","companyTruncated":"Radionetics Oncology \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP expression","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Neurology","graph2":"Preclinical","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Neurology","graph2":"Preclinical","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-456","moa":"CXCR-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Invectys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invectys \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tiancheng Pharma. Co., Ltd.","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"BT524","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Tianjin Tiancheng Pharma. Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tianjin Tiancheng Pharma. Co., Ltd. \/ Grifols International","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tiancheng Pharma. Co., Ltd. \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BT524","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Grifols International","highestDevelopmentStatusID":"2","companyTruncated":"Alkahest \/ Grifols International"},{"orgOrder":0,"company":"Shift Bioscience","sponsor":"BGF","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Shift Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shift Bioscience \/ BGF","highestDevelopmentStatusID":"4","companyTruncated":"Shift Bioscience \/ BGF"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"RepliCel","sponsor":"InnovaCell Biotechnologie","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cultured, Autologous Hair Follicle Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"RepliCel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"RepliCel \/ InnovaCell Biotechnologie","highestDevelopmentStatusID":"6","companyTruncated":"RepliCel \/ InnovaCell Biotechnologie"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"BioAge Labs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taisho Pharmaceutical \/ BioAge Labs","highestDevelopmentStatusID":"6","companyTruncated":"Taisho Pharmaceutical \/ BioAge Labs"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Designs for Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Designs for Health","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Designs for Health"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Selah Therapeutics","sponsor":"Juvenescence","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Selah Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Selah Therapeutics \/ Juvenescence","highestDevelopmentStatusID":"1","companyTruncated":"Selah Therapeutics \/ Juvenescence"},{"orgOrder":0,"company":"Buck Institute for Research on Aging","sponsor":"Hevolution Foundation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Buck Institute for Research on Aging","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Buck Institute for Research on Aging \/ Hevolution Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Buck Institute for Research on Aging \/ Hevolution Foundation"},{"orgOrder":0,"company":"Multiply Labs","sponsor":"Retro Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Multiply Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multiply Labs \/ Retro Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Multiply Labs \/ Retro Biosciences"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"BioAge Labs","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.55000000000000004,"dosageForm":"Undisclosed","sponsorNew":"BioAge Labs \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"BioAge Labs \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ponce De Leon Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Alpha-Ketoglutarate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ponce De Leon Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ponce De Leon Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ponce De Leon Health \/ Inapplicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Beauty Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organicell Regenerative Medicine \/ Beauty Health","highestDevelopmentStatusID":"1","companyTruncated":"Organicell Regenerative Medicine \/ Beauty Health"},{"orgOrder":0,"company":"panCELLa","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human Embryonic Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"panCELLa","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"panCELLa \/ NRC IRAP","highestDevelopmentStatusID":"3","companyTruncated":"panCELLa \/ NRC IRAP"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"GERO.AI","sponsor":"Bulba Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"GERO.AI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GERO.AI \/ Bulba Ventures","highestDevelopmentStatusID":"2","companyTruncated":"GERO.AI \/ Bulba Ventures"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Inapplicable"},{"orgOrder":0,"company":"Anew Medical","sponsor":"Japan\u2019s Okinawa Research Center","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anew Medical \/ Japan\u2019s Okinawa Research Center","highestDevelopmentStatusID":"4","companyTruncated":"Anew Medical \/ Japan\u2019s Okinawa Research Center"},{"orgOrder":0,"company":"Ois\u00edn Biotechnologies","sponsor":"AbbVie Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ois\u00edn Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ois\u00edn Biotechnologies \/ AbbVie Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ois\u00edn Biotechnologies \/ AbbVie Ventures"},{"orgOrder":0,"company":"Ois\u00edn Biotechnologies","sponsor":"Methuselah Foundation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ois\u00edn Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ois\u00edn Biotechnologies \/ Methuselah Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ois\u00edn Biotechnologies \/ Methuselah Foundation"},{"orgOrder":0,"company":"Pluristyx","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"ESI Human Embryonic Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Pluristyx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluristyx \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pluristyx \/ AgeX Therapeutics"},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Renaissance Capital"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Elixirgen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Elixirgen Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Taisho Pharmaceutical \/ Elixirgen Therapeutics"},{"orgOrder":0,"company":"IFM Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IFM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmuneSensor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTA2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATV-1601","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atavistik Bio \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ UCLA"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"2","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Numinus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Numinus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numinus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Numinus \/ Inapplicable"},{"orgOrder":0,"company":"Numinus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Numinus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numinus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Numinus \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA A-alpha-4\/beta-2\/delta receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"DCR-A1203","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"ABMRF","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ ABMRF","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ ABMRF"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"PsyLabs","sponsor":"Psyence Biomed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyLabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PsyLabs \/ Psyence Biomed","highestDevelopmentStatusID":"6","companyTruncated":"PsyLabs \/ Psyence Biomed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"5 Horizons Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Naproxen","moa":"||COX-1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sen-Jam Pharmaceutical \/ 5 Horizons Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Pharmaceutical \/ 5 Horizons Capital"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aragen Life Sciences \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ Clearmind Medicine"},{"orgOrder":0,"company":"SABI Mind","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SABI Mind","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SABI Mind \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SABI Mind \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tempero Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Oral Capsule","sponsorNew":"Tempero Bio \/ 8VC","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ 8VC"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"IMP Clinical Supply Services","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ IMP Clinical Supply Services","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ IMP Clinical Supply Services"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Origin Therapeutics","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Origin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Origin Therapeutics \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Origin Therapeutics \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cyproheptadine Hydrochloride","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kinnov Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kinnov Therapeutics \/ ECSOR","highestDevelopmentStatusID":"8","companyTruncated":"Kinnov Therapeutics \/ ECSOR"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Adenomed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Adenomed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Adenomed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Boudicca Dx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Boudicca Dx","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Boudicca Dx"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Maxim Group LLC"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Awakn Life Sciences Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Cybin","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Cybin"},{"orgOrder":0,"company":"Camino Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Camino Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Camino Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Camino Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Journey Colab","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Journey Colab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Colab \/ MBX Capital","highestDevelopmentStatusID":"4","companyTruncated":"Journey Colab \/ MBX Capital"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adamis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Psilera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PSIL-006","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psilera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Inapplicable"},{"orgOrder":0,"company":"Awakn Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Awakn Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Awakn Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Awakn Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"B.More","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B.More \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ Inapplicable"},{"orgOrder":0,"company":"B.More","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B.More \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPJ-001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen","moa":"||COX-1","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ UMass Chan Medical School","highestDevelopmentStatusID":"2","companyTruncated":"Astellas Pharma \/ UMass Chan Medical School"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Simcere Zaiming","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Simcere Zaiming","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Simcere Zaiming"},{"orgOrder":0,"company":"Xcovery","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xcovery \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Inapplicable"},{"orgOrder":0,"company":"Xcovery","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xcovery \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP900","moa":"||YES1\/Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biosana Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Biosana Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosana Pharma \/ Alvotech","highestDevelopmentStatusID":"6","companyTruncated":"Biosana Pharma \/ Alvotech"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder for Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder for Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder for Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IgGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Inapplicable"},{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Vivimed Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivimed Labs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivimed Labs \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seattle Gummy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Inapplicable"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Funding","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"Conatus Pharmaceuticals","sponsor":"Histogen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Conatus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Conatus Pharmaceuticals \/ Histogen","highestDevelopmentStatusID":"6","companyTruncated":"Conatus Pharmaceuticals \/ Histogen"},{"orgOrder":0,"company":"Histogen","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Conatus Pharmaceuticals"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX72021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX72021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Cholestenone-5-alpha-reductase","graph1":"Dermatology","graph2":"Preclinical","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Veradermics","sponsor":"Suvretta Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Veradermics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Veradermics \/ Suvretta Capital","highestDevelopmentStatusID":"9","companyTruncated":"Veradermics \/ Suvretta Capital"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hope Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chime Biologics \/ Hope Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Chime Biologics \/ Hope Medicine"},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hope Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pelage Pharmaceuticals","sponsor":"Main Street Advisors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"PP405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Pelage Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Pelage Pharmaceuticals \/ Main Street Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Pelage Pharmaceuticals \/ Main Street Advisors"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Stemson Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Exicure \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ AbbVie Inc"},{"orgOrder":0,"company":"Ingenza","sponsor":"Amplifica","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ingenza","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ingenza \/ Amplifica","highestDevelopmentStatusID":"1","companyTruncated":"Ingenza \/ Amplifica"},{"orgOrder":0,"company":"Follica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Follica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Follica \/ Inapplicable"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DLQ01","moa":"F2-alpha receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Dermaliq Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ IQVIA"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-beta-1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-beta-1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ET-02","moa":"CD19","graph1":"Dermatology","graph2":"Phase I","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Eirion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eirion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"ViaDerma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Inapplicable"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"ViaDerma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"SRD5A2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Almirall \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Amplifica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMP-303","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Amplifica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifica \/ Inapplicable"},{"orgOrder":0,"company":"Amplifica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMP-303","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Amplifica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifica \/ Inapplicable"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Genoa Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Human Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemson Therapeutics \/ Genoa Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Genoa Ventures"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Triple Hair","sponsor":"Akums Drugs & Pharmaceuticals Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Dermatology","graph2":"Phase II","graph3":"Triple Hair","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Mallia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"LITHUANIA","productType":"Protein","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"CD-38","graph1":"Dermatology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northway Biotechpharma \/ Mallia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Mallia Therapeutics"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX104C","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX104C","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vestige Marketing","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Biotin","moa":"Krebs cycle activatior","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Vestige Marketing","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vestige Marketing \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vestige Marketing \/ Inapplicable"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ALY-101","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Alys Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alys Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"EQ101","moa":"IL-2\/IL-9\/IL-15 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"EQ101","moa":"IL-2\/IL-9\/IL-15 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"IL-2\/IL-9\/IL-15 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Terran Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Terran Biosciences"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"HCW9302","moa":"T-cell","graph1":"Dermatology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"ILT-7 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL-7-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL-7-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"STS-01","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Soterios Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soterios Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"STS-01","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Soterios Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soterios Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Coacillium","moa":"E selectin expression","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Legacy Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Coacillium","moa":"E selectin expression","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Legacy Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Guide Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Guide Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guide Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Guide Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-3001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-3001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Z Factor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Z Factor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AlveoGene","sponsor":"Oxford Science Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"AVG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AlveoGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AlveoGene \/ Oxford Science Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"AlveoGene \/ Oxford Science Enterprises"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VX-634","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VX-814","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korro Bio \/ Eventide Asset Management","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio \/ Eventide Asset Management"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ GSK"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korro Bio \/ Genevant Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio \/ Genevant Sciences"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGN-S11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TGN-S11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Evrys Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"SIRT2","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evrys Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evrys Bio \/ US Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evrys Bio \/ US Department of Defense"},{"orgOrder":0,"company":"Tessellate BIO","sponsor":"Omico","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Tessellate BIO","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessellate BIO \/ Omico","highestDevelopmentStatusID":"2","companyTruncated":"Tessellate BIO \/ Omico"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADEL-Y01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oscotec \/ ADEL Inc","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ ADEL Inc"},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADEL-Y01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oscotec \/ ADEL Inc","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ ADEL Inc"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Posdinemab","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Affinity Asset Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Affinity Asset Advisors","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Affinity Asset Advisors"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ BTIG","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ BTIG"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Leede Jones Gable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Leede Jones Gable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Great Point Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Great Point Partners","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Great Point Partners"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"Jaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JB111","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Jaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Biorasi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"ALZN002","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzamend Neuro \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Biorasi"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"BitNile Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZN002","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzamend Neuro \/ BitNile Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ BitNile Holdings"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ALZN002","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ BofA Securities"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ University of Florida"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"APOE-2\/APOE-3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"APOE-2\/APOE-3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"APOE-2\/APOE-3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LX1001","moa":"APOE-2\/APOE-3","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Cerveau Technologies \/ Lexeo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Cerveau Technologies \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Banner Alzheimer's Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Banner Alzheimer's Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Banner Alzheimer's Institute \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Banner Alzheimer's Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"AL003","moa":"CD33","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ AbbVie Inc"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Halozyme Therapeutics \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ AbbVie Inc"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Astrocyte Pharmaceuticals \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PRX005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"PRX005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ National Institute on Aging"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"||MTBR-tau","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"||Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"University of Kentucky","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kentucky","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Kentucky \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Kentucky \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Citigroup","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Citigroup"},{"orgOrder":0,"company":"APRINOIA Therapeutics","sponsor":"ROSS Acquisition Corp II","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"APNmAb005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"APRINOIA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II","highestDevelopmentStatusID":"6","companyTruncated":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gosuranemab","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Aphios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"||PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aphios \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai Inc \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Biogen"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"IND Enabling","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Alliance Global Partners"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Inapplicable"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Alzheimer's Memory Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alzheimer\\'s Memory Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzheimer\\'s Memory Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzheimer\\'s Memory Center \/ Inapplicable"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Neurotrope"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Hoag","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Hoag","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Hoag"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ K2 HealthVentures"},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Axoltis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"NX210c","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"InSilicoTrials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InSilicoTrials \/ Axoltis Pharma","highestDevelopmentStatusID":"6","companyTruncated":"InSilicoTrials \/ Axoltis Pharma"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Lonza Group","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Lonza Group"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ AC Immune"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BMD-001","moa":"miR-485-3p","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biorchestra \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestra \/ Inapplicable"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"BMD-001","moa":"miR-485-3p","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biorchestra \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestra \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ European Innovation Council","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ European Innovation Council"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Semorinemab","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Semorinemab","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ AC Immune"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Banner Alzheimer\u2019s Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VY7523","moa":"C-terminal epitope Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Regeneration Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RB-ADSC","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Regeneration Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Regeneration Biomedical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regeneration Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Neomorph","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Neomorph","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neomorph \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ Biogen"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LHP588","moa":"Gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lighthouse Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LHP588","moa":"Gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lighthouse Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"DGX-001","moa":"AVPR1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Viage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Neurology","graph2":"Preclinical","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DTx Pharma \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"4","companyTruncated":"DTx Pharma \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"reMYND","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"reMYND \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ Inapplicable"},{"orgOrder":0,"company":"reMYND","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"reMYND \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ Inapplicable"},{"orgOrder":0,"company":"reMYND","sponsor":"Korys Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"reMYND \/ Korys Investments","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ Korys Investments"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"Treventis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Treventis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treventis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Treventis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biotech \/ Core One Labs"},{"orgOrder":0,"company":"Cure Genetics","sponsor":"Frametact","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cure Genetics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cure Genetics \/ Frametact","highestDevelopmentStatusID":"3","companyTruncated":"Cure Genetics \/ Frametact"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Donepezil","moa":"||AChE","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vitalunga","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Vitalunga","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitalunga \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"2","companyTruncated":"Vitalunga \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Eisai \/ Washington University School of Medicine"},{"orgOrder":0,"company":"University of Oslo","sponsor":"BioArctic AB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"APOE","graph1":"Neurology","graph2":"Discovery","graph3":"University of Oslo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Oslo \/ BioArctic AB","highestDevelopmentStatusID":"2","companyTruncated":"University of Oslo \/ BioArctic AB"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRx-237-801","moa":"Tau aggregation","graph1":"Neurology","graph2":"IND Enabling","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Universitat Aut\u00f2noma de Barcelona","sponsor":"Anew Medical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Universitat Aut\u00f2noma de Barcelona","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Universitat Aut\u00f2noma de Barcelona \/ Anew Medical","highestDevelopmentStatusID":"4","companyTruncated":"Universitat Aut\u00f2noma de Barcelona \/ Anew Medical"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC-0027875","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC-0027875","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD680","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"GliaPharm","sponsor":"Wyss Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"GliaPharm","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GliaPharm \/ Wyss Center","highestDevelopmentStatusID":"3","companyTruncated":"GliaPharm \/ Wyss Center"},{"orgOrder":0,"company":"AC Immune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"ACI3024","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AC Immune \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"AC Immune \/ Eli Lilly"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASN90","moa":"OGA","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron \/ Inapplicable"},{"orgOrder":0,"company":"Concept Life Sciences","sponsor":"AstronauTx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Astrocyte","graph1":"Neurology","graph2":"Discovery","graph3":"Concept Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Concept Life Sciences \/ AstronauTx","highestDevelopmentStatusID":"2","companyTruncated":"Concept Life Sciences \/ AstronauTx"},{"orgOrder":0,"company":"Medicines Discovery Catapult","sponsor":"Alchemab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Medicines Discovery Catapult","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicines Discovery Catapult \/ Alchemab","highestDevelopmentStatusID":"2","companyTruncated":"Medicines Discovery Catapult \/ Alchemab"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DUBs","graph1":"Neurology","graph2":"Discovery","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mission Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Mission Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Chk-1\/2","graph1":"Neurology","graph2":"Discovery","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Birmingham \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"University of Birmingham \/ Inapplicable"},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Discovery","graph3":"Wren Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wren Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"2","companyTruncated":"Wren Therapeutics \/ Baupost Group"},{"orgOrder":0,"company":"Oxford Drug Discovery","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Oxford Drug Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Drug Discovery \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Drug Discovery \/ Exscientia"},{"orgOrder":0,"company":"AstronauTx","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AstronauTx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstronauTx \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"AstronauTx \/ Novartis Venture Fund"},{"orgOrder":0,"company":"TRIMTECH Therapeutics","sponsor":"Cambridge Innovation Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"TRIM21","graph1":"Neurology","graph2":"Preclinical","graph3":"TRIMTECH Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"TRIMTECH Therapeutics \/ Cambridge Innovation Capital","highestDevelopmentStatusID":"4","companyTruncated":"TRIMTECH Therapeutics \/ Cambridge Innovation Capital"},{"orgOrder":0,"company":"Neurodon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurodon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurodon \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"Neurodon \/ National Institute on Aging"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Biogen","highestDevelopmentStatusID":"2","companyTruncated":"C4 Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Aitia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Charles River Laboratories, Inc \/ Aitia","highestDevelopmentStatusID":"2","companyTruncated":"Charles River Laboratories, Inc \/ Aitia"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VG-3927","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icapamespib","moa":"Epichaperome","graph1":"Neurology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VG-3927","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arkuda Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"ARKD-104","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Arkuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arkuda Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Arkuda Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"C101248","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"C101248","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"SBIR","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cayman Chemical Company Inc \/ SBIR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Chemical Company Inc \/ SBIR"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"CCM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"CCM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CCM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CCM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"PF-05251749","moa":"CK1","graph1":"Neurology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Biogen"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olatec Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Olatec Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Metabolon\u202f","sponsor":"BioFINDER","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Metabolon\u202f","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metabolon\u202f \/ BioFINDER","highestDevelopmentStatusID":"2","companyTruncated":"Metabolon\u202f \/ BioFINDER"},{"orgOrder":0,"company":"EydisBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EydisBio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"EydisBio \/ National Institutes of Health"},{"orgOrder":0,"company":"DZNE","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"DZNE","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DZNE \/ Eisai","highestDevelopmentStatusID":"2","companyTruncated":"DZNE \/ Eisai"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Cleveland Clinic"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Inapplicable"},{"orgOrder":0,"company":"UC Berkeley","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"UC Berkeley","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UC Berkeley \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"UC Berkeley \/ Genentech"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Canary Speech","sponsor":"Halia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Canary Speech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canary Speech \/ Halia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Canary Speech \/ Halia Therapeutics"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PBT2","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Professor Colin Masters","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PBT2","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Professor Colin Masters","highestDevelopmentStatusID":"4","companyTruncated":"Alterity Therapeutics \/ Professor Colin Masters"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shape Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Shape Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"COR588","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AVANIR PHARMS","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Deudextromethorphan Hydrobromide","moa":"||MAO","graph1":"Neurology","graph2":"Phase III","graph3":"AVANIR PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc."},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Yale University"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Ault Global Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Ault Global Holdings"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Digital Power Lending","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Digital Power Lending","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Digital Power Lending"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Neurology","graph2":"Phase I","graph3":"SciNeuro Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciNeuro Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciNeuro Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Neurology","graph2":"Phase I","graph3":"SciNeuro Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciNeuro Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciNeuro Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"The Israeli Medical Center for Alzheimer's","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"The Israeli Medical Center for Alzheimer's","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Israeli Medical Center for Alzheimer's \/ SciSparc","highestDevelopmentStatusID":"8","companyTruncated":"The Israeli Medical Center for Alzheimer's \/ SciSparc"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deudextromethorphan Hydrobromide","moa":"||MAO","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Holdings \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deudextromethorphan Hydrobromide","moa":"||MAO","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Moleac","sponsor":"National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"MLC901","moa":"Cholinesterase","graph1":"Neurology","graph2":"Phase II","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Moleac \/ National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Moleac \/ National University Hospital"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"MK-1167","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.48999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Neuphoria Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ National Institute on Aging"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Undisclosed"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"T3D-959","moa":"PPA-delta\/gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"T3D-959","moa":"PPA-delta\/gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"T3D-959","moa":"PPA-delta\/gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Canaccord Genuity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Bionomics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Donepepzil","moa":"||nACh receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bionomics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Bionomics \/ Merck & Co"},{"orgOrder":0,"company":"KeifeRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"KeifeRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KeifeRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KeifeRx \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"||NMDA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Galantamine Hydrobromide","moa":"ACh receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Prolonged Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Essential Pharma"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biotech \/ Core One Labs"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biotech \/ Core One Labs"},{"orgOrder":0,"company":"Core One Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Core One Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Core One Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Core One Labs \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"GNS healthcare","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Arvinas \/ GNS healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Arvinas \/ GNS healthcare"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aphios","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Bryoid","moa":"PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Aphios \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ National Institute on Aging"},{"orgOrder":0,"company":"Aphios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Bryoid","moa":"PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Aphios \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ Inapplicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ Inapplicable"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ O-Bank Co., Ltd."},{"orgOrder":0,"company":"Spinogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"AmyriAD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AmyriAD \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ Inapplicable"},{"orgOrder":0,"company":"AmyriAD","sponsor":"Societal CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AmyriAD \/ Societal CDMO","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ Societal CDMO"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Roskamp Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nilvadipine","moa":"L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Roskamp Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Roskamp Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Roskamp Institute \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"AmyriAD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ AmyriAD","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ AmyriAD"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Idalopirdine","moa":"5-HT6 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Denovo Biopharma"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Genuv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"MEK1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genuv \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Cleveland Clinic","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Cleveland Clinic"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ SK Chemicals"},{"orgOrder":0,"company":"Mediforum","sponsor":"Vision Sensing Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"PM012","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Mediforum","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mediforum \/ Vision Sensing Acquisition Corp","highestDevelopmentStatusID":"9","companyTruncated":"Mediforum \/ Vision Sensing Acquisition Corp"},{"orgOrder":0,"company":"AriBio","sponsor":"Adaptive Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Adaptive Research","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Adaptive Research"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Undisclosed"},{"orgOrder":0,"company":"Genuv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"MEK1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genuv \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Inapplicable"},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"EI-1071","moa":"CSF-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron Immunotherapeutics \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Pangu Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"EI-1071","moa":"CSF-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Pangu Capital","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron Immunotherapeutics \/ Pangu Capital"},{"orgOrder":0,"company":"IXICO","sponsor":"Cyclerion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase II","graph3":"IXICO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IXICO \/ Cyclerion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"IXICO \/ Cyclerion Therapeutics"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GAL-201","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galimedix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GAL-201","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galimedix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Alerce Medical Technology Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series E Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Alerce Medical Technology Partners","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Alerce Medical Technology Partners"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ National Institute on Aging"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Burke Neurological Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Funding","leadProduct":"Benfotiamine","moa":"Transketolase","graph1":"Neurology","graph2":"Phase II","graph3":"Burke Neurological Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Burke Neurological Institute \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Burke Neurological Institute \/ National Institutes of Health"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Hauck Aufh\u00e4user Lampe Privatbank AG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Hauck Aufh\u00e4user Lampe Privatbank AG","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Hauck Aufh\u00e4user Lampe Privatbank AG"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Nordic Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Nordic Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Nordic Bioscience"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masupirdine","moa":"||5-HT6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masupirdine","moa":"||5-HT6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Linical","sponsor":"Alpha Cognition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Linical \/ Alpha Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Linical \/ Alpha Cognition"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Genetika","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"Genetika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Genetika \/ NeuroSense Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genetika \/ NeuroSense Therapeutics"},{"orgOrder":0,"company":"Evonik","sponsor":"Cassava Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Evonik \/ Cassava Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Evonik \/ Cassava Sciences"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"B. Dyson Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ B. Dyson Capital Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ B. Dyson Capital Advisors"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institute on Aging"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MorphoSys \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"LifeSci Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ LifeSci Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ LifeSci Capital LLC"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Maxim Group LLC"},{"orgOrder":0,"company":"INmune Bio","sponsor":"OmniScience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ OmniScience","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ OmniScience"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Walgreens","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Walgreens","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Walgreens \/ Prothena","highestDevelopmentStatusID":"6","companyTruncated":"Walgreens \/ Prothena"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Axon Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Axon Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AC Immune","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Axon Drugs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Drugs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Axon Drugs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Drugs \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Houston Methodist Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Houston Methodist Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Houston Methodist Research Institute"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Hyaluronidase Enzyme","moa":"||Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARScience Bio","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"ARScience Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARScience Bio \/ Coya Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ARScience Bio \/ Coya Therapeutics"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NDX-1017","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"NDX-1017","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Perceptive Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Perceptive Advisors"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Charsire Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Multiglycan Complex","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Charsire Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Charsire Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Charsire Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Injection","sponsorNew":"Zylo Therapeutics \/ Silo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Zylo Therapeutics \/ Silo Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Exeltis"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Myung In Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Myung In Pharm"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Zambon Group SpA","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Zambon Group SpA"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Santa Lucia Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Santa Lucia Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Santa Lucia Foundation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Santa Lucia Foundation \/ Inapplicable"},{"orgOrder":0,"company":"MedRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"MedRx \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MedRx \/ Inapplicable"},{"orgOrder":0,"company":"ICURE PHARM, INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"ICURE PHARM, INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"ICURE PHARM, INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ICURE PHARM, INC \/ Inapplicable"},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Phase III","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daehwa Pharmaceutical Co. Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GNE-0723","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DNL919","moa":"TREM2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Bioresearch \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Bioresearch \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"CST-3056","moa":"Adrenergic-alpha-1A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"CuraSen Therapeutics \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Gabaeron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human IPSC-Derived Interneuron Progenitors","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Gabaeron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabaeron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gabaeron \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"ST-501","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sangamo Therapeutics \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Biogen"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"Duvax","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"AV-1959D","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Beta-Amyloid Vaccine","moa":"Beta-amyloid","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"University of California","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ National Institute on Aging"},{"orgOrder":0,"company":"Gates Biomanufacturing Facility","sponsor":"Institute for Molecular Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV-1980R","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Gates Biomanufacturing Facility","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gates Biomanufacturing Facility \/ Institute for Molecular Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Gates Biomanufacturing Facility \/ Institute for Molecular Medicine"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bepranemab","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"THN391","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therini Bio \/ Dementia Discovery Fund","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Dementia Discovery Fund"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"THN391","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therini Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"NSERC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"INM-900","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ NSERC","highestDevelopmentStatusID":"4","companyTruncated":"InMed Pharmaceuticals \/ NSERC"},{"orgOrder":0,"company":"Universite de Sherbrooke Department of Medicine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"||DGAT","graph1":"Neurology","graph2":"Preclinical","graph3":"Universite de Sherbrooke Department of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclica \/ Arctoris","highestDevelopmentStatusID":"1","companyTruncated":"Cyclica \/ Arctoris"},{"orgOrder":0,"company":"DP Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPT0416","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DP Technology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Inapplicable"},{"orgOrder":0,"company":"Muna Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Muna Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Muna Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Muna Therapeutics \/ GSK"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PRX123","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Allergan Aesthetics","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT\u2011240","moa":"AOPE","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"InSysBio","sponsor":"Discoveric Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"NIDB-3101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"InSysBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSysBio \/ Discoveric Bio","highestDevelopmentStatusID":"4","companyTruncated":"InSysBio \/ Discoveric Bio"},{"orgOrder":0,"company":"Cureverse","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"CV-01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cureverse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cureverse \/ Angelini Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Cureverse \/ Angelini Pharma"},{"orgOrder":0,"company":"ANL Bio","sponsor":"Biovian","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"ANL-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"ANL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANL Bio \/ Biovian","highestDevelopmentStatusID":"4","companyTruncated":"ANL Bio \/ Biovian"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AD1503","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ALZ-201","moa":"Amyloid-beta-42 aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"BAN1503","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.3500000000000001,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"BAN1503","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":1.3500000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.3500000000000001,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"BAN2802","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Eisai Inc","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Eisai Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trontinemab","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ASN51","moa":"OGA","graph1":"Neurology","graph2":"Phase II","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asceneuron \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Asceneuron \/ EQT Life Sciences"},{"orgOrder":0,"company":"Merry Life Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Curcumin Analog","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Merry Life Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merry Life Biomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Merry Life Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MAPT N279K","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DSP-0038","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Sumitomo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Neuro-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NBP14","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuro-Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuro-Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neuro-Bio \/ Inapplicable"},{"orgOrder":0,"company":"Jawaharlal Nehru Centre for Advanced Scientific Research","sponsor":"IGC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Jawaharlal Nehru Centre for Advanced Scientific Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jawaharlal Nehru Centre for Advanced Scientific Research \/ IGC Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Jawaharlal Nehru Centre for Advanced Scientific Research \/ IGC Pharma"},{"orgOrder":0,"company":"Aevisbio","sponsor":"KB investment","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"3,6\u2019-dithiopomalidomide","moa":"TNF-alpha receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aevisbio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevisbio \/ KB investment","highestDevelopmentStatusID":"5","companyTruncated":"Aevisbio \/ KB investment"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EM-036","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuMentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EuMentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VENT-02","moa":"NLRP3","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMRA-511","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Damona Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DPX-101","moa":"Alpha-5-GABAA-R","graph1":"Neurology","graph2":"Preclinical","graph3":"Damona Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Damona Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Damona Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"NB-02","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VY1706","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Columbia University"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SPC-14","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Burke Neurological Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Burke Neurological Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burke Neurological Institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Burke Neurological Institute \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PPeptide-conjugated Ketamine","moa":"Glutamate allosteic receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"AIkido Pharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIkido Pharm \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Praetego","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"PTG-630","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Praetego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praetego \/ National Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"Praetego \/ National Eye Institute"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irvine School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Irvine School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"TTR mRNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"TTR mRNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"ATTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"ATTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"University of Tennessee Graduate School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ University of Tennessee Graduate School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ University of Tennessee Graduate School of Medicine"},{"orgOrder":0,"company":"Corino Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolcapone","moa":"COMT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Corino Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corino Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corino Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"American Porphyria Foundation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"American Porphyria Foundation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Porphyria Foundation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"American Porphyria Foundation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nucresiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"TTR mRNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Brain Trust Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Riluzole","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"Brain Trust Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Brain Trust Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Brain Trust Bio \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ARO-SOD1","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ION541","moa":"Ataxin-2","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION541","moa":"Ataxin-2","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ION363","moa":"FUS","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION363","moa":"FUS","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"AcuraStem","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AS-202","moa":"PIKfyve","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"AcuraStem \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AcuraStem","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Funding","leadProduct":"AS-202","moa":"PIKfyve","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"AcuraStem \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ US Department of Defense"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ EQT Life Sciences"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Abbhi Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Abbhi Investments","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Abbhi Investments"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB078","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BIIB078","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"PrimeStreet Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ PrimeStreet Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ PrimeStreet Capital"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novus Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anelixis Therapeutics","sponsor":"Novus Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Anelixis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anelixis Therapeutics \/ Novus Therapeutics, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anelixis Therapeutics \/ Novus Therapeutics, Inc"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CK0803","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CK0803","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALS001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALS001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EpicentRx","sponsor":"FightMND","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"RRx-001","moa":"CD47","graph1":"Neurology","graph2":"Preclinical","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"EpicentRx \/ FightMND"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aruna Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Progranulin","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Progranulin","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Progranulin","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VCAP-102","moa":"SOD1","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Coya Therapeutics"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ ALS Association"},{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Insitro","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insitro \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Insitro \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Insitro","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insitro \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Insitro \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Libra Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Libra Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Libra Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Libra Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Modulo Bio","sponsor":"Initialized Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Modulo Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Modulo Bio \/ Initialized Capital","highestDevelopmentStatusID":"2","companyTruncated":"Modulo Bio \/ Initialized Capital"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Eli Lilly"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Blackrock","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Blackrock","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Blackrock"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NB-4746","moa":"SARM1","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Caffeine","moa":"||SARM1","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ US Department of Defense"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Ferrer Internacional"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Arbor Biotechnologies, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Molecular Therapeutics \/ Arbor Biotechnologies, Inc","highestDevelopmentStatusID":"4","companyTruncated":"4D Molecular Therapeutics \/ Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"Locanabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Hexanucleotide","graph1":"Neurology","graph2":"Preclinical","graph3":"Locanabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Locanabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Locanabio \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"miR-155","graph1":"Neurology","graph2":"Preclinical","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regulus Therapeutics \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Regulus Therapeutics \/ Brigham and Women's Hospital"},{"orgOrder":0,"company":"Trace Neuroscience","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Trace Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trace Neuroscience \/ Third Rock Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Trace Neuroscience \/ Third Rock Ventures"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe Therapeutics \/ Biogen"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"eIF2B","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"VectorY","sponsor":"Annogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Annogen","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Annogen"},{"orgOrder":0,"company":"Intravacc","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Polyglycine alanine","graph1":"Neurology","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intravacc \/ European Union","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ European Union"},{"orgOrder":0,"company":"VectorY","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Forbion"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotuletinib","moa":"CSF-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"The Sheffield Institute for Translational Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-34712","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience","highestDevelopmentStatusID":"5","companyTruncated":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"ALS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NRG Therapeutics \/ ALS Foundation","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ ALS Foundation"},{"orgOrder":0,"company":"Aquinnah Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Aquinnah Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aquinnah Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Aquinnah Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Faze Medicines","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Faze Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Faze Medicines \/ Third Rock Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Faze Medicines \/ Third Rock Ventures"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Capsida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CRISPR Therapeutics \/ Capsida","highestDevelopmentStatusID":"3","companyTruncated":"CRISPR Therapeutics \/ Capsida"},{"orgOrder":0,"company":"Eikonizo Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"EKZ-102","moa":"HDAC-6","graph1":"Neurology","graph2":"IND Enabling","graph3":"Eikonizo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eikonizo Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Eikonizo Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CVN293","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QRL-101","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amylyx Pharmaceuticals \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Target ALS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ Target ALS Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Target ALS Foundation"},{"orgOrder":0,"company":"Disarm Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"Preclinical","graph3":"Disarm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Disarm Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Disarm Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Myrobalan Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Myrobalan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Myrobalan Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Myrobalan Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"QurAlis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QurAlis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Eli Lilly"},{"orgOrder":0,"company":"QurAlis","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QurAlis \/ Polaris Partners","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Polaris Partners"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Financing","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Yumanity Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Anew Medical","sponsor":"Redwoods Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anew Medical \/ Redwoods Acquisition Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Anew Medical \/ Redwoods Acquisition Corp."},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Eikonizo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"HDAC-6","graph1":"Neurology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"McQuade Center for Strategic Research and Development \/ Eikonizo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Eikonizo Therapeutics"},{"orgOrder":0,"company":"Mitochon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MP101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Mitochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mitochon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mitochon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"FightMND","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"M102","moa":"Nrf2","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Therapeutics \/ FightMND"},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"Medical College of Wisconsin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"M102","moa":"Nrf2","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ Medical College of Wisconsin","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Therapeutics \/ Medical College of Wisconsin"},{"orgOrder":0,"company":"FundaMental Pharma","sponsor":"BGV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"FundaMental Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FundaMental Pharma \/ BGV","highestDevelopmentStatusID":"4","companyTruncated":"FundaMental Pharma \/ BGV"},{"orgOrder":0,"company":"Alpha-5 integrin","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Alpha-5 integrin","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha-5 integrin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpha-5 integrin \/ Pasithea Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpha-5 integrin \/ Pasithea Therapeutics"},{"orgOrder":0,"company":"Georgetown University","sponsor":"KeifeRx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"KFRX03","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Georgetown University \/ KeifeRx","highestDevelopmentStatusID":"5","companyTruncated":"Georgetown University \/ KeifeRx"},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kineta \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Merck & Co"},{"orgOrder":0,"company":"Aural Analytics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Aural Analytics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aural Analytics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aural Analytics \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase II","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"WideTrial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ WideTrial","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ WideTrial"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Orphazyme","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ Orphazyme"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"IL-12 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"IL-12 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OrphAI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Neurology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"||IL-12 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kintai Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kintai Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"The University of Kansas","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"PharmaTher \/ The University of Kansas","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ The University of Kansas"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProJenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prosetin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ProJenX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ Inapplicable"},{"orgOrder":0,"company":"ProJenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prosetin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ProJenX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ Inapplicable"},{"orgOrder":0,"company":"Treeway","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Treeway","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Treeway \/ Specialised Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Treeway \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Morningside Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Morningside Ventures"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Viking Global Investors","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Viking Global Investors"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"The Canadian Neuromuscular Disease Registry","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ The Canadian Neuromuscular Disease Registry","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ The Canadian Neuromuscular Disease Registry"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Treeway","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Treeway","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Treeway"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ George Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ George Clinical"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Maryland Board of Public Works","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Maryland Board of Public Works","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Maryland Board of Public Works"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis II, LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Series D Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis II, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis II, LLC"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Astellas Pharma"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DNL788","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DNL788","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"The ALS Association","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirasemtiv","moa":"Troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ The ALS Association","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ The ALS Association"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CB03","moa":"KCNQ2\/3","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"VectorY","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ MRL Ventures Fund","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ MRL Ventures Fund"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"UMC Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ UMC Utrecht","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ UMC Utrecht"},{"orgOrder":0,"company":"VectorY","sponsor":"University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ University Medical Center"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Biogen"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"NeuraLight","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ NeuraLight","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ NeuraLight"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"PhaseV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ PhaseV","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ PhaseV"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuromagen Pharma","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"AGS-499","moa":"TERT","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuromagen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Neuromagen Pharma \/ Israel Innovation Authority","highestDevelopmentStatusID":"4","companyTruncated":"Neuromagen Pharma \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Tikomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LMW-Dextran Sulfate","moa":"TGF-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ Inapplicable"},{"orgOrder":0,"company":"Tikomed","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"LMW-Dextran Sulfate","moa":"TGF-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ IQVIA"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avextra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avextra \/ Inapplicable"},{"orgOrder":0,"company":"Charit\u00e9 Universit\u00e4tsmedizin","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Adrenergic-beta-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Charit\u00e9 Universit\u00e4tsmedizin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charit\u00e9 Universit\u00e4tsmedizin \/ Actimed Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Charit\u00e9 Universit\u00e4tsmedizin \/ Actimed Therapeutics"},{"orgOrder":0,"company":"Locanabio","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"C9orf2 -ALS","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Locanabio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locanabio \/ Vida Ventures LLC","highestDevelopmentStatusID":"2","companyTruncated":"Locanabio \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Funding","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloom Science \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Science \/ ALS Association"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"NPT1220-312","moa":"Toll-like-2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuropore Therapies \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore Therapies \/ ALS Association"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PAS-003","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Alpha-5 integrin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"PAT 103","moa":"Alpha-5\/beta-1 integrin","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Alpha-5 integrin","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea Therapeutics \/ Alpha-5 integrin"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PAS-003","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Raya Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raya Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raya Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Aeterna Zentaris"},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Aeterna Zentaris"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RAG-17","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"RXR nuclear receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Brainever","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Homeoprotein Engrailed 1","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Brainever","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brainever \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Brainever \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"CTx-TFEB","moa":"Transcription Factor EB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AstroRx","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV-VecTabs","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ORY-4001","moa":"HDAC-6","graph1":"Neurology","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ ALS Association"},{"orgOrder":0,"company":"Alchemab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alchemab \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ Eli Lilly"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Faraday Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Adrenergic-beta-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Faraday Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Faraday Pharmaceuticals"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Adrenergic-beta-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Universities of Liverpool","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Neurology","graph2":"Preclinical","graph3":"Universities of Liverpool","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universities of Liverpool \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Universities of Liverpool \/ Inapplicable"},{"orgOrder":0,"company":"University of Kansas","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kansas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"University of Kansas \/ PharmaTher"},{"orgOrder":0,"company":"Apic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"APB-102","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apic Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Apic Bio","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"APB-102","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apic Bio \/ Uniqure","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/ Uniqure"},{"orgOrder":0,"company":"QurAlis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"QRL-204","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Eli Lilly"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"QRA-244","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"QRA-244","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"QRA-244","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"SOLA Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SOL-257","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"SOLA Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLA Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SOLA Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"15-LOX","graph1":"Neurology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Woolsey Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woolsey Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Woolsey Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Woolsey Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woolsey Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Woolsey Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Topiramate","moa":"Caveolin-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikonoklastes Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklastes Therapeutics \/ Forge Biologics"},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Topiramate","moa":"Caveolin-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikonoklastes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklastes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"FundaMental Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FP802","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"FundaMental Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FundaMental Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"FundaMental Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Treg-Derived Exosome","moa":"T-cell","graph1":"Neurology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Neurizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Neurizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Neurizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASHA-624","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"The ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"ASHA-624","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Therapeutics \/ The ALS Association","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ The ALS Association"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leal Therapeutics","sponsor":"Chugai Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"LTX-002","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Leal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leal Therapeutics \/ Chugai Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Leal Therapeutics \/ Chugai Venture Fund"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"AMX0114","moa":"CAPN2","graph1":"Neurology","graph2":"Phase I","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"SineuGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SNUG01","moa":"TRIM72","graph1":"Neurology","graph2":"Phase I","graph3":"SineuGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"SineuGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SineuGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QRL-101","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Harrow","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Harrow"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Crescita Therapeutics \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"KALEO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2022","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valeo Pharma \/ KALEO INC","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ KALEO INC"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Nasal Dry Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ OrbiMed Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ OrbiMed Advisors"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dipivefrin","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Acquisition","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Aimmune Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"ALK","sponsor":"Grandpharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Epinephrine Bitartrate","moa":"Adrenergic-alpha-1A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"ALK \/ Grandpharma","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Grandpharma"},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Windgap Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Windgap Medical \/ Taiwania Capital","highestDevelopmentStatusID":"1","companyTruncated":"Windgap Medical \/ Taiwania Capital"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"De Motu Cordis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"De Motu Cordis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"De Motu Cordis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"De Motu Cordis \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tolmar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tolmar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Vifor Pharma"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Blau Farmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Epoetin Alpha","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"JSR Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"JSR Life Sciences \/ Blau Farmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"JSR Life Sciences \/ Blau Farmaceutica"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Polifarma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Darbepoetin Alpha","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Polifarma","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Polifarma"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB-331","moa":"Matriptase-2","graph1":"Hematology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Sanofi \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Rallybio"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ NovaQuest Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog-1","graph1":"Hematology","graph2":"Approved FDF","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Wanbury Limited","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Folic Acid","moa":"||Dihydrofolate reductase","graph1":"Hematology","graph2":"Approved FDF","graph3":"Wanbury Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Wanbury Limited \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Wanbury Limited \/ Cipla"},{"orgOrder":0,"company":"Spherix Global Insights","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spherix Global Insights","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spherix Global Insights \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Spherix Global Insights \/ Astellas Pharma"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0998","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Preclinical","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HemaXellerate","moa":"Undisclosed","graph1":"Hematology","graph2":"IND Enabling","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Fulcrum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Fulcrum Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"CAMP4 Therapeutics \/ Fulcrum Therapeutics"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Hematology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ANX1502","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Hematology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Vifor Pharma","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Vifor Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vifor Pharma \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"Vifor Pharma \/ CSL"},{"orgOrder":0,"company":"Vifor Pharma","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Vifor Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vifor Pharma \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"Vifor Pharma \/ CSL"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Inapplicable"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"CIAO2B","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuance Pharma \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Nuance Pharma \/ RTW Investments"},{"orgOrder":0,"company":"Nemysis","sponsor":"Avia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Financing","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nemysis \/ Avia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nemysis \/ Avia Pharma"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shield Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sidero Bioscience","sponsor":"SRS Life Sciences Pte ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"FTH1","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sidero Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidero Bioscience \/ SRS Life Sciences Pte ltd","highestDevelopmentStatusID":"1","companyTruncated":"Sidero Bioscience \/ SRS Life Sciences Pte ltd"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Kamau Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Kamau Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Kamau Therapeutics"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Sickle Cell Disease Association Of America","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Sickle Cell Disease Association Of America","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Sickle Cell Disease Association Of America"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Aruvant Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Aruvant Sciences"},{"orgOrder":0,"company":"RoslinCT","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"RoslinCT","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RoslinCT \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RoslinCT \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Hercules Capital"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Medicaid","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Medicaid","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Medicaid"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ DRI Healthcare Trust","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTQ923","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTQ923","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aldevron","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aldevron \/ Aruvant Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Aldevron \/ Aruvant Sciences"},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tessera Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tessera Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"IMMvention Therapeutix","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"IMM\u2013004","moa":"BACH1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IMMvention Therapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"IMMvention Therapeutix \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"IMMvention Therapeutix \/ Novo Nordisk"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"DHA level","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"15","companyTruncated":"Lobe Sciences \/ Pentec Health"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BEAM-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BEAM-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BEAM-101","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, And Blood Institute"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Newco","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Newco","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Newco"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olinciguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Theris Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Theris Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Patch","sponsorNew":"Theris Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theris Medical \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"E-selectin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Indian Council of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"ExCellThera","sponsor":"IRICoR","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExCellThera \/ IRICoR","highestDevelopmentStatusID":"4","companyTruncated":"ExCellThera \/ IRICoR"},{"orgOrder":0,"company":"Kind Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AND017","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kind Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kind Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kind Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Global Blood Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Global Blood Therapeutics"},{"orgOrder":0,"company":"Hitachi Chemicals","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hitachi Chemicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hitachi Chemicals \/ Bluebird Bio","highestDevelopmentStatusID":"7","companyTruncated":"Hitachi Chemicals \/ Bluebird Bio"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Orna Therapeutics","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.69999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Orna Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Orna Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Magenta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"MGTA-117","moa":"CD117","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Magenta Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Beam Therapeutics \/ Magenta Therapeutics"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lipid Nanoparticles","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Collaboration","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"PBGENE-HbE","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Hematology","graph2":"Preclinical","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwality Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kwality Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.16,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"Alliance Pharmaceutical Company","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"EGYPT","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tetracaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alliance Pharmaceutical Company","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alliance Pharmaceutical Company \/ Valeo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Alliance Pharmaceutical Company \/ Valeo Pharma"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"A.forall","sponsor":"Sagent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A.forall \/ Sagent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"A.forall \/ Sagent Pharmaceuticals"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Gesval S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Gesval S.A","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Gesval S.A"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Vitruvias Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Vitruvias Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Vitruvias Therapeutics"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Milla Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Slayback Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cisatracurium Besylate","moa":"nACh receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Lidocaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Sandoz B2B"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zinc Sulphate","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Piramal Pharma Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Pharma Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Avet Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avet Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avet Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avet Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RP-2000","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"JOS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ JOS Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ JOS Pharmaceuticals"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"ACh-alpha-4\/beta-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi USA \/ Inapplicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hospira, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Genixus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"ACh-alpha-4\/beta-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genixus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genixus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genixus \/ Inapplicable"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SINTETICA SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SINTETICA SA \/ Inapplicable"},{"orgOrder":0,"company":"Foundation for Angelman Syndrome Therapeutics","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"LB-100","moa":"PP2A","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Foundation for Angelman Syndrome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION582","moa":"UB3EA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ION582","moa":"UB3EA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ION582","moa":"UB3EA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"GeneTx Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ GeneTx Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ GeneTx Biotherapeutics"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Gaboxadol","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Angelini Pharma"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABAA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biom Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BIO017","moa":"TRPV1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Biom Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biom Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biom Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"University of Connecticut","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Gaboxadol","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ University of Connecticut","highestDevelopmentStatusID":"1","companyTruncated":"Ovid Therapeutics \/ University of Connecticut"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"University of North Carolina \/ AskBio"},{"orgOrder":0,"company":"Zylka Lab","sponsor":"University of North Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Zylka Lab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zylka Lab \/ University of North Carolina","highestDevelopmentStatusID":"4","companyTruncated":"Zylka Lab \/ University of North Carolina"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"University of North Carolina \/ AskBio"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Fountain Healthcare Partners"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ranolazine","moa":"SCN4A\/SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isosorbide Mononitrate","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharming \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ General Atlantic","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ General Atlantic"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Ascenta Capital"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series C Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ypsomed \/ Astria Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Ypsomed \/ Astria Therapeutics"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"MALTA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Slayback Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Lyophilized Human C1-esterase","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Pharming","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"OTL-105","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Pharming","highestDevelopmentStatusID":"4","companyTruncated":"Orchard Therapeutics \/ Pharming"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Private Placement","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Catabasis Pharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quellis Biosciences Inc","sponsor":"Catabasis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Quellis Biosciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quellis Biosciences Inc \/ Catabasis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Quellis Biosciences Inc \/ Catabasis Pharmaceuticals"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Short Wave Pharma","sponsor":"The Sheba Center for Eating Disorders","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Short Wave Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Short Wave Pharma \/ The Sheba Center for Eating Disorders","highestDevelopmentStatusID":"7","companyTruncated":"Short Wave Pharma \/ The Sheba Center for Eating Disorders"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Anamorelin HCl","moa":"GHS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Oberland Capital Management"},{"orgOrder":0,"company":"Xpira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Xpira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xpira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xpira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Kings College London","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Kings College London","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Kings College London"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Series B Financing","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Kyorin Pharmaceutical"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Sungen Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SGC001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Beijing Sungen Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Sungen Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Sungen Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GC1109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.23999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Adenovirus-vectored Anthrax Vaccine","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ BARDA"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Adenovirus-vectored Anthrax Vaccine","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"LPOXY Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Sidiprev","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"Xeno Biosciences \/ LPOXY Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ LPOXY Therapeutics"},{"orgOrder":0,"company":"Monash University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"QPX9003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monash University \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monash University \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-155","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Human Biome Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HBI-06","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Human Biome Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Human Biome Institute \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Human Biome Institute \/ Inapplicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Gebro Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"CASI Pharmaceuticals \/ Gebro Pharma","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Gebro Pharma"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Blood coagulation factor","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Covis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Blood coagulation factor","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Covis Pharma \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Norgine"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nanoform \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nanoform \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Inapplicable"},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PN-1007","moa":"IgM","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyneuron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PN-1007","moa":"IgM","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyneuron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GlucoCorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glucocorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alivexis","sponsor":"Melodia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MDI-0151","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alivexis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ Melodia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Alivexis \/ Melodia Therapeutics"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"CFB","graph1":"Immunology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ART5803","moa":"NMDA receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arialys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arialys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Avalon BioVentures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"ART5803","moa":"NMDA receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arialys Therapeutics \/ Avalon BioVentures","highestDevelopmentStatusID":"4","companyTruncated":"Arialys Therapeutics \/ Avalon BioVentures"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marengo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cadrenal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BRII-297","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Endosane Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"PreveCeutical Medical \/ Endosane Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Endosane Pharmaceuticals"},{"orgOrder":0,"company":"GABA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etifoxine","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GABA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"GABA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GABA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glyph Allopregnanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seaport Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaport Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Incannex Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Incannex Healthcare"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Baergic Bio","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"BAER-101","moa":"GABAA-alpha-2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Baergic Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baergic Bio \/ Avenue Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Baergic Bio \/ Avenue Therapeutics"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Grossman School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Grossman School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Filament Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Filament Health","highestDevelopmentStatusID":"5","companyTruncated":"Psyence \/ Filament Health"},{"orgOrder":0,"company":"Filament Health","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Filament Health \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ Psyence"},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxepin Hydrochloride","moa":"H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VQW-765","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Loxapine","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Controlled Substance","year":"2023","type":"Divestment","leadProduct":"Clobazam","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Pharmanovia"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Mind Medicine"},{"orgOrder":0,"company":"Cannex Scientific","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cannex Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cannex Scientific \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Cannex Scientific \/ Brigham and Women's Hospital"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EVM301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Vectura Fertin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurora Cannabis \/ Vectura Fertin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aurora Cannabis \/ Vectura Fertin Pharma"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Synendos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cannabidiol","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Marijuana Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tetrahydrocannabinol Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"MZ Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Tetrahydrocannabinol Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ MZ Group","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ MZ Group"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"4-Ethylphenol Sulfate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldfinch Bio, Inc \/ Karuna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Goldfinch Bio, Inc \/ Karuna Therapeutics"},{"orgOrder":0,"company":"Sensorium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"SENS-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sensorium Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sensorium Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AffaMed Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Avance Clinical"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntelGenx \/ Cybin","highestDevelopmentStatusID":"1","companyTruncated":"IntelGenx \/ Cybin"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"ACH000029","moa":"Adrenergic-alpha-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center","highestDevelopmentStatusID":"4","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incannex Healthcare \/ Monash University","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Monash University"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Series B Financing","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Engrail Therapeutics \/ F-Prime Capital","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ F-Prime Capital"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Engrail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Liechti Lab"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlordiazepoxide","moa":"||Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Exhale Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exhale Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Monash University","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Monash University \/ Incannex Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Monash University \/ Incannex Healthcare"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"BDD Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ BDD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ BDD Pharma"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Mylan Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Lorazepam","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Mylan Group","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Mylan Group"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Almirall \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Neuraxpharm"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Leerink Partners"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Mitacs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Mitacs","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Mitacs"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVM201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Hospital Basel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Basel \/ Mind Medicine"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Nectero Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pentagalloyl Glucose","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Nectero Medical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Nectero Medical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nectero Medical \/ Inapplicable"},{"orgOrder":0,"company":"Nectero Medical","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Pentagalloyl Glucose","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Nectero Medical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Nectero Medical \/ Norwest Venture Partners","highestDevelopmentStatusID":"9","companyTruncated":"Nectero Medical \/ Norwest Venture Partners"},{"orgOrder":0,"company":"Elastin BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elastin BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elastin BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elastin BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rancho Santa Fe Bio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ataciguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Rancho Santa Fe Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Rancho Santa Fe Bio"},{"orgOrder":0,"company":"Inositec AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INS-3001","moa":"Vascular calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inositec AG \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inositec AG \/ Inapplicable"},{"orgOrder":0,"company":"Inositec AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INS-3001","moa":"Vascular calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inositec AG \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inositec AG \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bioresearch \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bioresearch \/ National Institutes of Health"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"D1\/D5 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"D1\/D5 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eagle Pharmaceuticals \/ Enalare Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Enalare Therapeutics"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Neurology","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL-1","graph1":"Nephrology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"InMed Pharmaceuticals \/ Radicle Science","highestDevelopmentStatusID":"15","companyTruncated":"InMed Pharmaceuticals \/ Radicle Science"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"CBR","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cronos Group \/ Ginkgo Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Red Blood Cell-Encapsulated Arginine Deiminase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"||EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"ENGOT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ ENGOT","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ ENGOT"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ The Institute of Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Sixth element capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Sixth element capital","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Sixth element capital"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Divestment","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Intraputaminal Infusion","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ ClearPoint Neuro"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Sotalol Hydrochloride","moa":"hREG","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quinidine sulphate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-401","moa":"PKP2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"TN-401","moa":"PKP2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-401","moa":"PKP2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-401","moa":"PKP2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-A601","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-A601","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RP-A601","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LX2020","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Population Health Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Tideglusib","moa":"GSK-3-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Population Health Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"AMO Pharma \/ Population Health Research Institute"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RJB-0402","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rejuvenate Biomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rejuvenate Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"LX2021","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexeo Therapeutics \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lexeo Therapeutics \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"StrideBio","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"StrideBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StrideBio \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Renovacor","sponsor":"University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"DSG2","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renovacor \/ University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Partnership","leadProduct":"Menaquinone-7","moa":"||Pregnane X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SunWay Biotech \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"SunWay Biotech \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Constellation Alpha Holdings","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Constellation Alpha Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Constellation Alpha Holdings"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Agreement","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Taiwan Liposome Company \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Endo International"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Taiwan Liposome Company \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Inapplicable"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"TLC BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TLC BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TLC BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Shionogi"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Veristat"},{"orgOrder":0,"company":"The Valens Company","sponsor":"Valens Company","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"||TRPV1","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"The Valens Company \/ Valens Company","highestDevelopmentStatusID":"15","companyTruncated":"The Valens Company \/ Valens Company"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"NEXGEL Advanced Hydrogel Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"NEXGEL Advanced Hydrogel Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"NEXGEL Advanced Hydrogel Solutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NEXGEL Advanced Hydrogel Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Global Stem Cell Technology","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Arti-Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Global Stem Cell Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Stem Cell Technology \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"Global Stem Cell Technology \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Medac","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medac \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Methylprednisolone Sodium Succinate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"Toll-like-4 receptor","graph1":"Rheumatology","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-adMSCs","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hope Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"PIF Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"PIF Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIF Partners \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PIF Partners \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ aMoon","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ aMoon"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series C Financing","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Access Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Access Biotechnology"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Affibody","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Affibody"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck Group \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Adalimumab","moa":"||IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SHL Medical AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SHL Medical AG \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SHL Medical AG \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuClone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"NeuClone","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuClone \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuClone \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Immunology","graph2":"Phase I","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Immunology","graph2":"Phase I","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaMar \/ Pharmapark","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Pharmapark"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cadila Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ethypharm","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ethypharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ethypharm \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ethypharm \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Biogen"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Equillium \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Equillium \/ University of Oxford"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ABBV-3373","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"G-CSF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Immunology","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Northway Biotechpharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Northway Biotechpharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mycenax Biotech \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Mycenax Biotech \/ Gedeon Richter"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NX-0479","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Vitalli Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VIT-801","moa":"ITK\/BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vitalli Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitalli Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vitalli Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"NX-0479","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Vitalli Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"DWP213388","moa":"ITK\/BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Vitalli Bio","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Vitalli Bio"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Immunology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-589","moa":"PAD4","graph1":"Immunology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"AC BioScience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"LX2931","moa":"S1P lyase","graph1":"Immunology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ AC BioScience","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ AC BioScience"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"||JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Alfasigma"},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Alfasigma"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"T19","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Matrix Partners China","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"T19","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Matrix Partners China","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Matrix Partners China"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Peficitinib Hydrobromide","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Menarini"},{"orgOrder":0,"company":"William Harvey Research Institute","sponsor":"Cyxone AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rabeximod","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase II","graph3":"William Harvey Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"William Harvey Research Institute \/ Cyxone AB","highestDevelopmentStatusID":"8","companyTruncated":"William Harvey Research Institute \/ Cyxone AB"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Indomethacin","moa":"COX-1\/COX-2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Indomethacin","moa":"COX-1\/COX-2","graph1":"Immunology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Samsung Bioepis"},{"orgOrder":0,"company":"Quallent Pharmaceuticals","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CAYMAN ISLANDS","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Quallent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quallent Pharmaceuticals \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"Quallent Pharmaceuticals \/ Alvotech"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Accord BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Accord BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Accord BioPharma"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Citryll","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Inapplicable"},{"orgOrder":0,"company":"Citryll","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Johnson & Johnson"},{"orgOrder":0,"company":"Citryll","sponsor":"ReumaNederland","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ ReumaNederland","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ ReumaNederland"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Binnopharm Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Binnopharm Group \/ Mabwell","highestDevelopmentStatusID":"15","companyTruncated":"Binnopharm Group \/ Mabwell"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Etanercept","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mabxience \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lupin Ltd \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Sandoz B2B"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Enzene Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Enzene Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"University of Maryland","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silo Pharma \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ University of Maryland"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL-1-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL-1-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"||G-CSF receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||IL-6-alpha receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Biosciences \/ Theramex"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SynAct Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"SBT-77-7101","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Ally Bridge Group","highestDevelopmentStatusID":"5","companyTruncated":"Sonoma Biotherapeutics \/ Ally Bridge Group"},{"orgOrder":0,"company":"Baylx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BX-U001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ Inapplicable"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Biotherapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Yale University","sponsor":"Aptorum","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Aptorum","highestDevelopmentStatusID":"4","companyTruncated":"Yale University \/ Aptorum"},{"orgOrder":0,"company":"Bioqube Ventures","sponsor":"Metrion Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"KV1.3 potassium ion channel","graph1":"Immunology","graph2":"Discovery","graph3":"Bioqube Ventures","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioqube Ventures \/ Metrion Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Bioqube Ventures \/ Metrion Biosciences"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Imotope","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"AM-411","moa":"NFkB","graph1":"Immunology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raphael Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CB2\/CB1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Raphael Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphael Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Raphael Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CPL\u2019 116","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Standigm","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Standigm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standigm \/ SK Chemicals","highestDevelopmentStatusID":"4","companyTruncated":"Standigm \/ SK Chemicals"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"University of Glasgow \/ Eli Lilly"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"IL-17 receptor\/BAFF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Tibulizumab","moa":"IL-17 receptor\/BAFF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Zura Bio"},{"orgOrder":0,"company":"DeepCure","sponsor":"LIRMM","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"DC-9476","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ LIRMM","highestDevelopmentStatusID":"4","companyTruncated":"DeepCure \/ LIRMM"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evoq Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naproxen","moa":"COX-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Immunology","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CEL-4000","moa":"IL-17-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEL-SCI \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ National Institutes of Health"},{"orgOrder":0,"company":"Fosun Wanbang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fosun Wanbang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Fosun Wanbang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Wanbang Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Arboretum Ventures"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milvexian","moa":"FXIa","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV channel-alpha-subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Anika Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Martin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Docarpamine","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mitsubishi Tanabe Pharma \/ Martin Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Martin Pharmaceuticals"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocelot Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocelot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Alfred E Tiefenbacher GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Lupin Ltd \/ Alfred E Tiefenbacher GmbH","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Alfred E Tiefenbacher GmbH"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Pictet Alternative Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pulmocide \/ Pictet Alternative Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Pictet Alternative Advisors"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Cipla","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Cipla"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"NovaBiotics Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Np339","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NovaBiotics Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaBiotics Ltd \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NovaBiotics Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Fursultiamine","moa":"Hepcidin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"CF PharmTech","sponsor":"Biotrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Series F Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CF PharmTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"CF PharmTech \/ Biotrack Capital","highestDevelopmentStatusID":"1","companyTruncated":"CF PharmTech \/ Biotrack Capital"},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Frevecitinib","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"Kinaset Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Frevecitinib","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"Kinaset Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"PGD2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"PGD2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"PGD2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ENV-294","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveda Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Simulations Plus","sponsor":"Food and Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Simulations Plus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Simulations Plus \/ Food and Drug Administration","highestDevelopmentStatusID":"4","companyTruncated":"Simulations Plus \/ Food and Drug Administration"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"AazeinTX","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"NEO6860","moa":"TRPV1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"adMare BioInnovations \/ AazeinTX","highestDevelopmentStatusID":"4","companyTruncated":"adMare BioInnovations \/ AazeinTX"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Steroid","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Vectura Ltd"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Vectura Ltd \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Vectura Ltd \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transpire Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Transpire Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Transpire Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transpire Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"VR588","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Kinaset Therapeutics \/ Vectura Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Therapeutics \/ Vectura Ltd"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Respirent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Lannett Company, Inc. \/ Respirent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Respirent Pharmaceuticals"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Lannett Company, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Formoterol Fumarate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Mankind Pharma"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Propeller Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Propeller Health","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Propeller Health"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vilanterol Trifenatate","moa":"||Adrenergic-beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Propeller Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Propeller Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Propeller Health \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Propeller Health \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Transpire Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"TRB-1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Transpire Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Transpire Bio \/ Recipharm AB","highestDevelopmentStatusID":"4","companyTruncated":"Transpire Bio \/ Recipharm AB"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Assia Chemical Industries Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Assia Chemical Industries Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Assia Chemical Industries Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2024","type":"Financing","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Abingworth","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Abingworth"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Launch Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Launch Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Launch Therapeutics"},{"orgOrder":0,"company":"H&T Presspart","sponsor":"Bilim Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Collaboration","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"H&T Presspart","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"H&T Presspart \/ Bilim Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"H&T Presspart \/ Bilim Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Elarekibep","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Elarekibep","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Iconovo","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Amneal Pharmaceuticals \/ Iconovo","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Iconovo"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Pressurised Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ GSK"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ GSK"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Upstream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Upstream \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aiolos Bio \/ Atlas Venture","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Upstream","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series A Financing","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Upstream \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IBI3002","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"APG333","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ Enavate Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Enavate Sciences"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Inapplicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Inapplicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ J.P. Morgan"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Alvotech","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Alvotech"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Generium JSC","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"KBI Biopharma \/ Generium JSC","highestDevelopmentStatusID":"15","companyTruncated":"KBI Biopharma \/ Generium JSC"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Apollo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Apollo Therapeutics"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"ES Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"AVTX-007","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ ES Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ ES Therapeutics"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Camoteskimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sublingual Liquid","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-MUC5AC","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Linvemastat","moa":"MMP-12","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lanier Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LNR 125","moa":"IL-25 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lanier Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lanier Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lanier Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Korea Institute of Advanced Technology","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Korea Institute of Advanced Technology","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Korea Institute of Advanced Technology"},{"orgOrder":0,"company":"Jemincare","sponsor":"Rapt Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"JYB1904","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Rapt Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Rapt Therapeutics"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perrigo Company plc \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Windward Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series A Financing","leadProduct":"HBM-9378","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Windward Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Windward Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Windward Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Windward Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"HBM-9378","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Harbour BioMed","amount2":0.96999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.96999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Windward Bio","highestDevelopmentStatusID":"6","companyTruncated":"Harbour BioMed \/ Windward Bio"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Covis Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Avillion LLP \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Avillion LLP \/ AstraZeneca"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Longitude Capital"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Quince Therapeutics"},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Quince Therapeutics"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Acasti Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Acasti Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BRB-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bitterroot Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bitterroot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BRB-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bitterroot Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bitterroot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"BRB-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bitterroot Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bitterroot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ 5Am Ventures"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kyttaro","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Kyttaro","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Kyttaro"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bitterroot Bio \/ Biotheus","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot Bio \/ Biotheus"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bitterroot Bio \/ Arch Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot Bio \/ Arch Ventures"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BERMUDA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ University of Michigan"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Repair Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Repair Biotechnologies","highestDevelopmentStatusID":"5","companyTruncated":"Genevant Sciences \/ Repair Biotechnologies"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Ziltivekimab","moa":"IL-6 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corvidia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvidia Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Corvidia Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"Lipoprotein","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tourmaline Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TATX-21","moa":"LDL uptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TATX-21","moa":"LDL uptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Camonsertib","moa":"Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Repare Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"IBUTILIDE FUMARATE","moa":"hREG","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Premier"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AP30663","moa":"SK ion channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acesion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xyra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Budiodarone","moa":"Ion Channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Xyra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xyra \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xyra \/ Inapplicable"},{"orgOrder":0,"company":"Xyra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Budiodarone","moa":"Ion Channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Xyra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xyra \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xyra \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"T20G","moa":"Non-vitamin K","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic-beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ARCA Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ARCA Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic-beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ARCA Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ARCA Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"PhysIQ","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ PhysIQ","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ PhysIQ"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AP31969","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acesion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"AP31969","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acesion Pharma \/ Canaan Partners","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Pharma \/ Canaan Partners"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dronedarone Hydrochloride","moa":"Na\/K\/Ca channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dronedarone Hydrochloride","moa":"Na\/K\/Ca channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cadrenal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Cadrenal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"Nav1.5 channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Correvio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Correvio Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Correvio Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Vivasc Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CTP-Amio","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Vivasc Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivasc Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Vivasc Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"17-beta-estradiol","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"GRI Bio \/ Aardvark Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ Aardvark Therapeutics"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Magdalena Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Magdalena Biosciences \/ Jaguar Health","highestDevelopmentStatusID":"4","companyTruncated":"Magdalena Biosciences \/ Jaguar Health"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiefenbacher Group \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Tiefenbacher Group \/ OnDosis"},{"orgOrder":0,"company":"3Z","sponsor":"biotx.ai","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ICELAND","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"3Z","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"3Z \/ biotx.ai","highestDevelopmentStatusID":"2","companyTruncated":"3Z \/ biotx.ai"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ The Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ The Lind Partners"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Commave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Commave Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Commave Therapeutics"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Corium","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Hercules Capital"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IQVIA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Centanafadine","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Societal CDMO \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Aegis Capital"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Dr. Vince Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Indegene","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indegene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Indegene \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Indegene \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Societal CDMO \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centanafadine","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Cediprof","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Cediprof"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dasotraline","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Controlled Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Controlled Release","sponsorNew":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"Medomie","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine Sulfate","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Medomie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Medomie \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Medomie \/ Aytu BioPharma"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Magnesium L-Threonate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Neurocentria","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocentria \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurocentria \/ Inapplicable"},{"orgOrder":0,"company":"3Z","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ICELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"3Z","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3Z \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"3Z \/ Inapplicable"},{"orgOrder":0,"company":"Liechti Laboratory","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Liechti Laboratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liechti Laboratory \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Liechti Laboratory \/ Mind Medicine"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Maastricht University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Maastricht University","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Maastricht University"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ BridgeBio Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"NNC6019","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"CFB","graph1":"Hematology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Lind Partners"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Vox Nova","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Vox Nova","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Vox Nova"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Fragile X Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Fragile X Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Synaptogenix \/ Fragile X Foundation"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"AJA001","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/ AJNA BioSciences"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scioto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scioto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"FIN-211","moa":"Gut microbiome","graph1":"Neurology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"PoloMar Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Collaboration","leadProduct":"Emodin","moa":"P2X7 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PaxMedica \/ PoloMar Health","highestDevelopmentStatusID":"4","companyTruncated":"PaxMedica \/ PoloMar Health"},{"orgOrder":0,"company":"Stalicla","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Firefly Neuroscience","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Firefly Neuroscience"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ SPRIM Global Investments","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"The Autism Impact Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ The Autism Impact Fund","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ The Autism Impact Fund"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Negev Autism Center Soroka University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Negev Autism Center Soroka University Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Negev Autism Center Soroka University Medical Center"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Soroka Medical Center"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sangamo Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Neurology","graph2":"IND Enabling","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAla Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmAla Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Hebrew University","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"7-nitroindazole","moa":"nNOS","graph1":"Neurology","graph2":"Preclinical","graph3":"Hebrew University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebrew University \/ Beyond Air","highestDevelopmentStatusID":"4","companyTruncated":"Hebrew University \/ Beyond Air"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Soroka Medical Center"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Neurology","graph2":"IND Enabling","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"EM-113","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuMentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EuMentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lys-MDA","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Advanced Medicine Partners","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Advanced Medicine Partners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Medicine Partners \/ Deerfield Management","highestDevelopmentStatusID":"4","companyTruncated":"Advanced Medicine Partners \/ Deerfield Management"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"King\u2019s College London","sponsor":"Compass Pathways","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"King\u2019s College London","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"King\u2019s College London \/ Compass Pathways","highestDevelopmentStatusID":"4","companyTruncated":"King\u2019s College London \/ Compass Pathways"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Shaare Zedek Scientific Ltd.\u00a0","sponsor":"Greater Cannabis Company","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shaare Zedek Scientific Ltd.\u00a0","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company","highestDevelopmentStatusID":"1","companyTruncated":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"National Institutes of Mental Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rumi Scientific \/ National Institutes of Mental Health","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scientific \/ National Institutes of Mental Health"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"S-1117","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seismic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northway Biotechpharma \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Zenas BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Zenas BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Zenas BioPharma"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HNSA-5487","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HNSA-5487","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MaxCyte \/ TG Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ TG Therapeutics"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Century Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NexImmune \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Curia","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Curia \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ Replicate Bioscience"},{"orgOrder":0,"company":"Atomwise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atomwise \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Inapplicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ligand Pharmaceuticals \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pharmaceuticals \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Lysosomal targeting chimera","graph1":"Immunology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lycia Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Radar Therapeutics","sponsor":"NFX Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Radar Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radar Therapeutics \/ NFX Bio","highestDevelopmentStatusID":"2","companyTruncated":"Radar Therapeutics \/ NFX Bio"},{"orgOrder":0,"company":"Stanford Medical","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Stanford Medical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stanford Medical \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Stanford Medical \/ Sanofi"},{"orgOrder":0,"company":"TRexBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRexBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"TRexBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Kanvas Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Federation Bio \/ Kanvas Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Federation Bio \/ Kanvas Biosciences"},{"orgOrder":0,"company":"GenEdit","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GenEdit","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenEdit \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"GenEdit \/ Genentech"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"R552","moa":"RIPK1","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rigel Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Evozyne","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Evozyne","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evozyne \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"2","companyTruncated":"Evozyne \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EpimAb Biotherapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"EpimAb Biotherapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"HitGen","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ Morphic Therapeutic","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Morphic Therapeutic"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yangtze River Pharmaceutical Group \/ Alvotech","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze River Pharmaceutical Group \/ Alvotech"},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ Tavotek Biotherapeutics"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minapharm Pharmaceuticals \/ Bioventure Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Minapharm Pharmaceuticals \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"PrecisionLife","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ PrecisionLife","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ PrecisionLife"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"MabGenesis","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"MabGenesis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MabGenesis \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"MabGenesis \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chiome Bioscience \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bioscience \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fujifilm holding \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm holding \/ Sana Biotechnology"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chugai Pharmaceutical \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Argenx"},{"orgOrder":0,"company":"PolTREG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PolTREG \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PolTREG \/ Inapplicable"},{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"FairJourney Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FairJourney Biologics \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"FairJourney Biologics \/ Argenx"},{"orgOrder":0,"company":"Aqilion","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqilion \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ Merck & Co"},{"orgOrder":0,"company":"GlycoEra","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GlycoEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GlycoEra \/ 5Am Ventures","highestDevelopmentStatusID":"3","companyTruncated":"GlycoEra \/ 5Am Ventures"},{"orgOrder":0,"company":"Mysthera Therapeutics","sponsor":"Forty51 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Mysthera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mysthera Therapeutics \/ Forty51 Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mysthera Therapeutics \/ Forty51 Ventures"},{"orgOrder":0,"company":"Iontas","sponsor":"Quellis Biosciences Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iontas \/ Quellis Biosciences Inc","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Quellis Biosciences Inc"},{"orgOrder":0,"company":"Sygnature Discovery","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sygnature Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sygnature Discovery \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sygnature Discovery \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Bit Bio","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bit Bio \/ BlueRock Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Avilar Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avilar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Avilar Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elektrofi \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Elektrofi \/ Eli Lilly"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PKC theta","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ S.R. One","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ S.R. One"},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Metaphore Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metaphore Biotechnologies \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Metaphore Biotechnologies \/ Flagship Pioneering"},{"orgOrder":0,"company":"TetraGenetics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TetraGenetics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TetraGenetics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"TetraGenetics \/ AbCellera"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-1B receptor","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventus Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Ventus Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"ImmuneID","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"ImmuneID","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmuneID \/ Alta Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmuneID \/ Alta Partners"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Candid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Candid Therapeutics"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seismic Therapeutic \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seismic Therapeutic \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolojic Design \/ Nektar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Exo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Exo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thymmune Therapeutics \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GRO Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GRO Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"GRO Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evoq Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immetas Therapeutics \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Therapeutics \/ GC Biopharma"},{"orgOrder":0,"company":"Dualogics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Dualogics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dualogics \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Dualogics \/ AbCellera"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shattuck Labs \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Shattuck Labs \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"GentiBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forge Biologics \/ GentiBio","highestDevelopmentStatusID":"4","companyTruncated":"Forge Biologics \/ GentiBio"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microba Life Sciences \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Microba Life Sciences \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Monash University","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monash University \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Monash University \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Gentbio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seattle Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seattle Children\u2019s Research Institute \/ Gentbio","highestDevelopmentStatusID":"3","companyTruncated":"Seattle Children\u2019s Research Institute \/ Gentbio"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpine Immune Sciences \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Horizon Therapeutics"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"MyMD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Akers Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akers Biosciences \/ MyMD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Akers Biosciences \/ MyMD Pharmaceuticals"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Columbus Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nuvig Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvig Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Nuvig Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Pandion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Surveyor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Surveyor Capital"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Viela Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Viela Bio","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Viela Bio"},{"orgOrder":0,"company":"Agility Life Sciences","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"CDT1656","moa":"Glucokinase","graph1":"Immunology","graph2":"Phase I","graph3":"Agility Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agility Life Sciences \/ Conduit Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Agility Life Sciences \/ Conduit Pharma"},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"AUR300","moa":"M2 macrophages dysregulation","graph1":"Immunology","graph2":"IND Enabling","graph3":"Riptide Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Riptide Bioscience \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Riptide Bioscience \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"XmAb564","moa":"IL-2-beta-receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Immunovant","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanall Biopharma \/ Immunovant","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ Immunovant"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP144G","moa":"Complement factor B","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Dianthus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Merger","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Magenta Therapeutics \/ Dianthus Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Dianthus Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Bempikibart","moa":"IL-7-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Bempikibart","moa":"IL-7-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Bempikibart","moa":"IL-7-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20111117","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Seismic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ SVB Leerink"},{"orgOrder":0,"company":"Thunderbolt","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"IND Enabling","graph3":"Thunderbolt","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Thunderbolt \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Thunderbolt \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genovis","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Immunoglobulin G Protease","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Genovis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genovis \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Genovis \/ Selecta Biosciences"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD8 T-cell","graph1":"Immunology","graph2":"Discovery","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Mozart Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"SciRhom","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"SR-878","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"SciRhom","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciRhom \/ Andera Partners","highestDevelopmentStatusID":"5","companyTruncated":"SciRhom \/ Andera Partners"},{"orgOrder":0,"company":"AB Studio","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"AB Studio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Studio \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"AB Studio \/ Candid Therapeutics"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Lysosomal-Targeted Chimeras","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Lycia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lycia Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Lycia Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"TRexBio","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Series A Financing","leadProduct":"TRB-051","moa":"T-cell","graph1":"Immunology","graph2":"Discovery Platform","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"TRexBio \/ Polaris Partners"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Northpond Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Kyverna Therapeutics \/ Northpond Ventures"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT115301","moa":"T-cell effector","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stanford University","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"VT-109","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Vera Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Vera Therapeutics"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HCW9302","moa":"T-cell","graph1":"Immunology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Tolerogenic Nanoparticle","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cour Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Cour Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"DT-001","moa":"TNF2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Dualyx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dualyx \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"5","companyTruncated":"Dualyx \/ Fountain Healthcare Partners"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CS12192","moa":"JAK3\/JAK1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Lilly Asia Ventures","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0.93000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93000000000000005,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Candid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/ Fuji Pharma"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunAbs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IM-101","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"ImmunAbs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunAbs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunAbs \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Avacta Group"},{"orgOrder":0,"company":"Aqilion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TAK1","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqilion \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ Inapplicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Argenx","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Argenx"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"ISB 880","moa":"IL-1RAP","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Sciences \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Ichnos Sciences \/ Almirall"},{"orgOrder":0,"company":"MiroBio","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Medicxi","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Medicxi"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"MiroBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Inapplicable"},{"orgOrder":0,"company":"Sareum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Inapplicable"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GIM-407","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Georgiamune \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"AnaptysBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CBS004","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ AnaptysBio","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ AnaptysBio"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"RPT-2950","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rome Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Rome Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"KYV-201","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Kyverna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Kyverna Therapeutics"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Immunology","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"mRNA-6231","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"SoftBank Vision Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ SoftBank Vision Fund","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ SoftBank Vision Fund"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"PT627","moa":"PD-1","graph1":"Immunology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ Pandion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Danuo Science Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"EN1001","moa":"TNF1 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Enosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enosi Therapeutics \/ Danuo Science Group","highestDevelopmentStatusID":"4","companyTruncated":"Enosi Therapeutics \/ Danuo Science Group"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmuneSensor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"COYA 201","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"Oblenio Bio","sponsor":"Aditum Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LBL-051","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Oblenio Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oblenio Bio \/ Aditum Bio","highestDevelopmentStatusID":"4","companyTruncated":"Oblenio Bio \/ Aditum Bio"},{"orgOrder":0,"company":"Steritas","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Steritas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steritas \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Steritas \/ Argenx"},{"orgOrder":0,"company":"Slate Bio","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Financing","leadProduct":"IL233","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Slate Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slate Bio \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Slate Bio \/ Epidarex Capital"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"IL-2 Mutein","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyrus Biotechnology \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Selecta Biosciences"},{"orgOrder":0,"company":"Nudge Therapeutics","sponsor":"Veralox Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"cGAS","graph1":"Immunology","graph2":"Preclinical","graph3":"Nudge Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nudge Therapeutics \/ Veralox Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nudge Therapeutics \/ Veralox Therapeutics"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ART5803","moa":"NMDA receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arialys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arialys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Bessemer Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series B Financing","leadProduct":"S-1117","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Bessemer Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Bessemer Venture Partners"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ASLAN Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ K2 HealthVentures"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Nephrology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"IL-2 induced T-cell kinase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Savara \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Jefferies"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AB2 Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Tadekinig Alpha","moa":"IL-18 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"WuXi Biologics \/ AB2 Bio"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMG-008","moa":"IL-36 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ University of Oxford","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ University of Oxford"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Calcilytix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Calcilytix Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Calcilytix Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calcilytix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calcilytix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calcilytix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calcilytix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like-3 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Vipragen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangoceuticals \/ Vipragen Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Mangoceuticals \/ Vipragen Biosciences"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"Vaxxas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Inapplicable"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nicotinamide","moa":"Fatty-acid amide hydrolase-1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anglo-French Drugs and industries \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Anglo-French Drugs and industries \/ Lupin Ltd"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Michigan State University","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Orbus Therapeutics \/ Michigan State University","highestDevelopmentStatusID":"1","companyTruncated":"Orbus Therapeutics \/ Michigan State University"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase II","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-810","moa":"PPA-alpha receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"AP-SA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ HighCape Capital"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline","moa":"MMP-13","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ertapenem Sodium","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Xeruborbactam","moa":"Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ BARDA"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xeruborbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xeruborbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Xeruborbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Shionogi"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Series C Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Qpex Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"QPX9003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Qpex Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Qpex Biopharma"},{"orgOrder":0,"company":"Bugworks","sponsor":"University Of Tokyo Edge Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"GYROX-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bugworks \/ University Of Tokyo Edge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ University Of Tokyo Edge Capital"},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KSP-1007","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitovant Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitovant Biopharma \/ Sumitomo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sumitovant Biopharma \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tetracycline Hydrochloride","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Valeo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Binnopharm Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Binnopharm Group \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Binnopharm Group \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Trimethoprim","moa":"Tetrahydrofolate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"XPhyto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"XPhyto \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arixa Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ARX-1796","moa":"Bacterial-beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arixa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arixa Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Arixa Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Felix Biotechnology","sponsor":"The National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Felix Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Felix Biotechnology \/ The National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Felix Biotechnology \/ The National Science Foundation"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-B3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Gifu University","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Gifu University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gifu University \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Gifu University \/ Astellas Pharma"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Luminarie","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Nemonoxacin","moa":"Topoisomerase II","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Luminarie","highestDevelopmentStatusID":"15","companyTruncated":"TaiGen Biotechnology \/ Luminarie"},{"orgOrder":0,"company":"Vernalis","sponsor":"Unison Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vernalis \/ Unison Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/ Unison Medicines"},{"orgOrder":0,"company":"Cipla","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Cipla \/ SIGA Technologies"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Omniose","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Omniose","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omniose \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Omniose \/ AstraZeneca"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"3","companyTruncated":"Locus Biosciences \/ Hercules Capital"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"CMTX-301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ CARB-X","highestDevelopmentStatusID":"2","companyTruncated":"Clarametyx Biosciences \/ CARB-X"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Veritaz Healthcare","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Azithromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Veritaz Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veritaz Healthcare \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"Veritaz Healthcare \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Felix Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Felix Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Felix Biotechnology"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AFTX-201","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Affinia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Affinia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"ALSA Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ ALSA Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ ALSA Ventures"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rhythm Pharmaceuticals \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Upadia Holding","sponsor":"EsoCap","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Upadia Holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upadia Holding \/ EsoCap","highestDevelopmentStatusID":"4","companyTruncated":"Upadia Holding \/ EsoCap"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Pharmanovia","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Barth Syndrome Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Barth Syndrome Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Scenic Biotech \/ Barth Syndrome Foundation"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"PellePharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"PellePharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PellePharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm \/ Inapplicable"},{"orgOrder":0,"company":"PellePharm","sponsor":"Phyton Biotech LLC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"PellePharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PellePharm \/ Phyton Biotech LLC","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm \/ Phyton Biotech LLC"},{"orgOrder":0,"company":"PellePharm","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"PellePharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PellePharm \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sol-Gel Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sol-Gel Technologies \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLN7","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Funding","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Williamsburg Venture Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"ORGCAR19","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orgenesis \/ Williamsburg Venture Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Orgenesis \/ Williamsburg Venture Holdings"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Cr-Cp Life Science Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"Autoleucel Relmacabtagen","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Therapeutics \/ Cr-Cp Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"JW Therapeutics \/ Cr-Cp Life Science Fund"},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"Mirae Asset Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"IKS03","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Iksuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iksuda Therapeutics \/ Mirae Asset Capital","highestDevelopmentStatusID":"4","companyTruncated":"Iksuda Therapeutics \/ Mirae Asset Capital"},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"miCAR19","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antion Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antion Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"enGene","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Forbion"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"enGene","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Deep Track Capital"},{"orgOrder":0,"company":"enGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SYS6020","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisinicline Analog","moa":"Nicotinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"Innate defense","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"Innate defense","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Dusquetide","moa":"Innate defense","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Vera Therapeutics"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"5","companyTruncated":"Disc medicine \/ Mabwell"},{"orgOrder":0,"company":"Errant Gene Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Errant Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Errant Gene Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Errant Gene Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"EdiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EdiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"EdiGene","sponsor":"Haihe Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EdiGene \/ Haihe Laboratory","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ Haihe Laboratory"},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Disc medicine","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Disc medicine"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"EdiGene","sponsor":"3H Health Investment","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"Botulinum Toxin A","moa":"ACh receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EdiGene \/ 3H Health Investment","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ 3H Health Investment"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MaxCyte \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"MaxCyte \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Divestment","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta-globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Porton Advanced Solutions \/ BRL Medicine"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Porton Advanced Solutions \/ BRL Medicine"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taro Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Hepcidin","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GPH102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kanglin Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"KL003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Kanglin Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kanglin Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kanglin Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Coave Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OBiO Technology","sponsor":"Chinagene","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"ZVS101e","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"OBiO Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"OBiO Technology \/ Chinagene","highestDevelopmentStatusID":"7","companyTruncated":"OBiO Technology \/ Chinagene"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Bintrafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Merck Group \/ GSK"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Bintrafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ J.P. Morgan"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"||PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"||PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"INCB001158","moa":"||Aarginase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Incyte Corporation"},{"orgOrder":0,"company":"Burning Rock Dx","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Brigimadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase II","graph3":"Burning Rock Dx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Burning Rock Dx \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Burning Rock Dx \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Brigimadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foundation Medicine \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Foundation Medicine \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tasurgratinib Succinate","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"NFL Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"NFL-301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athena Pharmaceutiques \/ NFL Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Athena Pharmaceutiques \/ NFL Biosciences"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Praxis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Praxis Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ University of Florida"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Westar Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Westar Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Westar Capital Limited"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACT-539313","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Anson Funds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Anson Funds","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Anson Funds"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HOPE Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Merger","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HOPE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HOPE Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"HOPE Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Government of Canada"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Alvogen","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Alvogen"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"NeuroRX Pharma","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NeuroRX Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroRX Pharma \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"NeuroRX Pharma \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Streeterville Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Streeterville Capital","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Streeterville Capital"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Laboratoires Delbert","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Lithium Carbonate","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Laboratoires Delbert","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Laboratoires Delbert"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Wellcome Trust"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Campbell Neurosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Campbell Neurosciences","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Campbell Neurosciences"},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"The University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of British Columbia \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"The University of British Columbia \/ Inapplicable"},{"orgOrder":0,"company":"Neurotheryx","sponsor":"Cyclica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Neurotheryx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotheryx \/ Cyclica","highestDevelopmentStatusID":"1","companyTruncated":"Neurotheryx \/ Cyclica"},{"orgOrder":0,"company":"University of Oxford","sponsor":"BD2","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ BD2","highestDevelopmentStatusID":"2","companyTruncated":"University of Oxford \/ BD2"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"4MT2001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"4M Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MTX-005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Ysios Capital"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"MTX-005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Swisscanto","highestDevelopmentStatusID":"6","companyTruncated":"Memo Therapeutics \/ Swisscanto"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Vera Therapeutics"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Morgan Stanley"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"Orthogon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orthogon Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Orthogon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orthogon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AiCuris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AIC468","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiCuris \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Vicineum","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Cardinal Health \/ Sesen Bio"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Relmapirazin","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Runway Growth Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Relmapirazin","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Runway Growth Capital LLC","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Runway Growth Capital LLC"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Pivekimab Sunirine","moa":"CD123","graph1":"Oncology","graph2":"Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Vivo Capital"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Tarsus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LianBio \/ Tarsus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Tarsus Pharmaceuticals"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Attillaps Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"AChE","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaukos \/ Attillaps Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Glaukos \/ Attillaps Holdings"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Levation Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Levation Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGlu5 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGlu5 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Tenpoint Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"3","companyTruncated":"Tenpoint Therapeutics \/ British Patient Capital"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Photoreceptor Neural Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ACRO Biomedical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Versiti","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Phase III","graph3":"Versiti","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versiti \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Versiti \/ National Institutes of Health"},{"orgOrder":0,"company":"Lowell Therapeutics","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lowell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lowell Therapeutics \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lowell Therapeutics \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meitheal Pharmaceuticals \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Velico Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Inapplicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARCA Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARCA Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARCA Biopharma \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Biopharma \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV.7m8-L-opsin","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Biddle Sawyer Corporation","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"TC-220","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biddle Sawyer Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biddle Sawyer Corporation \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Biddle Sawyer Corporation \/ TAE Life Sciences"},{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Menaquinone-7","moa":"Pregnane X receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"NattoPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"NattoPharma \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"NattoPharma \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Redwire Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"ELP-004","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Redwire Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redwire Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Redwire Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2A","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Israeli Phage Therapy Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center"},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Icahn School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine \/ Cell BioEngines","highestDevelopmentStatusID":"3","companyTruncated":"Icahn School of Medicine \/ Cell BioEngines"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"7HP935","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ CPRIT"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ National Cancer Institute"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Aurum Ventures"},{"orgOrder":0,"company":"Tilray","sponsor":"Aphria","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"Tilray \/ Aphria","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Aphria"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Nice & Green"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ BARDA"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RHB-106","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Rotating Boulder Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Series E Financing","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Rotating Boulder Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Rotating Boulder Fund"},{"orgOrder":0,"company":"Talus Bioscience","sponsor":"Two Bear Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Talus Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talus Bioscience \/ Two Bear Capital","highestDevelopmentStatusID":"4","companyTruncated":"Talus Bioscience \/ Two Bear Capital"},{"orgOrder":0,"company":"Medefil","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"mAChR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Medefil","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medefil \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medefil \/ Inapplicable"},{"orgOrder":0,"company":"Teligent, Inc","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Atropine","moa":"mAChR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Teligent, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Teligent, Inc \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Teligent, Inc \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Day One Biopharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ XOMA","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ XOMA"},{"orgOrder":0,"company":"Tempus","sponsor":"Novellus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Plixorafenib","moa":"BRAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Tempus \/ Novellus"},{"orgOrder":0,"company":"Novellus","sponsor":"Pontifax Medison Debt Financing","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Plixorafenib","moa":"BRAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novellus \/ Pontifax Medison Debt Financing","highestDevelopmentStatusID":"7","companyTruncated":"Novellus \/ Pontifax Medison Debt Financing"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"Plixorafenib","moa":"BRAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fore Biotherapeutics \/ SR One Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Fore Biotherapeutics \/ SR One Capital Management"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ University of Oxford"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Human Ghrelin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"University of Kansas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Human Ghrelin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Avance Clinical"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Erase PTSD","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Erase PTSD","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Erase PTSD"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Thinkequity"},{"orgOrder":0,"company":"Oragenics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Thinkequity"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"},{"orgOrder":0,"company":"NeurAegis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Calpain-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeurAegis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeurAegis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeurAegis \/ Inapplicable"},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ECP-101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECP Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAVHSC16","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"BHV-8000","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"ARTIS Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"DLX-1","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ ARTIS Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ ARTIS Ventures"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Canadian Cancer Society","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Neurology","graph2":"Phase III","graph3":"Canadian Cancer Society","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canadian Cancer Society \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Cancer Society \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Suffield Research Centre","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Suffield Research Centre","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Suffield Research Centre"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Defence R&D Canada","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Defence R&D Canada","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Defence R&D Canada"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"||Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"SanBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Inapplicable"},{"orgOrder":0,"company":"NorthShore University HealthSystem","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"NorthShore University HealthSystem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Inapplicable"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Inapplicable"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Inapplicable"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Advanced Technology International","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Advanced Technology International","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Advanced Technology International"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"AMRMC","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Alpha Cognition \/ AMRMC","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ AMRMC"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"EuMentis Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"EuMentis Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Corporation \/ Mississippi State University"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Walter Reed Army Institute","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Noveome Biotherapeutics \/ Walter Reed Army Institute","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Walter Reed Army Institute"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Oragenics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Avance Clinical"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Corporation \/ Mississippi State University"},{"orgOrder":0,"company":"Ischemix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"CMX-2043","moa":"AKT phosphorylation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ischemix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ischemix \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ischemix \/ US Department of Defense"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Curia","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Incannex Healthcare \/ Curia","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Curia"},{"orgOrder":0,"company":"HempMeds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HempMeds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"HempMeds \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HempMeds \/ Inapplicable"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Incannex Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Incannex Healthcare"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio \/ Department of Defense"},{"orgOrder":0,"company":"Tikomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LMW-Dextran Sulfate","moa":"MMP","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ Inapplicable"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ University of Georgia Research Foundation"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Wesana Health \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abliva","sponsor":"Owl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"OWL-1410","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Owl Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Abliva \/ Owl Therapeutics"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Tri-Ax","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halberd Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Halberd Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ECP-101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECP Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Egret Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EGT 101","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Egret Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egret Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Egret Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"ZN-A-1041","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Zion Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ United States Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Plus Therapeutics \/ United States Department of Defense"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Preclinical","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Isotope Technologies Munich","highestDevelopmentStatusID":"4","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"NYIP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Private Placement","leadProduct":"Emapticap pegol","moa":"CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ NYIP","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ NYIP"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Hoag Memorial Hospital Presbyterian","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"QBS10072S","moa":"SLC7A5","graph1":"Oncology","graph2":"Phase I","graph3":"Quadriga BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quadriga BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quadriga BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mosaic ImmunoEngineering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Acquisition","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Mosaic ImmunoEngineering","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Mosaic ImmunoEngineering"},{"orgOrder":0,"company":"HypoSpray Pharma","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"HypoSpray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HypoSpray Pharma \/ Nascent Biotech","highestDevelopmentStatusID":"6","companyTruncated":"HypoSpray Pharma \/ Nascent Biotech"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QBS72S","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Quadriga BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Quadriga BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quadriga BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VCAP-102","moa":"SOD1","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Miami Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Miami Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Miami Cancer Institute"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-300","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-300","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-300","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Vocimagene Amiretrorepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Denovo Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Forte Biosciences \/ Denovo Biopharma"},{"orgOrder":0,"company":"City of Hope","sponsor":"Chimeric","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Chimeric","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Chimeric"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Texas Children\u2019s Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpicentRx \/ Texas Children\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Texas Children\u2019s Hospital"},{"orgOrder":0,"company":"Siren Biotechnology","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Siren Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siren Biotechnology \/ Cirm","highestDevelopmentStatusID":"4","companyTruncated":"Siren Biotechnology \/ Cirm"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"HDX Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"BNCT","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAE Life Sciences \/ HDX Corporation","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ HDX Corporation"},{"orgOrder":0,"company":"Bioasis","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioasis \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ATR","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Genuv","sponsor":"Nanocarry Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"GNUV201","moa":"PD-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genuv \/ Nanocarry Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Genuv \/ Nanocarry Therapeutics"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Midatech Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathios Therapeutics \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Therapeutics \/ UK Government"},{"orgOrder":0,"company":"Cypris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Cypris Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cypris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Cypris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1244","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1244","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNS Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Matica Biotechnology","sponsor":"Treovir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"G207","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Matica Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matica Biotechnology \/ Treovir","highestDevelopmentStatusID":"8","companyTruncated":"Matica Biotechnology \/ Treovir"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE705","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KSQ-4279","moa":"USP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PARP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"pharma&","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Rucaparib Camsylate","moa":"PARP-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"pharma& \/ Tolmar"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ATX-968","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Accent Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Nelipepimut-S","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Accord healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Accord healthcare"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Levena Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Levena Biopharma \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Levena Biopharma \/ Sichuan Kelun-Biotech Biopharmaceutical"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Levena Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Levena Biopharma"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"||CD4 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"||Helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Caris Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Caris Life Sciences"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Epacadostat","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Epacadostat","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inycte","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inycte","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inycte"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"NYCBS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ NYCBS","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ NYCBS"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SV-BR-1-GM","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Aston Sci","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aston Sci","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Aston Sci \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aston Sci \/ Inapplicable"},{"orgOrder":0,"company":"Aston Sci","sponsor":"Timefolio Asset","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aston Sci","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Aston Sci \/ Timefolio Asset","highestDevelopmentStatusID":"8","companyTruncated":"Aston Sci \/ Timefolio Asset"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"National Institutes of Health \/ BriaCell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"GP2","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GP2","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GP2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Ottawa Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Ottawa Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Ottawa Hospital"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ The Benchmark Company","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ The Benchmark Company"},{"orgOrder":0,"company":"Kortuc","sponsor":"AXA Japan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Hydrogen Peroxide","moa":"Free radical","graph1":"Oncology","graph2":"Phase II","graph3":"Kortuc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Kortuc \/ AXA Japan","highestDevelopmentStatusID":"8","companyTruncated":"Kortuc \/ AXA Japan"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Bristol Myers Squibb \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Zetagen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZetaMAST","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zetagen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Zetagen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Zetagen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Adlai Nortye","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Adlai Nortye","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Adlai Nortye"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI Innovative Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI Innovative Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI Innovative Cancer Research"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI Innovative Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI Innovative Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI Innovative Cancer Research"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI-Innovative Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI-Innovative Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI-Innovative Cancer Research"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pelareorep","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Public Offering","leadProduct":"Pelareorep","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Leede Jones Gable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Leede Jones Gable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Agreement","leadProduct":"Pertuzumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Trastuzumab Imbotolimod","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Monomethyl Auristatin E","moa":"EphA5 MMAE","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MBrace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"P-MUC1C-ALLO1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Cowen"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX788","moa":"||HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"||HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"||HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Rostaporfin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Kintara Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Zhejiang Medicine Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Zhejiang Medicine Co Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Zhejiang Medicine Co Ltd"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Zymeworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Zymeworks","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Zymeworks"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ ALX Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ ALX Oncology"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Fulvestrant","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||ErbB2","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Immutep"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"IKS014","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WuXi Biologics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Medac","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Medac"},{"orgOrder":0,"company":"Byondis","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Syneos Health"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Alteogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ALT-P7","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alteogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Financing","leadProduct":"IKS014","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LegoChem Biosciences \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"LegoChem Biosciences \/ Orion Corporation"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ EirGenix","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ EirGenix"},{"orgOrder":0,"company":"EirGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"EirGenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EirGenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EirGenix \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"huMNC2-CAR22","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Minerva Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minerva Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minerva Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Imprime PGG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Imprime PGG","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Imprime PGG"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ASN004","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syneos Health \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Everolimus","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aragen Life Sciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Aragen Life Sciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"||LIV-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Applied Biomedical Science Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"HER2\/HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied Biomedical Science Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Applied Biomedical Science Institute \/ Hillstream BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Applied Biomedical Science Institute \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Cullgen","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cullgen \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ Astellas Pharma"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anixa Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Applied Biomedical Science Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied Biomedical Science Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Applied Biomedical Science Institute \/ Hillstream BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Applied Biomedical Science Institute \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"Beta Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Flashpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flashpoint Therapeutics \/ Beta Lab","highestDevelopmentStatusID":"4","companyTruncated":"Flashpoint Therapeutics \/ Beta Lab"},{"orgOrder":0,"company":"Precirix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Inapplicable"},{"orgOrder":0,"company":"Precirix","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabelled Compounds","year":"2022","type":"Series B Financing","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ INKEF Capital","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ INKEF Capital"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Kexing Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Eribulin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xiling Lab \/ Kexing Biopharm","highestDevelopmentStatusID":"15","companyTruncated":"Xiling Lab \/ Kexing Biopharm"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"China Life Private Equity Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Series C Financing","leadProduct":"GQ1001","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GeneQuantum Healthcare \/ China Life Private Equity Investment","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantum Healthcare \/ China Life Private Equity Investment"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SH-105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Kurma Partners\u2019 Growth Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SH-105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Kurma Partners\u2019 Growth Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Oncology \/ Kurma Partners\u2019 Growth Opportunities Fund"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"SH-105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Seroba Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Oncology \/ Seroba Life Sciences"},{"orgOrder":0,"company":"Procaps Group","sponsor":"BDR Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"TYK","graph1":"Oncology","graph2":"Undisclosed","graph3":"Procaps Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Procaps Group \/ BDR Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Procaps Group \/ BDR Pharmaceuticals"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PIC Therapeutics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"eIF4F-CAP complex","graph1":"Oncology","graph2":"Discovery","graph3":"PIC Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PIC Therapeutics \/ OrbiMed Advisors","highestDevelopmentStatusID":"2","companyTruncated":"PIC Therapeutics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAT-179","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAT-179","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Precirix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Partnership","leadProduct":"131-I Conjugated Anti-HER2 sdAb 2Rs15d","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Evergreen Theragnostics \/ Precirix","highestDevelopmentStatusID":"7","companyTruncated":"Evergreen Theragnostics \/ Precirix"},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Eoc Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Eoc Pharma"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Celcuity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Gedatolisib","moa":"PI3K\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ Celcuity","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Celcuity"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Viatris","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viatris \/ Beximco Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Beximco Pharmaceuticals"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Sesen Bio"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eribulin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Systems Oncology LLC","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ErSO","moa":"Unfolded protein response","graph1":"Oncology","graph2":"Preclinical","graph3":"Systems Oncology LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Systems Oncology LLC \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Systems Oncology LLC \/ Bayer AG"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Vivo Capital"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Agendia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Agendia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Agendia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agendia \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Aurigene","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Aurigene"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ BVF Partners","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ BVF Partners"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Exactis Innovation","sponsor":"Sermonix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Partnership","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exactis Innovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exactis Innovation \/ Sermonix Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Exactis Innovation \/ Sermonix Pharmaceuticals"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Alisertib","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Puma Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Puma Biotechnology"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAY1895344","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Bayer AG"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART4215","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ETX-197","moa":"CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensem Therapeutics \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Care Access Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Care Access Research \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ Eli Lilly"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Cancer Research Uk","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MRT-048","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Cancer Research Uk","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Cancer Research Uk"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MRT-048","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SY-5609","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ National Comprehensive Cancer Network"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0682","moa":"Estrogen-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0682","moa":"Estrogen-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Olema Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Olema Oncology"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Inapplicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Boxer Capital","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Boxer Capital"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"H3B-6545","moa":"Selective estrogen covalent receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"H3 Biomedicine Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"H3 Biomedicine Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"H3 Biomedicine Inc \/ Inapplicable"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ Lantern Pharma","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ Lantern Pharma"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University Of Illinois Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ University Of Illinois Chicago","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University Of Illinois Chicago"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University Of Illinois Chicago","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ University Of Illinois Chicago","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University Of Illinois Chicago"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"TTC Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lantern Pharma \/ TTC Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ TTC Oncology"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CFI-402257","moa":"||Tyrosine threonine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CFI-402257","moa":"||Tyrosine threonine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Veru","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Adelaide \/ Veru","highestDevelopmentStatusID":"8","companyTruncated":"University of Adelaide \/ Veru"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Immunolight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Immunolight","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Immunolight \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunolight \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2020","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Collaboration","leadProduct":"Vepdegestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Amcenestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breast International Group \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Breast International Group \/ Sanofi"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Eisai","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Inbiomotion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clodronic Acid Disodium Salt","moa":"Bone resorption","graph1":"Oncology","graph2":"Phase III","graph3":"Inbiomotion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inbiomotion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inbiomotion \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imlunestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camizestrant","moa":"SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"NHS England","sponsor":"University of Manchester","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||COX-1","graph1":"Oncology","graph2":"Phase II","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NHS England \/ University of Manchester","highestDevelopmentStatusID":"8","companyTruncated":"NHS England \/ University of Manchester"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLU-222","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLU-222","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onapristone","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"||Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Menarini","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Artiva Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INB03","moa":"TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"||GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Glycotope","sponsor":"PentixaPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"Lewis Y","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ PentixaPharm","highestDevelopmentStatusID":"4","companyTruncated":"Glycotope \/ PentixaPharm"},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Sanofi"},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Sanofi"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"StemVacs-V","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"||TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pionyr Immunotherapeutics \/ Ikena Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Ikena Oncology"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molibresib","moa":"||BET","graph1":"Oncology","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT3645","moa":"CDK4\/6","graph1":"Oncology","graph2":"Preclinical","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eribulin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"Pol-theta","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Repare Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Andira Pharmaceuticals","sponsor":"University of British Columbia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Andira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andira Pharmaceuticals \/ University of British Columbia","highestDevelopmentStatusID":"4","companyTruncated":"Andira Pharmaceuticals \/ University of British Columbia"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"RBI-1000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Precision NanoSystems \/ Replicate Bioscience"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"GQ1005","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-329","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InventisBio","sponsor":"GL Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"D-0502","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ GL Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InventisBio \/ GL Ventures"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Oncolytics Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Docetaxel","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alphamab Oncology \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Sanofi"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP-1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oasmia Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oasmia Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenalisib","moa":"PI3K delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhizen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute of Cancer Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"The Institute of Cancer Research \/ AstraZeneca"},{"orgOrder":0,"company":"Cannabotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid Extract","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cannabotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cannabotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cannabotech \/ Inapplicable"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"EPS 201","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Epsilogen \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Cipla","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Georgetown University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"SP-2-225","moa":"HDAC-6","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Georgetown University","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Georgetown University"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Health \/ Ellipses Pharma"},{"orgOrder":0,"company":"SynDevRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I","graph3":"SynDevRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynDevRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SynDevRx \/ Inapplicable"},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACTR707","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Unum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abpro","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"ABP 102","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Celltrion","highestDevelopmentStatusID":"4","companyTruncated":"Abpro \/ Celltrion"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Austin Biosciences","sponsor":"Financial Strategies Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"ABC-0996","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Austin Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin Biosciences \/ Financial Strategies Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Austin Biosciences \/ Financial Strategies Acquisition Corp."},{"orgOrder":0,"company":"Stony Brook University","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","graph1":"Oncology","graph2":"Discovery","graph3":"Stony Brook University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stony Brook University \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"2","companyTruncated":"Stony Brook University \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Minerva Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"huMNC2-CAR44","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Alphamab Oncology"},{"orgOrder":0,"company":"Proteovant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PVTX-321","moa":"ER","graph1":"Oncology","graph2":"Preclinical","graph3":"Proteovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteovant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Proteovant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BP1003","moa":"STAT3","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series B Financing","leadProduct":"SBT6050","moa":"Toll-like-8 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Silverback Therapeutics \/ Venture Partners"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Kindeva Drug Delivery \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ Sandoz B2B"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HSK31858","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Chiesi Group"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva Strategic Opportunities LLC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Agreement","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities LLC"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ALTA-2530","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ALTA-2530","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"CyPA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"CyPA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Onspira Therapeutics","sponsor":"Altavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"OSP-101","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Onspira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Onspira Therapeutics \/ Altavant Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Onspira Therapeutics \/ Altavant Sciences"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"CSF-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"CSF-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Pari","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Cyclosporine A","moa":"Calcineurin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Zambon Group SpA \/ Pari","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Pari"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Azithromycin","moa":"70s ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TATX-03a","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Sahmyook University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Meclofenamic Acid","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Sahmyook University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sahmyook University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sahmyook University \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Calyptus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calyptus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Advent","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Vitamin A Palmitate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Advent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Advent \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Advent \/ National Institutes of Health"},{"orgOrder":0,"company":"EXO Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EXOB-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"EXO Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"EXO Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EXO Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Series C Financing","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Oak Hill Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"OHB-607","moa":"IGF-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Oak Hill Bio","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Oak Hill Bio"},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Mecasermin Rinfabate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill Bio \/ Chiesi Group"},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mecasermin Rinfabate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill Bio \/ Chiesi Group"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Pharmaceutical \/ Avenue Therapeutics"},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Pharmaceutical \/ Avenue Therapeutics"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"AnnJi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ AnnJi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ AnnJi Pharmaceutical"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Kennedy's Disease Association","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReviR Therapeutics \/ Kennedy's Disease Association","highestDevelopmentStatusID":"2","companyTruncated":"ReviR Therapeutics \/ Kennedy's Disease Association"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nido Biosciences \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ 5Am Ventures"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cellusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Inapplicable"},{"orgOrder":0,"company":"Cellusion","sponsor":"Hangzhou Celregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Hangzhou Celregen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Hangzhou Celregen Therapeutics"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cairo Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NKTR-255","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Cairo Laboratory","highestDevelopmentStatusID":"4","companyTruncated":"Nektar Therapeutics \/ Cairo Laboratory"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CASI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Merck & Co"},{"orgOrder":0,"company":"Cellogen Therapeutics","sponsor":"Natco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellogen Therapeutics \/ Natco Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Cellogen Therapeutics \/ Natco Pharma"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"NMT-cP12","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeoMatrix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RenovaCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tissue-Specific Pluripotent Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RenovaCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"RenovaCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RenovaCare \/ Inapplicable"},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cerium Oxide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioCurity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Cultured Keratinocytes Dermal Fibroblasts Murine Collagen","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Genfa Medica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Genfa Medica \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"Genfa Medica \/ MediWound"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cultured Epidermal Autograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Balance Medical","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Balance Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Balance Medical \/ MediWound","highestDevelopmentStatusID":"10","companyTruncated":"Balance Medical \/ MediWound"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXS-6302","moa":"Pan-LOX","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Pharmaxis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaxis \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avita Medical \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Albumin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Xeno-Skin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XenoTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"XenoTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"NIHR","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ NIHR","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ NIHR"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Zukunftsfonds Heilbronn","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Funding","leadProduct":"CPV-101","moa":"C3 receptor","graph1":"Nephrology","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn","highestDevelopmentStatusID":"4","companyTruncated":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"CFB","graph1":"Nephrology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"GHS receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Endevica Bio"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"S-Pindolol Benzoate","moa":"5-HTA1a\/beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Adrenergic-beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar Pmj","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"KRAS","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Boxcar Pmj","highestDevelopmentStatusID":"1","companyTruncated":"Immuneering Corporation \/ Boxcar Pmj"},{"orgOrder":0,"company":"Sanifit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNF472","moa":"Calcification","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ Inapplicable"},{"orgOrder":0,"company":"Sanifit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNF472","moa":"Calcification","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ad5 Norovirus GI.1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-G1.1-NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-G1.1-NN","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-G1.1-NN","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Kanghua Biological Products","sponsor":"HilleVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"HIL-216","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chengdu Kanghua Biological Products","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Kanghua Biological Products \/ HilleVax","highestDevelopmentStatusID":"4","companyTruncated":"Chengdu Kanghua Biological Products \/ HilleVax"},{"orgOrder":0,"company":"Cincinnati Children's Hospital Medical Center","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cincinnati Children's Hospital Medical Center","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cincinnati Children's Hospital Medical Center \/ Blue Water Vaccines","highestDevelopmentStatusID":"3","companyTruncated":"Cincinnati Children's Hospital Medical Center \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Command","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ US Naval Medical Research Command","highestDevelopmentStatusID":"5","companyTruncated":"Immuron \/ US Naval Medical Research Command"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Westriver Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"LMN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ Westriver Management","highestDevelopmentStatusID":"8","companyTruncated":"Lumen Bioscience \/ Westriver Management"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LMN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumen Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"VaxAlta","sponsor":"Scandinavian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Campylobacter Jejuni Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxAlta","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VaxAlta \/ Scandinavian Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"VaxAlta \/ Scandinavian Biopharma"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MYR-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MYR-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Pfizer Inc"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BBP-812","moa":"ASPA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BBP-812","moa":"ASPA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Resilience","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"BBP-812","moa":"ASPA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Resilience \/ BridgeBio Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Resilience \/ BridgeBio Pharma"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PH284","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BST204","moa":"IL-6 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Green Cross Well-being","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Well-being \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Well-being \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Akanda Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Akanda Corp","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Akanda Corp"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Cannvalate"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Medlab Clinical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Clinical \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK115","moa":"NGF","graph1":"Neurology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Q-State Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Q-State Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q-State Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Q-State Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"itheranostics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"itheranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"itheranostics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"itheranostics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Theolytics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theolytics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theolytics \/ Inapplicable"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Reset Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Reset Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Reset Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fluocytosine","moa":"Thymidylate synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nystatin","moa":"||Ergosterol sequestering agent","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nystatin","moa":"||Ergosterol sequestering agent","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ The Lind Partners","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ The Lind Partners"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Vectans Pharma","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Miconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vectans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vectans Pharma \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Vectans Pharma \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Fluconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Purna Female Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Miconazole Nitrate","moa":"||Ergosterol synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Cream","sponsorNew":"Hyloris Pharmaceuticals \/ Purna Female Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Pharmaceuticals \/ Purna Female Healthcare"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anebulo Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"PMC-403","moa":"Tie2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"PharmAbcine \/ National Institutes of Health"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GIBF2","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GIBF2"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Durlobactam","moa":"||Beta-lactamases A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Antabio","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ANT3310","moa":"||Serine-beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antabio \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Bpifrance"},{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Curetis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curetis \/ BioVersys AG","highestDevelopmentStatusID":"6","companyTruncated":"Curetis \/ BioVersys AG"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"BV200","moa":"Transcription factor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioVersys AG \/ AMR Action Fund","highestDevelopmentStatusID":"4","companyTruncated":"BioVersys AG \/ AMR Action Fund"},{"orgOrder":0,"company":"Mutabilis","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"EBL-1463","moa":"PBP2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mutabilis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mutabilis \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Mutabilis \/ CARB-X"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Polymyxin","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"MicuRx Pharmaceuticals \/ CARB-X"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"GORTEC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ GORTEC","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ GORTEC"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"VEGF2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"VEGF2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stamford Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-002","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Stamford Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Stamford Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stamford Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Varian Biopharmaceuticals","sponsor":"HealthTech BioActives","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRAN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"VAR-101","moa":"PKC iota","graph1":"Oncology","graph2":"Preclinical","graph3":"Varian Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Varian Biopharmaceuticals \/ HealthTech BioActives","highestDevelopmentStatusID":"4","companyTruncated":"Varian Biopharmaceuticals \/ HealthTech BioActives"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Soroka Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MWPC005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Soroka Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Soroka Medical Center"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"DermBiont","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Oncology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DermBiont \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Inapplicable"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Catumaxomab","moa":"EpCAM\/CD3","graph1":"Oncology","graph2":"Phase III","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindis Biotech \/ Pharmanovia","highestDevelopmentStatusID":"10","companyTruncated":"Lindis Biotech \/ Pharmanovia"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Catumaxomab","moa":"EpCAM\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Lindis Biotech \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Lindis Biotech \/ Pharmanovia"},{"orgOrder":0,"company":"Celonic","sponsor":"Lindis Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Catumaxomab","moa":"EpCAM\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Celonic \/ Lindis Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Celonic \/ Lindis Biotech"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"188RNL-BAM","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Plus Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ 3B Future Health Fund II"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Sante Ventures"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VGXI","sponsor":"Geneos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VGXI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VGXI \/ Geneos Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"VGXI \/ Geneos Therapeutics"},{"orgOrder":0,"company":"ImaginAb","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"ImaginAb \/ TriSalus Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"MedTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Merger","leadProduct":"Nelitolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ MedTech","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ MedTech"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABX196","moa":"||Invariant natural killer T-cells","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Cirm","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Cirm"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Isleworth Healthcare Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ Isleworth Healthcare Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Isleworth Healthcare Acquisition Corp."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"TF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ TF Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ TF Capital"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Naya Biosciences \/ INVO Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Naya Biosciences \/ INVO Bioscience"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BC3402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"JWATM214","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BC3402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceuticals","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Hengrui Pharmaceuticals \/ Elevar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceuticals \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Suzhou Limited \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Netrin-1","graph1":"Oncology","graph2":"Phase I","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NETRIS Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NETRIS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EU307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eutilex Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eutilex Inc \/ GenScript ProBio","highestDevelopmentStatusID":"6","companyTruncated":"Eutilex Inc \/ GenScript ProBio"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GT90001","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AFP TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tegavivint","moa":"||TBL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bavituximab","moa":"||Phosphatidylserine","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus Biosciences"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus Biosciences"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Adagene Suzhou Limited"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Immunitor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepcortespenlisimut-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Immunitor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunitor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunitor \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CT-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CT-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Hallberg Management AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Hallberg Management AB","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Hallberg Management AB"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Quotient Sciences"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharmaceuticals \/ TaiRx"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"CyPA","graph1":"Oncology","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yiviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Sorafenib","moa":"||NFAT","graph1":"Oncology","graph2":"Phase II","graph3":"Yiviva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yiviva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yiviva \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLRs","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Lion TCR","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LioCyx-M004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lion TCR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Lion TCR \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lion TCR \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sinopharm Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"GFH018","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Sinopharm Capital","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sinopharm Capital"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"||A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teclison","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirapazamine","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Teclison","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Trans-arterial Injection","sponsorNew":"Teclison \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Teclison \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"225-Ac","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioArdis","sponsor":"Shenogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"BIO-1262","moa":"FGFR4","graph1":"Oncology","graph2":"Phase III","graph3":"BioArdis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArdis \/ Shenogen","highestDevelopmentStatusID":"10","companyTruncated":"BioArdis \/ Shenogen"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TXR-311","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"twoXAR Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Naya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Naya Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Naya Biosciences \/ Maxim Group LLC"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"CytoLynx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CYT-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ CytoLynx","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ CytoLynx"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"CYT-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"NY-500","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Preclinical","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Naya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THIO-103","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"THIO-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ BeiGene"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"K1.1 mRNA","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Ori-C101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OriCell Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"OriCell Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fisogatinib","moa":"||FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CPT-6281","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCerise Therapeutics","sponsor":"National Cancer Centre Singapore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"RCT1213","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ReCerise Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReCerise Therapeutics \/ National Cancer Centre Singapore","highestDevelopmentStatusID":"2","companyTruncated":"ReCerise Therapeutics \/ National Cancer Centre Singapore"},{"orgOrder":0,"company":"GC Cell","sponsor":"PT Bifarma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Immuncell-LC","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Cell \/ PT Bifarma","highestDevelopmentStatusID":"10","companyTruncated":"GC Cell \/ PT Bifarma"},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"XNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XNK Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"XNK Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ymmunobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"YB-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ymmunobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ymmunobio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ymmunobio \/ Inapplicable"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Microorganism","year":"2021","type":"Private Placement","leadProduct":"Decoy20","moa":"||Toll-like-4 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intech Biopharm Ltd \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Intech Biopharm Ltd \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Replimune \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roblitinib","moa":"||FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SK1-I","moa":"SPHK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzo Biochem \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Biochem \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Oklahoma Medical Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Oklahoma Medical Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Oklahoma Medical Research Foundation"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pepper Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Pepper Bio","highestDevelopmentStatusID":"6","companyTruncated":"G1 Therapeutics, Inc \/ Pepper Bio"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Kinnevik AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Kinnevik AB","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Kinnevik AB"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"CohBar","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Private Placement","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"CohBar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Undisclosed"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"CohBar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"TuHURA Biosciences \/ CohBar","highestDevelopmentStatusID":"6","companyTruncated":"TuHURA Biosciences \/ CohBar"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ITI-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ITI-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ITI-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NantKwest \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Tempus","sponsor":"Kartos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Navtemadlin","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ Kartos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tempus \/ Kartos Therapeutics"},{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"KAIMRC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"FLASH-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Flashpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flashpoint Therapeutics \/ KAIMRC","highestDevelopmentStatusID":"7","companyTruncated":"Flashpoint Therapeutics \/ KAIMRC"},{"orgOrder":0,"company":"CanProbe","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"177-Lu Octreotate","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CanProbe","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CanProbe \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"CanProbe \/ Point Biopharma"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etoposide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Recurv Pharma","sponsor":"TVM Capital Life Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"RP-001","moa":"Microtubule","graph1":"Oncology","graph2":"Preclinical","graph3":"Recurv Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Recurv Pharma \/ TVM Capital Life Science","highestDevelopmentStatusID":"4","companyTruncated":"Recurv Pharma \/ TVM Capital Life Science"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD16","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tot Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Tot Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tot Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tot Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C901","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"F. Hoffmann-La Roche \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ NeoImmuneTech"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Genentech"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVM14","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Partnership for Accelerating Cancer Therapies","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Partnership for Accelerating Cancer Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Partnership for Accelerating Cancer Therapies \/ Candel Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Partnership for Accelerating Cancer Therapies \/ Candel Therapeutics"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Financing","leadProduct":"Aglatimagene Besadenovec","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Silicon Valley Bank","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Memgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MEM-288","moa":"IFN-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Memgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Memgen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Memgen \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Axplora","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Nivolumab","moa":"||Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Axplora \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Axplora \/ Exelixis"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ligand Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HMBD-002","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbird Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"XB002","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Iconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iconic Therapeutics \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Iconic Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-5552","moa":"||Bi-Steric mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series D Financing","leadProduct":"Mecbotamab Vedotin","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAtla \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Soleus Capital"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||TIL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cellular Biomedicine Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"C-TIL051","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Cellular Biomedicine Group","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Cellular Biomedicine Group"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"BioAtla","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAtla \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Acuta Capital Partners"},{"orgOrder":0,"company":"BioAtla","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAtla \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ J.P. Morgan"},{"orgOrder":0,"company":"BioAtla","sponsor":"Tungsten Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Private Placement","leadProduct":"Mecbotamab Vedotin","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAtla \/ Tungsten Advisors","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Tungsten Advisors"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Lifileucel","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LN-145","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ligand Pharmaceuticals \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"||HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"NKMax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ NKMax","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ NKMax"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Telisotuzumab Vedotin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"EMB-01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI110","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"EMB-01","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Tangdu Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Tangdu Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tangdu Hospital \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tangdu Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ BeiGene"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Sandoz B2B"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ EQRx"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Sanofi"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TG6050","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TG6050","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Gustave Roussy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gustave Roussy \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Gustave Roussy \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Rilvegostomig","moa":"PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Rilvegostomig","moa":"PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DS-3939","moa":"TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Biocad","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BCD-100","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocad \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Pharmapark"},{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Humedix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humedix \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Humedix \/ Kineta"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"NKMax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Inapplicable"},{"orgOrder":0,"company":"NKMax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Osimertinib","moa":"||HER3","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Center for Breakthrough Medicines"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rilvegostomig","moa":"PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NC318","moa":"||Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NC318","moa":"Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NEO-201","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NEO-201","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"OncoC4","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Docetaxel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"OncoC4 \/ BioNTech"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTX-2101","moa":"c-Myc cell proliferation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Yumanity Therapeutics \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Yumanity Therapeutics \/ Kineta"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MYTX-011","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mythic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"||TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunitas Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pimivalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"EQRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Undisclosed"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oncorus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ONCR-021","moa":"ICAM-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ Inapplicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Financing","leadProduct":"ONCR-021","moa":"ICAM-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorus \/ K2 HealthVentures","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ K2 HealthVentures"},{"orgOrder":0,"company":"SystImmune","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Biosion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CDX-585","moa":"PD-1\/ILT-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celldex Therapeutics \/ Biosion","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Biosion"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dimesna","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"LP-300","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Immutep"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Termination","leadProduct":"Bintrafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ GSK"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Australian Ethical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Australian Ethical","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Australian Ethical"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"||Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"||Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Alliance Global Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GC4711","moa":"||Dismutase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"OncoC4","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ OncoC4","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ OncoC4"},{"orgOrder":0,"company":"BioNTech","sponsor":"OncoC4","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ OncoC4","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ OncoC4"},{"orgOrder":0,"company":"Lyvgen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"LVGN7409","moa":"||CD40","graph1":"Oncology","graph2":"Preclinical","graph3":"Lyvgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyvgen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Lyvgen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ITIL-306","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Beverly Hills Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Beverly Hills Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Beverly Hills Cancer Center"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MT-8421","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Private Placement","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Stifel","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Stifel"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Merck & Co"},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Merck & Co"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SEA-TGT","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"MK-5890","moa":"||CD27","graph1":"Oncology","graph2":"Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Chinook Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Grid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Infinimmune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Infinimmune \/ Grid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Infinimmune \/ Grid Therapeutics"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CART-TnMUC1-01","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NK cell","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"ROS receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"ROS receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ociperlimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"Ociperlimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Ociperlimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Utidelone","moa":"Microtubule","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Avistone Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"c-Met receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avistone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avistone Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"1","companyTruncated":"Avistone Pharmaceuticals \/ Vivo Capital"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IO Biotech \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"IO Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Novadiscovery","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Novadiscovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novadiscovery \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Novadiscovery \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Korea Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korea Investment Partners"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korean Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Korean Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korean Investment Partners"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||5T4 protein","graph1":"Oncology","graph2":"Phase II","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Translational Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"NeoTX Therapeutics \/ Translational Drug Development"},{"orgOrder":0,"company":"GAIA BioMedicine","sponsor":"TreeFrog Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"GAIA-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GAIA BioMedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GAIA BioMedicine \/ TreeFrog Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"GAIA BioMedicine \/ TreeFrog Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basilea Pharmaceutica \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Innovent Biologics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enara Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Touchlight","sponsor":"University of Liverpool","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Touchlight \/ University of Liverpool","highestDevelopmentStatusID":"3","companyTruncated":"Touchlight \/ University of Liverpool"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"IMM60","moa":"CD1d","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Portage Biotech \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Portage Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Acquisition","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"XtalPi","sponsor":"EDDC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"XtalPi \/ EDDC","highestDevelopmentStatusID":"2","companyTruncated":"XtalPi \/ EDDC"},{"orgOrder":0,"company":"Montai Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Montai Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Montai Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Montai Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"||KRAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elicio Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MET receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AgilVax","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SLC7A11","graph1":"Oncology","graph2":"Preclinical","graph3":"AgilVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AgilVax \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AgilVax \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IO Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ IO Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ IO Biotech"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Tumor growth","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Novocure","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Novocure"},{"orgOrder":0,"company":"COTA","sponsor":"Clinical Research Data Sharing Alliance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"COTA","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"COTA \/ Clinical Research Data Sharing Alliance","highestDevelopmentStatusID":"2","companyTruncated":"COTA \/ Clinical Research Data Sharing Alliance"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"BNT116","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ BioNTech"},{"orgOrder":0,"company":"Traverse Biotech","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Traverse Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Traverse Biotech \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Traverse Biotech \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GT103","moa":"CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GT103","moa":"CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GT103","moa":"CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"CDK-4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GT103","moa":"||CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Oncoprex","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Oncoprex","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Oncoprex","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BIOKEY","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLEX 404","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABVC BioPharma \/ BIOKEY","highestDevelopmentStatusID":"5","companyTruncated":"ABVC BioPharma \/ BIOKEY"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"OrbiMed Asia Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ OrbiMed Asia Partners","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ OrbiMed Asia Partners"},{"orgOrder":0,"company":"Kinnjiu Biopharma","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnjiu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnjiu Biopharma \/ Kinnate Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Kinnjiu Biopharma \/ Kinnate Biopharma"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mateon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Guardant Health","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"Guardant Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Guardant Health \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Guardant Health \/ AnHeart Therapeutics"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"CID-078","moa":"Cyclin A\/Cyclin B RxL","graph1":"Oncology","graph2":"Preclinical","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circle Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Circle Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"||CXCL-12","graph1":"Oncology","graph2":"Preclinical","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Xcovery","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xcovery \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Newg Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Newg Lab","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Newg Lab"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Newg Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Newg Lab","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Newg Lab"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nippon Kayaku","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Nippon Kayaku","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Nippon Kayaku"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFH018","moa":"||TGF-beta-1","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ AnHeart Therapeutics"},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Shouyao","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"SY-707","moa":"ALK\/FAK\/IGF1R multi-target kinase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PharmaBlock Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaBlock Sciences \/ Shouyao","highestDevelopmentStatusID":"9","companyTruncated":"PharmaBlock Sciences \/ Shouyao"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Inapplicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Inapplicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Inapplicable"},{"orgOrder":0,"company":"Voronoi","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Voronoi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voronoi \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Voronoi \/ ORIC Pharmaceuticals"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"National Health Research Institutes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABT-101","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anbogen Therapeutics \/ National Health Research Institutes","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Therapeutics \/ National Health Research Institutes"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milciclib","moa":"||CDK","graph1":"Oncology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RBN-2397","moa":"||PARP-7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BLU-945","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Zai Lab","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Zai Lab"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"RBN-2397","moa":"||PARP-7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Amgen Inc"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"3-Aminopyrrolidine dihydrochloride","moa":"VISTA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"9","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BLU-945","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-104","moa":"||Liver X receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"ReHeva Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RH324","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ReHeva Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReHeva Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReHeva Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Hillhouse Capital Group","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Arrivent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Sofinnova Investments","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Sofinnova Investments"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"||TORC1\/TORC2","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"SHP2","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TPX-0046","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"TORC1\/TORC2","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"TORC1\/TORC2","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"||MAPK-1\/MAPK-2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"||MAPK-1\/MAPK-2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"||MAPK-1\/MAPK-2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Locust Walk","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Tomivosertib","moa":"||MAPK-1\/MAPK-2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Locust Walk","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Locust Walk"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Repotrectinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-2449","moa":"FAK\/ALK\/ROS1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"JAB-3312","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jacobio Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CStone Pharmaceuticals \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Blueprint Medicines"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"Pangea Biomed","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Rigosertib","moa":"||RAS pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pangea Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pangea Biomed \/ Onconova Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pangea Biomed \/ Onconova Therapeutics"},{"orgOrder":0,"company":"Biomica","sponsor":"Rambam Health Care Campus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Rambam Health Care Campus","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Rambam Health Care Campus"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Calithera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Sapanisertib","moa":"TORC1\/TORC2","graph1":"Oncology","graph2":"Preclinical","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Calithera Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Takeda Pharmaceutical \/ Calithera Biosciences"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Meteva AS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Bemcentinib","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Meteva AS","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Meteva AS"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ BridgeBio Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||RAS pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||RAS pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Baili","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Osimertinib","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Baili","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Baili \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Baili \/ AstraZeneca"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ OncoX BioPharma"},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BIO-11006","moa":"MARCKS protein","graph1":"Oncology","graph2":"Phase II","graph3":"Acquist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Nebulizer","sponsorNew":"Acquist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acquist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"PlusVitech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Nanoform \/ PlusVitech","highestDevelopmentStatusID":"8","companyTruncated":"Nanoform \/ PlusVitech"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"||PTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ The Column Group","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Whitehawk Therapeutics \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aumolertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ EQRx"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Arrivent"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Senaparib","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zorifertinib","moa":"EGFR-TKI reversible","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alpha Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zorifertinib","moa":"EGFR-TKI reversible","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alpha Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Baring Private Equity Asia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Baring Private Equity Asia","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Baring Private Equity Asia"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"GL Mountrose Investment Two","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ GL Mountrose Investment Two","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ GL Mountrose Investment Two"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lazertinib","moa":"EGFR mutant-selective","graph1":"Oncology","graph2":"Approved FDF","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yuhan Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yuhan Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DKY709","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Hutchmed"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Cancer Research Uk","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"AZD4547","moa":"FGFR1","graph1":"Oncology","graph2":"Phase II","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Birmingham \/ Cancer Research Uk","highestDevelopmentStatusID":"8","companyTruncated":"University of Birmingham \/ Cancer Research Uk"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VITRAC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Abdul Latif Jameel Health","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Abdul Latif Jameel Health"},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ CM Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CM Life Sciences"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qiagen","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qiagen \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Mirati Therapeutics"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"Pan-KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IDO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"MAbSilico solutions","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"||CTLs","graph1":"Oncology","graph2":"Phase II","graph3":"MAbSilico solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MAbSilico solutions \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"8","companyTruncated":"MAbSilico solutions \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OSE2101","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Bpifrance"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ European Investment Bank"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"OSE2101","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OSE2101","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"OBI-833","moa":"Globo H","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"OmRx Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OX-4224","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"OmRx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OmRx Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OmRx Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"PT199","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"M1231","moa":"MUC1-EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck Group"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Axitinib","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"AB154","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Genelux","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genelux \/ Inapplicable"},{"orgOrder":0,"company":"BIOKEY","sponsor":"Rgene Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"RGC-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIOKEY \/ Rgene Corporation","highestDevelopmentStatusID":"4","companyTruncated":"BIOKEY \/ Rgene Corporation"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BDC-2034","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBO-8520","moa":"GTP","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"L-DOS47","moa":"VEGF2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Helix BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Helix BioPharma"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Helix BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Camonsertib","moa":"Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alethia Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AB-16B5","moa":"||EMT","graph1":"Oncology","graph2":"Phase II","graph3":"Alethia Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alethia Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alethia Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rutherrin","moa":"Transferrin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National University Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Adg106","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ National University Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ National University Cancer Institute"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Burning Rock Dx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Burning Rock Dx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burning Rock Dx \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Burning Rock Dx \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"Jiangsu Wuzhong Pharmaceutical Group Corporation","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Endostatin","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Wuzhong Pharmaceutical Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Wuzhong Pharmaceutical Group Corporation \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Wuzhong Pharmaceutical Group Corporation \/ Denovo Biopharma"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ABK3376","moa":"||EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Wuxi Shuangliang Biotechnology","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"C-005","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wuxi Shuangliang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuxi Shuangliang Biotechnology \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Wuxi Shuangliang Biotechnology \/ PharmAbcine"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"STX-241","moa":"C797S","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Scorpion Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Scorpion Therapeutics"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IPH5201","moa":"||CD39","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Biose Industrie","sponsor":"Biomica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Agreement","leadProduct":"BMC121","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biose Industrie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biose Industrie \/ Biomica","highestDevelopmentStatusID":"4","companyTruncated":"Biose Industrie \/ Biomica"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Yunfeng Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Etana Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etana Biotechnologies \/ Yunfeng Capital","highestDevelopmentStatusID":"15","companyTruncated":"Etana Biotechnologies \/ Yunfeng Capital"},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Termination","leadProduct":"Farletuzumab Ecteribulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Zelluna Immunotherapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"ZI-MA4-1","moa":"MAGE-A4","graph1":"Oncology","graph2":"Preclinical","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultimovacs \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"4","companyTruncated":"Ultimovacs \/ Zelluna Immunotherapy"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-LR1109","moa":"LILRB1","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Aveo Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Aveo Oncology"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-207","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Checkpoint protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wellmarker Bio \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Wellmarker Bio \/ Merck & Co"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JDQ443","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Biosion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Biosion","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Biosion"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"WindMIL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Marrow-Infiltrating Lymphocytes","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase II","graph3":"WindMIL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WindMIL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WindMIL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"WindMIL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Marrow-Infiltrating Lymphocytes","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase II","graph3":"WindMIL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WindMIL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WindMIL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"NUV-520","moa":"ROS1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Deerfield Management","highestDevelopmentStatusID":"5","companyTruncated":"Nuvalent \/ Deerfield Management"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"MK-4830","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Merck & Co"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"JTX-4014","moa":"||ICOS","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Concentra Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Concentra Biosciences"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KTX-201","moa":"STAT3","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-203","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SHP099","moa":"SHP2","graph1":"Oncology","graph2":"Preclinical","graph3":"NYU Langone","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NYU Langone \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"YL202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Maxim Group LLC"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moffitt Cancer Center \/ Anixa Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Moffitt Cancer Center \/ Anixa Biosciences"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVOVA-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Centus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mural Oncology \/ Alkermes Plc","highestDevelopmentStatusID":"10","companyTruncated":"Mural Oncology \/ Alkermes Plc"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RC88","moa":"MSLN","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BNT325","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Duality Biologics"},{"orgOrder":0,"company":"GSK","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Cancer Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ENB003","moa":"||ETB receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Cancer Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Coherus Biosciences \/ Cancer Research Institute"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase II","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GATC Health","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"GATC Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GATC Health \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GATC Health \/ Lisata Therapeutics"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Gemcitabine HCl","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CTGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Gemcitabine","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CG200745","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CrystalGenomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP-8\/DPP-9","graph1":"Oncology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"OSE2101","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ HengRui","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ HengRui"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIfT Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diakonos Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Inapplicable"},{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Immunotech Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"HERV-E TCR Transduced CD8+\/CD34+ Enriched T Cell","moa":"HERV-E","graph1":"Oncology","graph2":"Phase I","graph3":"T-Cure Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-Cure Bioscience \/ Immunotech Biopharm","highestDevelopmentStatusID":"6","companyTruncated":"T-Cure Bioscience \/ Immunotech Biopharm"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Adagene Suzhou Limited \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adagene Suzhou Limited \/ National Institutes of Health"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Curve Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Curve Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Curve Therapeutics \/ Columbus Venture Partners"},{"orgOrder":0,"company":"BostonGene","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BostonGene \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BostonGene \/ Washington University School of Medicine"},{"orgOrder":0,"company":"GeneCentric Therapeutics","sponsor":"Atrium Health Levine Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"GeneCentric Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"GeneCentric Therapeutics \/ Atrium Health Levine Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"GeneCentric Therapeutics \/ Atrium Health Levine Cancer Institute"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-HIF2","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"ENEA Tech and Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Genenta Science \/ ENEA Tech and Biomedical","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ ENEA Tech and Biomedical"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sarah Cannon Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Sarah Cannon Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Sarah Cannon Research Institute"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Oncorena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-954","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NKT2152","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Tarus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Tarus Therapeutics"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PTT-3196","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ NiKang Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ NiKang Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"TYRO3","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dovitinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Oncoheroes Biosciences Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Oncoheroes Biosciences Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Oncoheroes Biosciences Inc."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Allarity Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Allarity Therapeutics"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Catamaran Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"MaxCyte \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Catamaran Bio"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Monrol","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"177-Lu DOTA Girentuximab","moa":"||CA IX","graph1":"Oncology","graph2":"Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Telix Pharmaceuticals \/ Monrol","highestDevelopmentStatusID":"8","companyTruncated":"Telix Pharmaceuticals \/ Monrol"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":1.6000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Casdatifan","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Casdatifan","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Hercules Capital"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Casdatifan","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Exelixis","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Arcus Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Arcus Biosciences"},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Axitinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Auro Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage CSF-1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Auro Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Auro Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Auro Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacare Premium","sponsor":"Midas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"MALTA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage CSF-1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacare Premium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharmacare Premium \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacare Premium \/ Midas Pharma"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage CSF-1 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Merck & Co"},{"orgOrder":0,"company":"Sotio","sponsor":"PPF Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ PPF Group","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ PPF Group"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iOmx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series C Financing","leadProduct":"AB-2100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArsenalBio \/ Arch Ventures","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ Arch Ventures"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-2100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArsenalBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CD70 CAR-NK Cell","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"XmAb30819","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Sass & Larsen Aps","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncology Venture \/ Sass & Larsen Aps","highestDevelopmentStatusID":"10","companyTruncated":"Oncology Venture \/ Sass & Larsen Aps"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"177-Lu DPI-4452","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Isotope Technologies Munich","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ VIB","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ VIB"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCA356","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CMN-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AVB-500","moa":"||AXL\/GAS6 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Genenta Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Genenta Science","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Genenta Science"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase I","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Lytix Biopharma \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Financing","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Hercules Capital"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ J.P. Morgan"},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ J.P. Morgan"},{"orgOrder":0,"company":"Replimune","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"ANK-101","moa":"||Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Replimune","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Collaboration","leadProduct":"INCB99280","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Incyte Corporation"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Checkpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Biologics \/ Checkpoint Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Biologics \/ Checkpoint Therapeutics"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"||C5a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ifx-1","moa":"||C5a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HLX07","moa":"EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-200","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-200","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rigosertib","moa":"KRAS","graph1":"Oncology","graph2":"Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remetinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Tsai Laboratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NFX-179","moa":"MEK receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Tsai Laboratory","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Tsai Laboratory \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tsai Laboratory \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Checkpoint Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Seagen"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Funding","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ EIC Accelerator"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AVB-500","moa":"||AXL\/GAS6 pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMC-001","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Exelixis"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IK-175","moa":"||AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Arcus Biosciences"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"4D Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck Group \/ 4D Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Merck Group \/ 4D Pharma"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6746","moa":"PPA-gamma receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Celanese","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Celanese","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Celanese \/ Secarna Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Celanese \/ Secarna Pharma"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Flagship Pioneering \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Novo Nordisk"},{"orgOrder":0,"company":"Neomorph","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Neomorph","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neomorph \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ Novo Nordisk"},{"orgOrder":0,"company":"NanoVation Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"NanoVation Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoVation Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"NanoVation Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Abbisko Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"DCR-NOVO1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dicerna Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Gensaic","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Gensaic","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gensaic \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Gensaic \/ Novo Nordisk"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salipro Biotech \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Salipro Biotech \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Photys Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Photys Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Photys Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Photys Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"AMPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Medera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Medera \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medera \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Qatar Investment Authority","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Qatar Investment Authority","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Qatar Investment Authority"},{"orgOrder":0,"company":"Shionogi","sponsor":"Stemrim","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Redasemtide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Stemrim","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/ Stemrim"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"HTX-001","moa":"IncRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAYA Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"Celixir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"iMP Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celixir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celixir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celixir \/ Inapplicable"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Mayo Clinic \/ Solid Biosciences"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"Thromboxane prostanoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Renovacor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REN-001","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renovacor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Inapplicable"},{"orgOrder":0,"company":"Renovacor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REN-001","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renovacor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Inapplicable"},{"orgOrder":0,"company":"Renovacor","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"REN-001","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renovacor \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Rocket Pharmaceuticals"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emprumapimod","moa":"MAPK\/p38-alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nuevocor","sponsor":"EVX Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuevocor \/ EVX Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ EVX Ventures"},{"orgOrder":0,"company":"Nuevocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"LMNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuevocor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ Inapplicable"},{"orgOrder":0,"company":"Nuevocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuevocor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ Inapplicable"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Phlox Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solid Biosciences \/ Phlox Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Solid Biosciences \/ Phlox Therapeutics"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CK-3772271","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ BofA Securities"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ LianBio"},{"orgOrder":0,"company":"LianBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"MyoKardia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ MyoKardia","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ MyoKardia"},{"orgOrder":0,"company":"LianBio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ RA Capital Management"},{"orgOrder":0,"company":"Mid America Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mid America Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mid America Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mid America Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ RTW Investments"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Bayer AG"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ J.P. Morgan"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ J.P. Morgan"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Royalty Pharma"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Jixing Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Jixing Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jixing Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Jixing Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"ACSL4\/MPC","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"CT-G20","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bora Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Bora Pharmaceuticals \/ Celltrion"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Tenaya Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fulcrum Therapeutics \/ MyoKardia","highestDevelopmentStatusID":"2","companyTruncated":"Fulcrum Therapeutics \/ MyoKardia"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Gubra","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Bayer AG"},{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human Ipsc-Derived Cardiac Tissues","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoSurface Biomedical \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ National Institutes of Health"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Exemed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Grindeks AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"LATVIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyl-GBB","moa":"GBBH","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Grindeks AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grindeks AS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grindeks AS \/ Inapplicable"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bisoprolol Fumarate","moa":"||ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athena Pharmaceutiques \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Pharmaceutiques \/ Undisclosed"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Amarin","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Seqirus"},{"orgOrder":0,"company":"Amarin","sponsor":"Vianex S.A","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Vianex S.A","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Vianex S.A"},{"orgOrder":0,"company":"Neopharm","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Neopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neopharm \/ Amarin","highestDevelopmentStatusID":"15","companyTruncated":"Neopharm \/ Amarin"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"||COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ferrer Internacional \/ CNIC","highestDevelopmentStatusID":"15","companyTruncated":"Ferrer Internacional \/ CNIC"},{"orgOrder":0,"company":"NOVOS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trehalose","moa":"||Amyloid-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NOVOS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"NOVOS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NOVOS \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Lipigon","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Secarna Pharma \/ Lipigon","highestDevelopmentStatusID":"1","companyTruncated":"Secarna Pharma \/ Lipigon"},{"orgOrder":0,"company":"Kardigan","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Kardigan","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Perceptive Advisors","highestDevelopmentStatusID":"3","companyTruncated":"Kardigan \/ Perceptive Advisors"},{"orgOrder":0,"company":"Trianni","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Trianni","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trianni \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Trianni \/ AbCellera"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VTX2735","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bayer AG"},{"orgOrder":0,"company":"Ncardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Cardiomyocytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Ncardia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ncardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Ncardia \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"BW-02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AZD0780","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"CSPC Pharmaceutical Group \/ AstraZeneca"},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epigenic Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Draupnir Bio","sponsor":"MP Healthcare Venture Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Draupnir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Draupnir Bio \/ MP Healthcare Venture Management","highestDevelopmentStatusID":"4","companyTruncated":"Draupnir Bio \/ MP Healthcare Venture Management"},{"orgOrder":0,"company":"Institute of Cardiovascular and Metabolic Diseases","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Institute of Cardiovascular and Metabolic Diseases","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Cardiovascular and Metabolic Diseases \/ CSL","highestDevelopmentStatusID":"2","companyTruncated":"Institute of Cardiovascular and Metabolic Diseases \/ CSL"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Silence Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Silence Therapeutics"},{"orgOrder":0,"company":"Menarini","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Hansoh Pharma","highestDevelopmentStatusID":"2","companyTruncated":"OliX Pharmaceutical \/ Hansoh Pharma"},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATX-304","moa":"Pan-AMPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Amplifier Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifier Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Amplifier Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CS585","moa":"Prostacyclin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Cereno Scientific \/ University of Michigan"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Transferrin-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bicycle Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Ignota Labs","sponsor":"Montage Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"PDE9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ignota Labs","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Ignota Labs \/ Montage Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ignota Labs \/ Montage Ventures"},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Medicure","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Reliance Life Sciences Private Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reliance Life Sciences Private Limited \/ Medicure","highestDevelopmentStatusID":"1","companyTruncated":"Reliance Life Sciences Private Limited \/ Medicure"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"STP125G","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Quotient Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Quotient Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Quotient Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Riparian Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Riparian Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Magnet Biomedicine","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Magnet Biomedicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Magnet Biomedicine \/ Newpath Partners","highestDevelopmentStatusID":"3","companyTruncated":"Magnet Biomedicine \/ Newpath Partners"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scipher Medicine \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Scipher Medicine \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tectonic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Viva Biotech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Riparian Pharmaceuticals \/ Viva Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Riparian Pharmaceuticals \/ Viva Biotech"},{"orgOrder":0,"company":"Syndesis Health","sponsor":"InSyBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Syndesis Health","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndesis Health \/ InSyBio","highestDevelopmentStatusID":"3","companyTruncated":"Syndesis Health \/ InSyBio"},{"orgOrder":0,"company":"Humacyte","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Oberland Capital Management"},{"orgOrder":0,"company":"Histogen","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"HST-003","moa":"Hyaline cartilage","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ US Department of Defense"},{"orgOrder":0,"company":"Medable","sponsor":"Every Cure","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Medable","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medable \/ Every Cure","highestDevelopmentStatusID":"1","companyTruncated":"Medable \/ Every Cure"},{"orgOrder":0,"company":"Angany","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ANG-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Angany","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angany \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Angany \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JZP-258","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NPI-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NPI-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"AMP-100","moa":"Na channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"SINTETICA SA \/ Harrow","highestDevelopmentStatusID":"10","companyTruncated":"SINTETICA SA \/ Harrow"},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CAP4196","moa":"Alpha A crystallin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Plex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Plex Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plex Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ iOR Partners"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ARM210","moa":"RYR2","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ARMGO Pharma \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Forbion"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biorasi \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CXCR-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Allogenica","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"XL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogenica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogenica \/ French Government","highestDevelopmentStatusID":"4","companyTruncated":"Allogenica \/ French Government"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Xencor","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Plamotamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Zuberitamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"March Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"MB-105","moa":"PSCA","graph1":"Oncology","graph2":"Phase II","graph3":"March Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"March Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"March Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"March Biosciences","sponsor":"Mission BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"MB-105","moa":"PSCA","graph1":"Oncology","graph2":"Phase II","graph3":"March Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"March Biosciences \/ Mission BioCapital","highestDevelopmentStatusID":"8","companyTruncated":"March Biosciences \/ Mission BioCapital"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vyant Bio","sponsor":"The Loulou Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Vyant Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyant Bio \/ The Loulou Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Vyant Bio \/ The Loulou Foundation"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Kanyos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Kanyos Bio"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"CALY-002","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Merger","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Merger","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Inapplicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Mayo Clinic"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ National Institutes of Health"},{"orgOrder":0,"company":"Zedira","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"TAK-227","moa":"TG2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zedira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zedira \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Zedira \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"Endoprotease 40 Glutenase","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Nemysis \/ European Union"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"EQ102","moa":"IL-15\/IL-21 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Celiac Disease Foundation","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celiac Disease Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celiac Disease Foundation \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Celiac Disease Foundation \/ Provention Bio"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DONQ52","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ordesekimab","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provention Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Provention Bio \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Celiac","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Beyond Celiac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beyond Celiac \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Celiac \/ Provention Bio"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Forte Biosciences \/ OrbiMed Advisors"},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"TAK-062","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PvP Biologics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biologics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Topas Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"TPM502","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Topas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topas Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Topas Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VTP-1000","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate Biopharmaceuticals \/ RDD Pharma"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MTX-101","moa":"KIR dependent CD8 T-cell","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"MTX-101","moa":"KIR dependent CD8 T-cell","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Hypoimmunogenic Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"AgeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Orbital Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Orbital Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Beam Therapeutics \/ Orbital Therapeutics"},{"orgOrder":0,"company":"Clock.bio","sponsor":"LocalGlobe","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Clock.bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clock.bio \/ LocalGlobe","highestDevelopmentStatusID":"4","companyTruncated":"Clock.bio \/ LocalGlobe"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Capsida","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Capsida \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Secarna Pharma \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Plexium","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexium \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ AbbVie Inc"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Encoded Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Switch Therapeutics","sponsor":"Insight Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Switch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Switch Therapeutics \/ Insight Partners","highestDevelopmentStatusID":"4","companyTruncated":"Switch Therapeutics \/ Insight Partners"},{"orgOrder":0,"company":"Vivera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vivera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vivera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bioasis","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bioasis \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Midatech Pharma"},{"orgOrder":0,"company":"Lacerta Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Lacerta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lacerta Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lacerta Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Undisclosed"},{"orgOrder":0,"company":"Complix","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Complix \/ Jiangsu Nhwa Pharmaceutical"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"HitGen","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"NeuShen Therapeutics","sponsor":"LAPAM","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"NeuShen Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuShen Therapeutics \/ LAPAM","highestDevelopmentStatusID":"2","companyTruncated":"NeuShen Therapeutics \/ LAPAM"},{"orgOrder":0,"company":"Iktos","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iktos \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"3","companyTruncated":"Iktos \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"Panaxia","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Panaxia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Panaxia \/ Neuraxpharm","highestDevelopmentStatusID":"1","companyTruncated":"Panaxia \/ Neuraxpharm"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Italian Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"NKCC","graph1":"Neurology","graph2":"Discovery","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Italian Institute of Technology","highestDevelopmentStatusID":"2","companyTruncated":"IAMA Therapeutics \/ Italian Institute of Technology"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sibylla Biotech \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Sibylla Biotech \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"EditForce","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RNA","graph1":"Neurology","graph2":"Discovery","graph3":"EditForce","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EditForce \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"2","companyTruncated":"EditForce \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Modalis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JCR Pharmaceuticals \/ Modalis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"JCR Pharmaceuticals \/ Modalis Therapeutics"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Axil Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LUCA Science \/ Axil Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Science \/ Axil Capital Partners"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Otsuka Pharmaceutical \/ Schrodinger","highestDevelopmentStatusID":"2","companyTruncated":"Otsuka Pharmaceutical \/ Schrodinger"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sumitomo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salipro Biotech \/ Sumitomo","highestDevelopmentStatusID":"3","companyTruncated":"Salipro Biotech \/ Sumitomo"},{"orgOrder":0,"company":"EpiPharm","sponsor":"CycloLab Cyclodextrin Research and Development Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EpiPharm \/ CycloLab Cyclodextrin Research and Development Laboratory","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/ CycloLab Cyclodextrin Research and Development Laboratory"},{"orgOrder":0,"company":"Icagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion Channel","graph1":"Neurology","graph2":"Discovery","graph3":"Icagen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Icagen \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Icagen \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PrecisionLife","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"PrecisionLife","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PrecisionLife \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"PrecisionLife \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"SwanBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Purespring Therapeutics \/ SwanBio Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Purespring Therapeutics \/ SwanBio Therapeutics"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biodexa Pharmaceuticals \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Biodexa Pharmaceuticals \/ Midatech Pharma"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Biomedica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Biogen","sponsor":"Envisagenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biogen \/ Envisagenics","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Envisagenics"},{"orgOrder":0,"company":"BPGbio","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BPGbio \/ University of Oxford","highestDevelopmentStatusID":"3","companyTruncated":"BPGbio \/ University of Oxford"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dyno Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Wu Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Korro Bio \/ Wu Capital","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio \/ Wu Capital"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affinia Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nepicastat","moa":"DBH","graph1":"Neurology","graph2":"Preclinical","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acorda Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Acorda Therapeutics \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Passage Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Pennsylvania \/ Passage Bio","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Passage Bio"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shape Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Shape Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capsigen","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Capsigen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Capsigen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Capsigen \/ Biogen"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"||NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenvie Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tenvie Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tenvie Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Tenvie Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"PharmAla Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ PharmAla Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Mindset Pharma \/ PharmAla Biotech"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"MycoMedica Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MycoMedica Life Sciences \/ Obvious Ventures","highestDevelopmentStatusID":"1","companyTruncated":"MycoMedica Life Sciences \/ Obvious Ventures"},{"orgOrder":0,"company":"Filament Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Filament Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Filament Health \/ Inapplicable"},{"orgOrder":0,"company":"Mind Cure Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"8-Methoxycoronaridine HCl","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Mind Cure Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Cure Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Cure Health \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest BioEnergy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Solarvest BioEnergy","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma \/ Solarvest BioEnergy"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Modalis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JCR Pharmaceuticals \/ Modalis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"JCR Pharmaceuticals \/ Modalis Therapeutics"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"4","companyTruncated":"Synendos Therapeutics \/ Kurma Partners"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vanderbilt University \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Carnegie Mellon University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Treg-Derived Exosome","moa":"T-cell","graph1":"Neurology","graph2":"Undisclosed","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Carnegie Mellon University","highestDevelopmentStatusID":"1","companyTruncated":"Coya Therapeutics \/ Carnegie Mellon University"},{"orgOrder":0,"company":"UT Southwestern","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"TGTX-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"UT Southwestern","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern \/ Taysha Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwestern \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"Boost Neuroscience","sponsor":"Gate Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Boost Neuroscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boost Neuroscience \/ Gate Neurosciences","highestDevelopmentStatusID":"3","companyTruncated":"Boost Neuroscience \/ Gate Neurosciences"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"ProLynx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Inapplicable"},{"orgOrder":0,"company":"Voronoi","sponsor":"METiS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Pan-RAF","graph1":"Oncology","graph2":"Discovery","graph3":"Voronoi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voronoi \/ METiS Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Voronoi \/ METiS Therapeutics"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ONC206","moa":"D2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoceutics Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoceutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arctic Therapeutics","sponsor":"EIC fund","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ICELAND","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Grapiprant","moa":"Aldose reductase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Arctic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Arctic Therapeutics \/ EIC fund","highestDevelopmentStatusID":"8","companyTruncated":"Arctic Therapeutics \/ EIC fund"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Arctic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Arctic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Nacuity Pharmaceuticals \/ Arctic Therapeutics"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Arctic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Arctic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Nacuity Pharmaceuticals \/ Arctic Therapeutics"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BIOX-101","moa":"FXIa\/XIIa","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioxodes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Inapplicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BIOX-101","moa":"FXIa\/XIIa","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioxodes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Inapplicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"BIOX-101","moa":"FXIa\/XIIa","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioxodes \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"WH602","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Novan \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ National Institutes of Health"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NVD-X3","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CB 4332","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deutivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sosei Group Corporation \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Fiocruz","sponsor":"Nortec Quimica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Benznidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fiocruz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fiocruz \/ Nortec Quimica","highestDevelopmentStatusID":"8","companyTruncated":"Fiocruz \/ Nortec Quimica"},{"orgOrder":0,"company":"University of Georgia","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AN15368","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ AN2 Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University of Georgia \/ AN2 Therapeutics"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Mitsubishi Tanabe Pharma \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"DNDi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ DNDi","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Reddy\\'s Laboratories \/ DNDi"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"7HP349","moa":"||Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Helixmith","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Donaperminogene Seltoplasmid","moa":"HGF receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helixmith \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-083","moa":"GDF8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ENCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ENCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ENCell \/ Inapplicable"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DTx-1252","moa":"PMP22","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"DTx Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"DTx-1252","moa":"PMP22","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"DTx Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ CMT Research Foundation","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Therapeutics \/ CMT Research Foundation"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"AGT-100216","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Augustine Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Augustine Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Augustine Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ CMT Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ CMT Research Foundation"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Charcot Marie Tooth Association","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Charcot Marie Tooth Association","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Charcot Marie Tooth Association"},{"orgOrder":0,"company":"Nanite","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Nanite","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nanite \/ CMT Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nanite \/ CMT Research Foundation"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Armatus Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Andelyn Biosciences \/ Armatus Bio","highestDevelopmentStatusID":"4","companyTruncated":"Andelyn Biosciences \/ Armatus Bio"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Inflectis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Sephin1","moa":"PPP1R15A\/PP1c phosphatase complex","graph1":"Genetic Disease","graph2":"Phase I","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Chicago \/ Inflectis Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"University of Chicago \/ Inflectis Bioscience"},{"orgOrder":0,"company":"Pharnext","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Alpha Blue Ocean","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Neovacs","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Neovacs","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Neovacs"},{"orgOrder":0,"company":"Charcot Marie Tooth Association","sponsor":"Pharnext","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Baclofen","moa":"||PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Charcot Marie Tooth Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Charcot Marie Tooth Association \/ Pharnext","highestDevelopmentStatusID":"10","companyTruncated":"Charcot Marie Tooth Association \/ Pharnext"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CKD-510","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORY-4001","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VCA-894A","moa":"IGHMBP2","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"VCA-894A","moa":"IGHMBP2","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Saniona","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ABS-0871","moa":"TRPV4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actio Biosciences \/ Saniona","highestDevelopmentStatusID":"6","companyTruncated":"Actio Biosciences \/ Saniona"},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Actio Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actio Biosciences \/ Canaan Partners","highestDevelopmentStatusID":"4","companyTruncated":"Actio Biosciences \/ Canaan Partners"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Quris","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Quris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quris \/ Merck Group","highestDevelopmentStatusID":"4","companyTruncated":"Quris \/ Merck Group"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SK10","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhiyi Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhiyi Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biomm","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomm \/ Lupin Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Lupin Ltd"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosnetupitant Chloride","moa":"NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosnetupitant Chloride","moa":"NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"DanCann Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tetra BioPharma \/ DanCann Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ DanCann Pharma"},{"orgOrder":0,"company":"Avicanna","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avicanna \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Avicanna \/ Tetra BioPharma"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ WEX Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ WEX Pharmaceuticals"},{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ German Pain Association","highestDevelopmentStatusID":"1","companyTruncated":"Avextra \/ German Pain Association"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efbemalenograstim Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Sonnet BioTherapeutics Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics Holdings"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"5-HT transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"5-HT transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"5-HT transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Relyens Innovation Sant\u00e9","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Amitriptyline Hydrochloride","moa":"5-HT transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Relyens Innovation Sant\u00e9","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Relyens Innovation Sant\u00e9"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Varicella Zoster Immune Globulin (Human)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Divestment","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ CEPI","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ CEPI"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Instituto Butantan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Instituto Butantan","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Instituto Butantan"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"CDMRP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Alhydrogel","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ CDMRP","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ CDMRP"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Biotech \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Evotec","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EVT894","moa":"Chikungunya viral protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evotec \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ National Institutes of Health"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Synthetic T-cell Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Gylden Pharma \/ Department of Health and Social Care","highestDevelopmentStatusID":"2","companyTruncated":"Gylden Pharma \/ Department of Health and Social Care"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"T Cell Adaptive Chikungunya Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gylden Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Access to Advanced Health Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Access to Advanced Health Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Access to Advanced Health Institute \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Access to Advanced Health Institute \/ National Institutes of Health"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"Chikungunya Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Bavarian Nordic"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"BBV87","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bharat Biotech \/ CEPI"},{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iodine","moa":"Immunostimulant","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Integrated Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Novo Integrated Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Integrated Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gemlapodect","moa":"PDE10A","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gemlapodect","moa":"PDE10A","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Vivera Pharmaceuticals","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"VVRA\u2013TM 008","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vivera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Vivera Pharmaceuticals \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Vivera Pharmaceuticals \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Texas Health San Antonio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"Chlamydia Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blue Water Vaccines \/ University of Texas Health San Antonio","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ University of Texas Health San Antonio"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Texas Health Science Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"BWV-401","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blue Water Vaccines \/ University of Texas Health Science Center","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ University of Texas Health Science Center"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ BARDA"},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ BARDA"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Xuanzhu Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"KM257","moa":"HER2D4","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"ZielBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ZB131","moa":"CSP","graph1":"Oncology","graph2":"Preclinical","graph3":"ZielBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZielBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZielBio \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-200","moa":"FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Mayo Clinic"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gunagratinib","moa":"Pan-FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gunagratinib","moa":"Pan-FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||SPHK2","graph1":"Oncology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-00420","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Soundny Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hubei Soundny Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Soundny Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighTide Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighTide Therapeutics \/ US Food & Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ US Food & Drug Administration"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighTide Therapeutics \/ US Food & Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ US Food & Drug Administration"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ HBM Healthcare Investments","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ HBM Healthcare Investments"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Merger","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ ChemomAb","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ ChemomAb"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Merger","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ ChemomAb","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ ChemomAb"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ Cormorant Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ Cormorant Asset Management"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BX003","moa":"Klebsiella pneumoniae","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Volixibat","moa":"AAK-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Volixibat","moa":"AAK-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5-beta-1\/alpha-5-beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5-beta-1\/alpha-5-beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5-beta-1\/alpha-5-beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5-beta-1\/alpha-5-beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5-beta-1\/alpha-5-beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5-beta-1\/alpha-5-beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Virginia Commonwealth University","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OnKai","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OnKai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OnKai \/ Galmed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"OnKai \/ Galmed Pharmaceuticals"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"TCG","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Series A Financing","leadProduct":"Aldafermin","moa":"Bile acid synthesis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ TCG","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ TCG"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rectify Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RTY-694","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Rectify Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rectify Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rectify Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"NP-300","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Streeterville","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2025","type":"Collaboration","leadProduct":"NP-300","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Napo Therapeutics \/ Streeterville","highestDevelopmentStatusID":"5","companyTruncated":"Napo Therapeutics \/ Streeterville"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Cholera Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Biovac Institute \/ The International Vaccine Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ The International Vaccine Institute"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Cholera Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Biovac Institute \/ Wellcome Trust","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ Wellcome Trust"},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DuoChol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The International Vaccine Institute \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"The International Vaccine Institute \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"EuBiologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Euvichol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"GC Biopharma \/ EuBiologics","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ EuBiologics"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VPO-227","moa":"CFTR","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"6","companyTruncated":"Vanda Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"BBV131","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ImmTOR","moa":"||Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linerixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"EP547","moa":"MRGPX4 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"NEA","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"EP547","moa":"MRGPX4 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ NEA","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ NEA"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Linerixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Volixibat","moa":"AAK-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenofibrate","moa":"PPA-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"nACh-alpha-7 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Med-Life Discoveries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ppi-1011","moa":"Plasmalogen","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Med-Life Discoveries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"Med-Life Discoveries \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Med-Life Discoveries \/ Inapplicable"},{"orgOrder":0,"company":"Two Cells","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"gMSC1","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Two Cells","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Two Cells \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Two Cells \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Genialis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Genialis","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Genialis"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Minaris","sponsor":"MaxiVAX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"MVX-ONCO-2","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Minaris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minaris \/ MaxiVAX","highestDevelopmentStatusID":"8","companyTruncated":"Minaris \/ MaxiVAX"},{"orgOrder":0,"company":"MMJ International Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MMJ-002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MMJ International Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MMJ International Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MMJ International Holding \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2021","type":"Financing","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Matrix Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Matrix Capital Management"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Public Offering","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ SVB Securities"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecular Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"4D-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ 4D Molecular Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ 4D Molecular Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Timrepigene Emparvovec","moa":"Human choroideremia gene","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"NightstaRx Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Timrepigene Emparvovec","moa":"Human choroideremia gene","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ NightstaRx Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ NightstaRx Ltd"},{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Vitaeris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitaeris \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"Vitaeris \/ CSL"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Arkin Bio Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Taplucanium","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Nocion Therapeutics \/ Arkin Bio Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Nocion Therapeutics \/ Arkin Bio Ventures"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Axalbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axalbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"Nosis Bio","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Nosis Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nosis Bio \/ Daiichi Sankyo","highestDevelopmentStatusID":"3","companyTruncated":"Nosis Bio \/ Daiichi Sankyo"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Nora Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Prucalopride Succinate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Undisclosed \/ Nora Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Nora Pharma"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Evommune","highestDevelopmentStatusID":"3","companyTruncated":"AccutarBio \/ Evommune"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR-5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Normal Human Immunoglobulin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Immunology","graph2":"Preclinical","graph3":"MetrioPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MetrioPharm \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MetrioPharm \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Amilo-5MER","moa":"Serum amyloid A","graph1":"Immunology","graph2":"Preclinical","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galmed Pharmaceuticals \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Galmed Pharmaceuticals \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MRG-110","moa":"miR-92a","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vifor Pharma","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Vifor Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vifor Pharma \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Vifor Pharma \/ CARA Therapeutics"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Divestment","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Leo Pharma \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Ixaka","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Rexmyelocel-T","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ixaka","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial Catheter","sponsorNew":"Ixaka \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ixaka \/ Undisclosed"},{"orgOrder":0,"company":"Hemostemix","sponsor":"Mcgill University Health Centre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"ACP-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hemostemix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hemostemix \/ Mcgill University Health Centre","highestDevelopmentStatusID":"8","companyTruncated":"Hemostemix \/ Mcgill University Health Centre"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BGC101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"BioGenCell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Inapplicable"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Marius Nacht","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"BGC101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"BioGenCell \/ Marius Nacht","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Marius Nacht"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"IsomAb","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ISM-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"IsomAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IsomAb \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"IsomAb \/ Pfizer Inc"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Regenexx \/ Biorestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/ Biorestorative Therapies"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Vast Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"ALX1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vast Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vast Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Vast Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"||ROR1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"Xiromed","sponsor":"IntelGenx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Xiromed \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Xiromed \/ IntelGenx"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methadone Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fathom Pharma","sponsor":"Consegna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"FP01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Fathom Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fathom Pharma \/ Consegna Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fathom Pharma \/ Consegna Pharma"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ K2 HealthVentures","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ K2 HealthVentures"},{"orgOrder":0,"company":"Aptinyx","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ SVB Leerink"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"European Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ European Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ European Pharmaceutical"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"FutuRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BSEN760","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"FutuRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FutuRx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"FutuRx \/ Inapplicable"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AK1780","moa":"P2X7 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asahi Kasei Pharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kasei Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Creative Bio-Peptides","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"RAP-103","moa":"CXCR-4 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Creative Bio-Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creative Bio-Peptides \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Creative Bio-Peptides \/ National Institutes of Health"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PNV-5030","moa":"Adenosine A1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EicOsis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EicOsis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"FZ002-037","moa":"SST4 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Guangzhou Fermion Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Guangzhou Fermion Technology \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Fermion Technology \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Quotient Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Nafamostat Hcl","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Emplicure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emplicure \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emplicure \/ Quotient Sciences"},{"orgOrder":0,"company":"Shed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Shed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shed \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Avicanna","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Cannabinoid","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Knopp Biosciences LLC \/ Avicanna","highestDevelopmentStatusID":"15","companyTruncated":"Knopp Biosciences LLC \/ Avicanna"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Silo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tanezumab","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Aveva Drug Delivery Sytems, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aveva Drug Delivery Sytems, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Aveva Drug Delivery Sytems, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveva Drug Delivery Sytems, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kindeva Drug Delivery \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Kindeva Drug Delivery \/ Nutriband"},{"orgOrder":0,"company":"Veranova","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Veranova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Veranova \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Veranova \/ Nutriband"},{"orgOrder":0,"company":"Neurasic Therapeutic","sponsor":"McGill University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Acid-sensing ion channel","graph1":"Neurology","graph2":"Discovery","graph3":"Neurasic Therapeutic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurasic Therapeutic \/ McGill University","highestDevelopmentStatusID":"2","companyTruncated":"Neurasic Therapeutic \/ McGill University"},{"orgOrder":0,"company":"Stevanato Group","sponsor":"Bexson Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Stevanato Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stevanato Group \/ Bexson Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Stevanato Group \/ Bexson Biomedical"},{"orgOrder":0,"company":"1910 Genetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"1910 Genetics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"1910 Genetics \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"1910 Genetics \/ National Institutes of Health"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Discovery","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Knopp Biosciences LLC \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Knopp Biosciences LLC \/ National Institutes of Health"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"Netcapital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Naltrexone Analog","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Pharmalabs \/ Netcapital","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ Netcapital"},{"orgOrder":0,"company":"Pipeline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pipeline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pipeline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pipeline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"PDE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ LianBio"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keymed Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Keymed Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keymed Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Keymed Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Etokimab","moa":"IL-33 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Sustained Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Sustained Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sustained Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sustained Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evommune \/ Maruho","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Maruho"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"THB335","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Morgan Stanley"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ RBC Capital Markets","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ RBC Capital Markets"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"MasT-cell","graph1":"Immunology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Longbio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Longbio Pharma \/ Qiming Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"VB517","moa":"c-KIT receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novelty Nobility \/ ValenzaBio","highestDevelopmentStatusID":"5","companyTruncated":"Novelty Nobility \/ ValenzaBio"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INCB000262","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Acellular Human Extracellular Matrix","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Enzyme","year":"2024","type":"Funding","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NS-229","moa":"JAK1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Pergamum AB","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Promore Pharma \/ Pergamum AB","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Pergamum AB"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXS-6302","moa":"Pan-LOX","graph1":"Dermatology","graph2":"Phase I","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Pharmaxis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pharmaxis \/ Inapplicable"},{"orgOrder":0,"company":"Innovo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INV-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"KB investment","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Financing","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ KB investment","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ KB investment"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LEM-S401","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lemonex Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bio \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Purion Processed Dehydrated Human Amnion\/Chorion Membrane","moa":"TGF-beta-1","graph1":"Dermatology","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"ReCode Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Leaps by Bayer"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Bioluminescence Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Bioluminescence Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Bioluminescence Ventures"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GEORGIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GEORGIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Agilent Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transcenta Holding \/ Agilent Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Transcenta Holding \/ Agilent Technologies"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Arovella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"SPX-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SparX Biopharmaceutical \/ Arovella Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SparX Biopharmaceutical \/ Arovella Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Claudin18.2 mRNA Vaccine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"FutureGen","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"Discovery Platform","graph3":"FutureGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FutureGen \/ Gracell Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"FutureGen \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Apatinib","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LaNova Medicines \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PD-29875","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Series D Financing","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ OrbiMed Advisors","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"BNT211","moa":"||CLDN-6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Axcynsis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AT03-65","moa":"CLDN-6","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axcynsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcynsis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Axcynsis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ARC101","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"Third Arc Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Third Arc Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Arc Bio \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Nextech","highestDevelopmentStatusID":"4","companyTruncated":"Context Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"TSHA-118","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gene Therapies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PF-06425090","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Crestone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CRS3123","moa":"Methionyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crestone \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crestone \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"Genetic transcription","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGB Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"Genetic transcription","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGB Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Summit Biosciences","sponsor":"Polar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Private Placement","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Summit Biosciences \/ Polar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Summit Biosciences \/ Polar Capital"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ADS024","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phase Genomics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Phase Genomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phase Genomics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Phase Genomics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Quest Products","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quest Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quest Products \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quest Products \/ Undisclosed"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orsini Specialty Pharmacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Inapplicable"},{"orgOrder":0,"company":"Bacthera","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bacthera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bacthera \/ Seres Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Bacthera \/ Seres Therapeutics"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"CDL200","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"iNtRON Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Fzata","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Series A Financing","leadProduct":"FZ002","moa":"ToxA\/ToxB","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Fzata","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fzata \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fzata \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Oaktree Capital"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series D Financing","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Baupost Group"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Affiliates of Magnetar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Series D Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Affiliates of Magnetar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Affiliates of Magnetar Capital"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ AXA IM Alts","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ AXA IM Alts"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ BARDA"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Alexander Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Alexander Capital","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Alexander Capital"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Alexander Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Alexander Capital","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Alexander Capital"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Leiden University Medical Centre","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Leiden University Medical Centre","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Leiden University Medical Centre"},{"orgOrder":0,"company":"BiomeBank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BiomeBank","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BiomeBank \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BiomeBank \/ Inapplicable"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ US Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ US Department of Defense"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"finnCap Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"NTCD-M3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Destiny Pharma \/ finnCap Limited","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ finnCap Limited"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"NTCD-M3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Destiny Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2023","type":"Collaboration","leadProduct":"NTCD-M3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Destiny Pharma \/ Sebela Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Sebela Pharmaceuticals"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMM-529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMM-529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Tillotts Pharma AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Tillotts Pharma AG","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Tillotts Pharma AG"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Astellas Pharma"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Rebiotix"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Rebiotix"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Rebiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Inapplicable"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Rebiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Inapplicable"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Rebiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Live Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crestone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRS3123","moa":"Methionyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crestone \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crestone \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"SAB-195","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SAB Biotherapeutics \/ Brookline Capital Markets","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biotherapeutics \/ Brookline Capital Markets"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"SAB-195","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SAB Biotherapeutics \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biotherapeutics \/ Department of Defense"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-195","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"REC-3964","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Merger","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Erasmus University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Erasmus University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Erasmus University Medical Center"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocin Analog","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lobe Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocin Analog","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lobe Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ HAVN Life Sciences"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ HAVN Life Sciences"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Liechti Lab"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Telisotuzumab Vedotin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MYTX-011","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mythic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Omburtamab","moa":"Beta\/gamma-radiation","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Nafamostat","moa":"SARS-CoV-2 S","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2 S","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Bar-Ilan University"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Agreement","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Metyrapone","moa":"||CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Embera NeuroTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"BIRAD","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BIRAD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BIRAD \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BIRAD \/ Clearmind Medicine"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone Analog","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Phoenix Pharmalabs \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"Elanco","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Diclazuril","moa":"||Merozoite","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elanco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elanco \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Elanco \/ Merck & Co"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andelyn Biosciences \/ UMass Chan Medical School","highestDevelopmentStatusID":"3","companyTruncated":"Andelyn Biosciences \/ UMass Chan Medical School"},{"orgOrder":0,"company":"BPGbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Benzoquinone Ubidecarenone","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Inapplicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Spearmint Extract","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Healthy Extracts \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"University of Montreal Hospital Research Centre","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tetra BioPharma \/ University of Montreal Hospital Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ University of Montreal Hospital Research Centre"},{"orgOrder":0,"company":"Aviv Clinics","sponsor":"Sagol Center for Hyperbaric Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Aviv Clinics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aviv Clinics \/ Sagol Center for Hyperbaric Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Aviv Clinics \/ Sagol Center for Hyperbaric Medicine"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Aptinyx","sponsor":"CogState","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-458","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ CogState","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ CogState"},{"orgOrder":0,"company":"Syndesi Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"SDI-118","moa":"SV2A","graph1":"Neurology","graph2":"Phase I","graph3":"Syndesi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndesi Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Syndesi Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SUVN-I6107","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CST-103","moa":"ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glysious","sponsor":"Tetra Pharm Technologies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"TPT0201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Glysious","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glysious \/ Tetra Pharm Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Glysious \/ Tetra Pharm Technologies"},{"orgOrder":0,"company":"Vandria","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"VNA-318","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ Innosuisse","highestDevelopmentStatusID":"6","companyTruncated":"Vandria \/ Innosuisse"},{"orgOrder":0,"company":"Vandria","sponsor":"ND Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"VNA-318","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ ND Capital","highestDevelopmentStatusID":"6","companyTruncated":"Vandria \/ ND Capital"},{"orgOrder":0,"company":"Vandria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VNA-318","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vandria \/ Inapplicable"},{"orgOrder":0,"company":"TheraVac","sponsor":"Perceiv AI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"TV-301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"TheraVac","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TheraVac \/ Perceiv AI","highestDevelopmentStatusID":"5","companyTruncated":"TheraVac \/ Perceiv AI"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BNC375","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Damona Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPX-101","moa":"Alpha-5-GABAA-R","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Damona Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Damona Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Damona Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Monument Therapeutics","sponsor":"Forster Foundation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"MT1988","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Monument Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monument Therapeutics \/ Forster Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Monument Therapeutics \/ Forster Foundation"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1","graph1":"Neurology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Pan-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Pan-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pan-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pan-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reistone Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Niclosamide","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"IND Enabling","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PNV-6005","moa":"ADORA2A","graph1":"Immunology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Celerion"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ SVB Leerink"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Tulisokibart","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Polpharma Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Olamkicept","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ I-Mab Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ I-Mab Biopharma"},{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Immutep"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Equillium"},{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ GSK"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roivant Sciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"OR-812","moa":"RAR-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ NIDDK"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thetis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Palisade Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Palisade Bio","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Palisade Bio"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amiselimod HCl","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"APL-1401","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APL-1401","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01003","moa":"JAK","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LNK01003","moa":"JAK","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"R-3750","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"SER-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ADS024","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Adiso Therapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Eli Lilly"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"VE202","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"FIN-524","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ensho Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Ensho Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensho Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensho Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"D. E. Shaw Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DES-7114","moa":"KV1.3 potassium ion channel","graph1":"Immunology","graph2":"Phase I","graph3":"D. E. Shaw Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"D. E. Shaw Research \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"D. E. Shaw Research \/ Eli Lilly"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Assembly Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AstraGin","moa":"Bacterial gut","graph1":"Immunology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NuLiv Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Science \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Kreos Capital"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MB310","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Microbiotica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Microbiotica \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Collaboration","leadProduct":"CP101","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Brigham and Women's Hospital"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Bacthera","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"MAP 315","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Microba Life Sciences \/ Bacthera","highestDevelopmentStatusID":"6","companyTruncated":"Microba Life Sciences \/ Bacthera"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Giiant pharma \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Giiant pharma \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Microbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MS-20","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Microbio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Microbio \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ BofA Securities"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Arena Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Arena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arena Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arena Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Arena Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Arena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arena Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arena Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"T21","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AC-101","moa":"RIPK2","graph1":"Immunology","graph2":"Phase I","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Accro Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Accro Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"T21","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LianBio \/ NImmune Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ NImmune Biopharma"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Immunology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Immunology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"KU Leuven","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ KU Leuven","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ KU Leuven"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ LianBio","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ LianBio"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"NImmune Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ NImmune Biopharma"},{"orgOrder":0,"company":"NIMML Institute","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"NIMML Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NIMML Institute \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"NIMML Institute \/ NImmune Biopharma"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NImmune Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"Alpha-4 integrin","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ EA Pharma"},{"orgOrder":0,"company":"LG Chem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"LG Chem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PN-943","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Suono Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SUO-2002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Suono Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Suono Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Suono Bio \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Foam","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Vinnova"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Cobitolimod","moa":"Toll-like-9 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Parexel Biotech \/ InDex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ InDex Pharmaceuticals"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TEV-48574","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ BVF Partners"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Duvakitug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Duvakitug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Beta-7 integrin ligand","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Beta-7 integrin ligand","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CLS-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comera Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA052","moa":"CD30","graph1":"Immunology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH-063","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vitality","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Cannabosides","moa":"CB1 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Vitality","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitality \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vitality \/ Undisclosed"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"Anbison","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Anbison","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbison \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Anbison \/ Ethypharm"},{"orgOrder":0,"company":"Centre for Chinese Herbal Medicine Drug Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CDD-2103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Centre for Chinese Herbal Medicine Drug Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Chinese Herbal Medicine Drug Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Chinese Herbal Medicine Drug Development \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lusvertikimab","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lusvertikimab","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Reprocell","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"HT-003","moa":"Toll-like-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Reprocell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reprocell \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Reprocell \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Massachusetts General Hospital \/ Royalty Pharma"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Applied BioMath","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsius Therapeutics \/ Applied BioMath","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ Applied BioMath"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CEL383","moa":"TREM1","graph1":"Immunology","graph2":"Preclinical","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celsius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB295","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KB295","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KB295","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sorriso Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SOR102","moa":"TNF-alpha\/IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sorriso Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorriso Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorriso Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Immunology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ColonaryConcepts \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Inapplicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"||SLC12A1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Faes Farma","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Faes Farma"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Centus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alkermes Plc \/ Clovis Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Alkermes Plc \/ Clovis Oncology"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"MedStar Washington Hospital Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"MedStar Washington Hospital Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MedStar Washington Hospital Center \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MedStar Washington Hospital Center \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MDNA223","moa":"IL-2-beta-receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Avelos Therapeutics","sponsor":"Stassets Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"AD1208","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avelos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avelos Therapeutics \/ Stassets Investment","highestDevelopmentStatusID":"5","companyTruncated":"Avelos Therapeutics \/ Stassets Investment"},{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DBPR115","moa":"Cancer cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase I","graph3":"National Health Research Institutes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Health Research Institutes \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Health Research Institutes \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabidivarin","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RNAimmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RNAimmune \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Preclinical","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV2tYF-PR1.7-hCNGB3","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CNGB3","moa":"CNGB3","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Welton Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"SN38","moa":"||Topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Lubrizol Life Science Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lubrizol Life Science Health \/ Welton Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lubrizol Life Science Health \/ Welton Pharma"},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Viatris"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"TG6002","moa":"FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Tianjin Tasly Group","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Liminatus Pharma","sponsor":"Iris Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Ad5.F35-hGCC-PADRE","moa":"GCC","graph1":"Oncology","graph2":"Phase II","graph3":"Liminatus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Liminatus Pharma \/ Iris Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Liminatus Pharma \/ Iris Acquisition Corp"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Hercules Capital"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Private Placement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Redmile Group"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ TD Cowen"},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ Inapplicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"MVA-209-FSP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Targovax \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ AstraZeneca"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Pivotal Bioventure Partners","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Pivotal Bioventure Partners","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Pivotal Bioventure Partners"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"ALT-702","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PH-762","moa":"||TIGIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PH-804","moa":"TIGIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL-12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A2 Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A2 Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A2 Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"Taiga Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TBX-3400","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taiga Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiga Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiga Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invios \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-101","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Merck & Co"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"LipoMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Promitil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Tumor vasculature disruption","graph1":"Oncology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Saposin C","moa":"||S1P receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Saposin C","moa":"S1P receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enzene Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Enzene Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asciminib","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"5 Fluorouracil","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Favezelimab","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FivepHusion \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Syneos Health"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FivepHusion \/ Allarity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Allarity Therapeutics"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Autogene Cevumeran","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Genentech"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Carina Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"BNC101","moa":"LGR5","graph1":"Oncology","graph2":"Phase I","graph3":"Bionomics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Bionomics \/ Carina Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Bionomics \/ Carina Biotech"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CuraTeQ Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"CuraTeQ Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CuraTeQ Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CuraTeQ Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Apobiologix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apobiologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apobiologix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apobiologix \/ Inapplicable"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Onco-Innovations \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Etana Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Etana Biotechnologies","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Etana Biotechnologies"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"PF-08046052","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lava Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"PALADIN LABS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ PALADIN LABS","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ PALADIN LABS"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Solasia Pharma KK","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Solasia Pharma KK"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Botensilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Tanner Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Tanner Pharma"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APR003","moa":"Toll-like-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Apros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trovagene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Inapplicable"},{"orgOrder":0,"company":"Trovagene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Inapplicable"},{"orgOrder":0,"company":"Trovagene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methoxyamine","moa":"||DNA base excision repair pathway","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Phenomic AI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phenomic AI \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Phenomic AI \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"EdiGene","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EdiGene \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"Chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nordic Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Lumicks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycostem Therapeutics \/ Lumicks","highestDevelopmentStatusID":"4","companyTruncated":"Glycostem Therapeutics \/ Lumicks"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Mountain Crest Acquisition Corp. V","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Mountain Crest Acquisition Corp. V","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Mountain Crest Acquisition Corp. V"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"WM-S1-030","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wellmarker Bio \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"Wellmarker Bio \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Neogap","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogap","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neogap \/ Karolinska University Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Neogap \/ Karolinska University Hospital"},{"orgOrder":0,"company":"NeoPhore","sponsor":"CRT Pioneer Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"MMR","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeoPhore \/ CRT Pioneer Fund","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ CRT Pioneer Fund"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celsius Therapeutics \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ Servier"},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Polaris Innovation Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Pin1","graph1":"Oncology","graph2":"Discovery","graph3":"Larkspur Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Larkspur Biosciences \/ Polaris Innovation Fund","highestDevelopmentStatusID":"2","companyTruncated":"Larkspur Biosciences \/ Polaris Innovation Fund"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ DCVC Bio"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"DHX9","graph1":"Oncology","graph2":"Preclinical","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Accent Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Accent Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperovax","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Esperovax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperovax \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Esperovax \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Sands Capital","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Sands Capital"},{"orgOrder":0,"company":"Rgenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Tenmile","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carina Biotech \/ Tenmile","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Tenmile"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erasca \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Pierre Fabre"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denosumab","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Erasca","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Erasca"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||PTK","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||PTK","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Accelerating Clinical Trial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Qbeco","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Accelerating Clinical Trial","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Accelerating Clinical Trial"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Foundation Medicine"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series B Financing","leadProduct":"Carboplatin","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ MPM BioImpact"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Angion Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Angion Biomedica","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Angion Biomedica"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"TIDAL-01","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TIDAL-01","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"APN-346958","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Xencor","highestDevelopmentStatusID":"4","companyTruncated":"Atreca \/ Xencor"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"TIDAL-01","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"myNEO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CAMYO-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"myNEO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"myNEO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"myNEO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"Neurotensin type-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Ipsen"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"SOT109","moa":"CDH17","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Sotio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Sotio"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SOT109","moa":"CDH17","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Angelor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ Angelor","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ Angelor"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EO4010","moa":"||Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EO2040","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"French Blood Establishment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ French Blood Establishment","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ French Blood Establishment"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"225-Ac","moa":"||Neurotensin type-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Fusion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Fusion Pharma"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"BioWin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDC*line Pharma \/ BioWin","highestDevelopmentStatusID":"4","companyTruncated":"PDC*line Pharma \/ BioWin"},{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Asciminib","moa":"DLL4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trigr \/ Elpiscience","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Elpiscience"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Ben-Gurion University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"P-Esbp Conjugated Doxorubicin","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxil Bio \/ Ben-Gurion University","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Ben-Gurion University"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"HTL0039732","moa":"EP4 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Group Corporation \/ Cancer Research"},{"orgOrder":0,"company":"Merus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR\/LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Merck & Co"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"P18-BE3CRC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"GCX","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gnubiotics Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gnubiotics Sciences \/ University of Zurich","highestDevelopmentStatusID":"5","companyTruncated":"Gnubiotics Sciences \/ University of Zurich"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"5-HTA1a\/beta-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||dUTPase","graph1":"Oncology","graph2":"IND Enabling","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV6 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CV6 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"In3Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IN01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"In3Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ Inapplicable"},{"orgOrder":0,"company":"In3Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IN01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"In3Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Luminous Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Financing","leadProduct":"PolyPEPI-1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Luminous Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Luminous Ventures"},{"orgOrder":0,"company":"Immunocore","sponsor":"Gadeta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"GDT201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Gadeta","highestDevelopmentStatusID":"4","companyTruncated":"Immunocore \/ Gadeta"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CNBX RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CNBX RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Purisys LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Purisys LLC","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Purisys LLC"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Aposense","highestDevelopmentStatusID":"1","companyTruncated":"Processa Pharmaceuticals \/ Aposense"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Sirtex Medical \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LRK-A","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Larkspur Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larkspur Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Larkspur Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LYT-200","moa":"Galectin-9","graph1":"Oncology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MiNK-215","moa":"FAP-expressing CAF","graph1":"Oncology","graph2":"Preclinical","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TNX-1700","moa":"||TFF2","graph1":"Oncology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"99mTc-Duramycin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"The French National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"Tipiracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ The French National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"XBiotech \/ The French National Cancer Institute"},{"orgOrder":0,"company":"GlycoMantra","sponsor":"University of Maryland","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"GM300","moa":"Galectin-3","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoMantra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoMantra \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"GlycoMantra \/ University of Maryland"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Ad5 CEA\/MUC1\/Brachyury Vaccine Tri-Ad5","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BA-1049","moa":"ROCK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"China Pharma Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"China Pharma Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"China Pharma Holdings \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"China Pharma Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"NMDA receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"NMDA receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"||NMDA receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lactiga","sponsor":"1517 Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ 1517 Fund","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ 1517 Fund"},{"orgOrder":0,"company":"Terragenx","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Iodine","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Terragenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Terragenx \/ Novo Integrated Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Terragenx \/ Novo Integrated Sciences"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Microneedle Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"Zosano Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"RVAC Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"RVM-V001","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GenScript ProBio \/ RVAC Medicines","highestDevelopmentStatusID":"6","companyTruncated":"GenScript ProBio \/ RVAC Medicines"},{"orgOrder":0,"company":"Bugworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bugworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CTS-2090","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Microviable Therapeutics","sponsor":"Inmunomet Intolerancia y Disbiosis SL","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Large Molecule","year":"2022","type":"Financing","leadProduct":"MVT-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microviable Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microviable Therapeutics \/ Inmunomet Intolerancia y Disbiosis SL","highestDevelopmentStatusID":"4","companyTruncated":"Microviable Therapeutics \/ Inmunomet Intolerancia y Disbiosis SL"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CV7301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"Eclipse Bioinnovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RNA-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Eclipse Bioinnovations","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eclipse Bioinnovations \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Eclipse Bioinnovations \/ Inapplicable"},{"orgOrder":0,"company":"Verndari","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"VaxiPatch","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verndari \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/ BARDA"},{"orgOrder":0,"company":"Codexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Codexis \/ GSK"},{"orgOrder":0,"company":"Transcell Oncologics","sponsor":"L2P Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Transcell Oncologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcell Oncologics \/ L2P Research","highestDevelopmentStatusID":"4","companyTruncated":"Transcell Oncologics \/ L2P Research"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Protein-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Dyadic International, Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Altesa Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Acuitas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-LNP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Pfizer Inc"},{"orgOrder":0,"company":"HitGen","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Evotec"},{"orgOrder":0,"company":"Baidu Research","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Baidu Research","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baidu Research \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Baidu Research \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Translate Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"bitBiome","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"bitBiome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"bitBiome \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"bitBiome \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"RevolKa","sponsor":"La Jolla Institute for Immunology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"RK009","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevolKa \/ La Jolla Institute for Immunology","highestDevelopmentStatusID":"2","companyTruncated":"RevolKa \/ La Jolla Institute for Immunology"},{"orgOrder":0,"company":"3PBiovian","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ SpyBiotech","highestDevelopmentStatusID":"1","companyTruncated":"3PBiovian \/ SpyBiotech"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"BAL2420","moa":"LptA","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Pharmaceutica \/ CARB-X"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxas \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Vaxxas \/ Merck & Co"},{"orgOrder":0,"company":"X-Chem","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"TNX-4200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X-Chem \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"X-Chem \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Arranta Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Arranta Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arranta Bio \/ Recipharm AB","highestDevelopmentStatusID":"1","companyTruncated":"Arranta Bio \/ Recipharm AB"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ US Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ US Department of Defense"},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Achilles Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"InSilicoTrials","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSilicoTrials \/ Achilles Vaccines","highestDevelopmentStatusID":"2","companyTruncated":"InSilicoTrials \/ Achilles Vaccines"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Nafithromycin","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Wockhardt \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Inapplicable"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Nafithromycin","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Wockhardt \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Inapplicable"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Jiangxi Jemincare Group Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Nafithromycin","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wockhardt \/ Jiangxi Jemincare Group Company","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ Jiangxi Jemincare Group Company"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eleva","sponsor":"3PBIOVIAN","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Factor H","moa":"CFH","graph1":"Nephrology","graph2":"Preclinical","graph3":"Eleva","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eleva \/ 3PBIOVIAN","highestDevelopmentStatusID":"4","companyTruncated":"Eleva \/ 3PBIOVIAN"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3 receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"SLN501","moa":"C3 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Perilesional Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Biopharmaceutical Research Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Biopharmaceutical Research Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopharmaceutical Research Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biopharmaceutical Research Company \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"Soin Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Neuroscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soin Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soin Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Soin Therapeutics","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soin Therapeutics \/ JanOne","highestDevelopmentStatusID":"4","companyTruncated":"Soin Therapeutics \/ JanOne"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ArrePath","sponsor":"PACE","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"AP-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ArrePath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArrePath \/ PACE","highestDevelopmentStatusID":"4","companyTruncated":"ArrePath \/ PACE"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Lactiplantibacillus Pentosus ONRICb0240","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Podophyllotoxin","moa":"TUBA4A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Toregem BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"TRG035","moa":"USAG1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Toregem BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Toregem BioPharma"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Enzyvant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"Allogeneic Processed Thymus Tissue","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altavant Sciences \/ Enzyvant Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Altavant Sciences \/ Enzyvant Therapeutics"},{"orgOrder":0,"company":"Enzyvant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Processed Thymus Tissue","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Enzyvant","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzyvant \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Enzyvant \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"AUG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ AUG Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ AUG Therapeutics"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTO-825","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Cam Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Cam Capital","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Cam Capital"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ SLR Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ SLR Capital Partners"},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rezolute"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AmideBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-G023","moa":"GCGR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AmideBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/ Inapplicable"},{"orgOrder":0,"company":"AmideBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-G023","moa":"GCGR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AmideBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"GLP-1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmideBio \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"AmideBio \/ NIDDK"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Islasertib","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MDL-101","moa":"Laminin-alpha-1 protein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modalis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2021","type":"Divestment","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Kedrion","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Kedrion"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Okogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"OKG-0301","moa":"Protein Biosynthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Okogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Okogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Okogen \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluorometholone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Quotient Sciences"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Nanomerics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Quotient Sciences \/ Nanomerics","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Nanomerics"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tetraphase Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetraphase Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"EA Pharma \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"EA Pharma \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lactulose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cadila Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Picosulfate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Menarini \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Lupin Ltd"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pradigastat","moa":"DGAT1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sennosides","moa":"AQP-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avrio Health \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Arcadia Consumer Healthcare"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sennosides","moa":"AQP-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avrio Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elobixibat Hydrate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Summit Pharmaceuticals","sponsor":"Quest Products","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Docusate Potassium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Summit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Summit Pharmaceuticals \/ Quest Products","highestDevelopmentStatusID":"15","companyTruncated":"Summit Pharmaceuticals \/ Quest Products"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"NEXT Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vasalgel","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"NEXT Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"NEXT Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NEXT Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aurohealth","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurohealth","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Aurohealth \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aurohealth \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"YourChoice Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"YourChoice Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quotient Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Slayback Pharma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Lupin Ltd"},{"orgOrder":0,"company":"AT Research Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Halogenated Fullerene Nanoparticle","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"AT Research Partners","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AT Research Partners \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AT Research Partners \/ Inapplicable"},{"orgOrder":0,"company":"Xiromed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Xiromed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xiromed \/ Inapplicable"},{"orgOrder":0,"company":"Morningside Pharmaceuticals","sponsor":"Aspire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Gestodene","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Morningside Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Morningside Pharmaceuticals \/ Aspire Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Morningside Pharmaceuticals \/ Aspire Pharma"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Theramex"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Organon"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Norethisterone","moa":"LH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Fuji Pharma"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Fuji Pharma"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estetrol","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estetrol","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2025","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Theramex \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Theramex \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Newco","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Demerger","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Merck & Co \/ Newco","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Newco"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Merck & Co \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Organon \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Merck & Co"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Norelgestromin","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Norelgestromin","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Gedeon Richter"},{"orgOrder":0,"company":"Vers\u00e9a Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Vers\u00e9a Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vers\u00e9a Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vers\u00e9a Health \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Nomegestrol Acetate","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theramex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Inapplicable"},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Population Council","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Partnership","leadProduct":"Segesterone Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lubrizol Life Science Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lubrizol Life Science Health \/ Population Council","highestDevelopmentStatusID":"1","companyTruncated":"Lubrizol Life Science Health \/ Population Council"},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Afaxys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Afaxys Pharma \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Afaxys Pharma \/ TherapeuticsMD"},{"orgOrder":0,"company":"Nuvisan GmbH","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Nuvisan GmbH","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Farmitalia","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Farmitalia","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Farmitalia"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Gynial","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Gynial","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Gynial"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Zentiva"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Bayer AG \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Cervical mucus","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ Cirqle Biomedical"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Bayer AG"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"NICHD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ NICHD","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ NICHD"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Avomeen","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Partnership","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Avomeen","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Avomeen"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Funding","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Financing","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ XOMA"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ulipristal Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"HRA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HRA Pharma \/ Perrigo Company plc","highestDevelopmentStatusID":"15","companyTruncated":"HRA Pharma \/ Perrigo Company plc"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Emmecell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EO2002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emmecell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Emmecell \/ Inapplicable"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Trefoil Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"AGC Biologics \/ Trefoil Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Trefoil Therapeutics"},{"orgOrder":0,"company":"Kuria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KTX-1161","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kuria Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kuria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kuria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neltependocel","moa":"ROCK","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ActualEyes","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Rho-Associated Kinase-Human Corneal Endothelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ActualEyes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ActualEyes \/ Arctic Vision","highestDevelopmentStatusID":"4","companyTruncated":"ActualEyes \/ Arctic Vision"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Xequel Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Inapplicable"},{"orgOrder":0,"company":"University of Miami","sponsor":"Provectus Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"University of Miami \/ Provectus Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Provectus Biopharmaceuticals"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Terumo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Terumo","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Terumo"},{"orgOrder":0,"company":"CureGene Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Benzenesulfonic Acid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"CureGene Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CureGene Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CureGene Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"AcuteBio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ascendia Pharmaceuticals \/ AcuteBio","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ AcuteBio"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ascendia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Marizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glutathione","moa":"||Glutathione peroxidase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Marizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marizyme \/ Inapplicable"},{"orgOrder":0,"company":"Sinomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sinomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sinomed \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Cordis","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Cordis","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Cordis"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-1175","moa":"Na channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Nocion Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"SiteOne Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"BELLUS Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"adMare BioInnovations \/ BELLUS Health","highestDevelopmentStatusID":"8","companyTruncated":"adMare BioInnovations \/ BELLUS Health"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Jefferies"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Jefferies"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ GSK"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ GSK"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"Createrna Science and Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QR052107B","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Createrna Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Createrna Science and Technology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Createrna Science and Technology \/ Inapplicable"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Orvepitant Maleate","moa":"NK-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NeRRe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeRRe Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"NeRRe Therapeutics \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axalbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Inapplicable"},{"orgOrder":0,"company":"Axalbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Foundation Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Brompheniramine Maleate","moa":"||H1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Foundation Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Foundation Consumer Healthcare"},{"orgOrder":0,"company":"University College London","sponsor":"Cure Parkinson\u2019S Trust","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Ambroxol","moa":"NO dependent soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College London \/ Cure Parkinson\u2019S Trust","highestDevelopmentStatusID":"8","companyTruncated":"University College London \/ Cure Parkinson\u2019S Trust"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Promethazine Hydrochloride","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reckitt Benckiser \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reckitt Benckiser \/ Inapplicable"},{"orgOrder":0,"company":"Taiko Pharmaceutical","sponsor":"Kitasato University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlorine Dioxide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Taiko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Taiko Pharmaceutical \/ Kitasato University","highestDevelopmentStatusID":"1","companyTruncated":"Taiko Pharmaceutical \/ Kitasato University"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ISPM21","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Taiwan Liposome Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Sensory Cloud","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"PUR 003","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Pulmatrix \/ Sensory Cloud","highestDevelopmentStatusID":"1","companyTruncated":"Pulmatrix \/ Sensory Cloud"},{"orgOrder":0,"company":"Enterin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"COV-ENT-1","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Enterin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterin \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PiN-21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Arizona \/ Sunshine Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Arizona \/ Sunshine Biopharma"},{"orgOrder":0,"company":"MolGenie","sponsor":"OntoChem","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MolGenie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"MolGenie \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"MolGenie \/ OntoChem"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Secarna Pharma \/ Sun Yat-sen University","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Abcore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Abcore","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Abcore \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Abcore \/ Inapplicable"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Applied Biology \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Inapplicable"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TMPRSS2","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Applied Biology \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Inapplicable"},{"orgOrder":0,"company":"Atomwise","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Atomwise \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Undisclosed"},{"orgOrder":0,"company":"Atreca","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Atreca \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ BeiGene"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Proteona","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Proteona","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Proteona"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Sosei Group Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Quantitative Biosciences Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Quantitative Biosciences Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Quantitative Biosciences Institute \/ National Institutes of Health","highestDevelopmentStatusID":"3","companyTruncated":"Quantitative Biosciences Institute \/ National Institutes of Health"},{"orgOrder":0,"company":"Personalized Stem Cells","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Personalized Stem Cells","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Personalized Stem Cells \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Personalized Stem Cells \/ Inapplicable"},{"orgOrder":0,"company":"Circularity Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Circularity Healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Circularity Healthcare \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Circularity Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Amyris","sponsor":"Infectious Disease Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Amyris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Amyris \/ Infectious Disease Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amyris \/ Infectious Disease Research Institute"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ OntoChem"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NSP-15","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ OntoChem"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ OntoChem"},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Ablexis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Berkeley Lights","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Berkeley Lights \/ Ablexis","highestDevelopmentStatusID":"4","companyTruncated":"Berkeley Lights \/ Ablexis"},{"orgOrder":0,"company":"Centivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Centivax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Centivax \/ Inapplicable"},{"orgOrder":0,"company":"Distributed Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Distributed Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Distributed Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Distributed Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CR Double-Crane Pharmaceuticals Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ligand Pharmaceuticals \/ CR Double-Crane Pharmaceuticals Co., Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Ligand Pharmaceuticals \/ CR Double-Crane Pharmaceuticals Co., Ltd"},{"orgOrder":0,"company":"Vascular BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vascular BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vascular BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vascular BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"BioDuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioDuro","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BioDuro \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BioDuro \/ Inapplicable"},{"orgOrder":0,"company":"Mercaptor Discoveries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"COX-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mercaptor Discoveries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mercaptor Discoveries \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mercaptor Discoveries \/ Inapplicable"},{"orgOrder":0,"company":"ThermoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ThermoGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ThermoGenesis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ThermoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"2","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Xencor","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Xencor \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Xencor \/ Vir Biotechnology"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NV-HHV-101","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Kimera Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kimera Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kimera Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kimera Labs \/ Inapplicable"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"University of Georgia","sponsor":"CEL-SCI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Georgia \/ CEL-SCI","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ CEL-SCI"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbbVie Inc \/ Scripps Research","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ Scripps Research"},{"orgOrder":0,"company":"NorthShore University","sponsor":"Johns Hopkins","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NorthShore University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NorthShore University \/ Johns Hopkins","highestDevelopmentStatusID":"8","companyTruncated":"NorthShore University \/ Johns Hopkins"},{"orgOrder":0,"company":"University of Illinois","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Illinois","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Illinois \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Illinois \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Viravaxx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Vienna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Medical University of Vienna \/ Viravaxx","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Vienna \/ Viravaxx"},{"orgOrder":0,"company":"VIB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"VIB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"VIB \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"International Centre for Genetic Engineering and Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Government of Canada","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Government of Canada"},{"orgOrder":0,"company":"Mannin Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mannin Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mannin Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mannin Research \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Medicago \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicago \/ Inapplicable"},{"orgOrder":0,"company":"Rapid Dose Therapeutics","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rapid Dose Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Rapid Dose Therapeutics \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Rapid Dose Therapeutics \/ McMaster University"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Virna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Toronto \/ Virna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of Toronto \/ Virna Therapeutics"},{"orgOrder":0,"company":"Academia Sinica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Academia Sinica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Academia Sinica \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Academia Sinica \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shanghai Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Shanghai Institute \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Shanghai Institute \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"CMAB Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Innovent Biologics \/ CMAB Biopharma Inc","highestDevelopmentStatusID":"5","companyTruncated":"Innovent Biologics \/ CMAB Biopharma Inc"},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Hong Kong \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"University of Hong Kong \/ CEPI"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab Oncology \/ Institut Pasteur Shanghai"},{"orgOrder":0,"company":"East China Normal University","sponsor":"ImmuneCyte Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"East China Normal University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"East China Normal University \/ ImmuneCyte Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"East China Normal University \/ ImmuneCyte Life Sciences"},{"orgOrder":0,"company":"Institute of Microbiology of the Chinese Academy of Sciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Microbiology of the Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Sino Biological","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sino Biological","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sino Biological \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"Sino Biological \/ GeoVax Labs"},{"orgOrder":0,"company":"Tianjin University","sponsor":"Beroni Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Tianjin University \/ Beroni Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin University \/ Beroni Group"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"WuXi Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Inapplicable"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"WuXi Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Vir Biotechnology"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Nuritas","sponsor":"Advanced Computing In Europe","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nuritas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nuritas \/ Advanced Computing In Europe","highestDevelopmentStatusID":"2","companyTruncated":"Nuritas \/ Advanced Computing In Europe"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Israeli Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Israeli Health Authorities","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Israeli Health Authorities"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans Medical \/ Mediforum Pharm"},{"orgOrder":0,"company":"IRBM","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IRBM","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IRBM \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Merck & Co"},{"orgOrder":0,"company":"Epsilon Molecular Engineering","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Epsilon Molecular Engineering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Epsilon Molecular Engineering \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"2","companyTruncated":"Epsilon Molecular Engineering \/ Mitsubishi UFJ Capital"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Fujitsu","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"PeptiDream \/ Fujitsu","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Fujitsu"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"The National Institutes of Biomedical Innovation, Health and Nutrition","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The National Institutes of Biomedical Innovation, Health and Nutrition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"The National Institutes of Biomedical Innovation, Health and Nutrition \/ Shionogi","highestDevelopmentStatusID":"4","companyTruncated":"The National Institutes of Biomedical Innovation, Health and Nutrition \/ Shionogi"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Chugai Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Large Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Luxna Biotech \/ Aligos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Aligos Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Utrecht University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Utrecht University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Utrecht University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Utrecht University \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Syntekabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Green Cross Lab Cell \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Green Cross Lab Cell \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ BARDA"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Oblique Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Oblique Therapeutics \/ Vinnova","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Therapeutics \/ Vinnova"},{"orgOrder":0,"company":"SciLifeLab","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SciLifeLab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SciLifeLab \/ Medivir","highestDevelopmentStatusID":"2","companyTruncated":"SciLifeLab \/ Medivir"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Exscientia \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ FairJourney Biologics"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SpyBiotech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SpyBiotech \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Touchlight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Touchlight \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Touchlight \/ Inapplicable"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Relation Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Relation Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Relation Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Storm Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Storm Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Academia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AstraZeneca \/ Academia","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ Academia"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elasmogen","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elasmogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Elasmogen \/ University of Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"Elasmogen \/ University of Minnesota"},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ FairJourney Biologics"},{"orgOrder":0,"company":"Ossianix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Transferrin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ossianix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen \/ Thairm Bio"},{"orgOrder":0,"company":"Rosalind Franklin Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rosalind Franklin Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Rosalind Franklin Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rosalind Franklin Institute \/ Inapplicable"},{"orgOrder":0,"company":"Diamond Light Source","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Diamond Light Source","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Diamond Light Source \/ Exscientia","highestDevelopmentStatusID":"1","companyTruncated":"Diamond Light Source \/ Exscientia"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ FairJourney Biologics"},{"orgOrder":0,"company":"RQ Biotechnology Ltd","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"RQ Biotechnology Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"RQ Biotechnology Ltd \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"RQ Biotechnology Ltd \/ AstraZeneca"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Birmingham \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Birmingham \/ Inapplicable"},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vabiotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vabiotech \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Vabiotech \/ Vingroup Innovation Foundation"},{"orgOrder":0,"company":"Kansas State University","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kansas State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kansas State University \/ Cocrystal Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kansas State University \/ Cocrystal Pharma"},{"orgOrder":0,"company":"IgNova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IgNova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IgNova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IgNova \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Codagenix"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BIOQUAL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BIOQUAL \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BIOQUAL \/ Inapplicable"},{"orgOrder":0,"company":"HHMI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha-receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HHMI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"HHMI \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HHMI \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Matrix-M","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Novavax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Novavax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Vir Biotechnology"},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Clear Creek Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Clear Creek Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Clear Creek Bio \/ Pfizer Inc"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nona Biosciences \/ Mount Sinai Health System","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Mount Sinai Health System"},{"orgOrder":0,"company":"PostEra","sponsor":"Breyer Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PostEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"PostEra \/ Breyer Capital","highestDevelopmentStatusID":"3","companyTruncated":"PostEra \/ Breyer Capital"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Repertoire Immune Medicines \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Repertoire Immune Medicines \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Poseida Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Poseida Therapeutics, Inc","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Poseida Therapeutics, Inc"},{"orgOrder":0,"company":"UMass Medical School","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"UMass Medical School","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"UMass Medical School \/ Johns Hopkins University","highestDevelopmentStatusID":"8","companyTruncated":"UMass Medical School \/ Johns Hopkins University"},{"orgOrder":0,"company":"Aerium Therapeutics","sponsor":"Lausanne University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aerium Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Aerium Therapeutics \/ Lausanne University Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Aerium Therapeutics \/ Lausanne University Hospital"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Coronavirus Immunotherapy Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium","highestDevelopmentStatusID":"4","companyTruncated":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Alnylam Pharmaceuticals \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Alnylam Pharmaceuticals \/ Vir Biotechnology"},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Vir Biotechnology"},{"orgOrder":0,"company":"Continuus Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Continuus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Continuus Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Continuus Pharmaceuticals \/ Department of Defense"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Generation Bio \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Generation Bio \/ Vir Biotechnology"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nona Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mayo Clinic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Inapplicable"},{"orgOrder":0,"company":"Lattice Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lattice Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Lattice Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lattice Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Indian Council of Medical Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indian Council of Medical Research \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hackensack Meridian CDI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Hackensack Meridian CDI \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Hackensack Meridian CDI \/ Merck & Co"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Tevogen Bio \/ Thomas Jefferson University","highestDevelopmentStatusID":"5","companyTruncated":"Tevogen Bio \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Beroni Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Beroni Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Group \/ Inapplicable"},{"orgOrder":0,"company":"Beroni Group","sponsor":"Tianjin University In China","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Beroni Group \/ Tianjin University In China","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Group \/ Tianjin University In China"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"Beroni Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"GenScript Biotech Corporation \/ Beroni Group","highestDevelopmentStatusID":"4","companyTruncated":"GenScript Biotech Corporation \/ Beroni Group"},{"orgOrder":0,"company":"Kedrion","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kedrion \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Kedrion \/ Columbia University"},{"orgOrder":0,"company":"Celularity","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celularity \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Celularity \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ENaC","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Chromocell Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chromocell Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Dante Labs","sponsor":"The Renato Dulbecco Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dante Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Dante Labs \/ The Renato Dulbecco Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Dante Labs \/ The Renato Dulbecco Foundation"},{"orgOrder":0,"company":"IAVI","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IAVI \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"IAVI \/ Merck Group"},{"orgOrder":0,"company":"Metropolitan AntiViral Drug Accelerator","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Metropolitan AntiViral Drug Accelerator","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Metropolitan AntiViral Drug Accelerator \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Metropolitan AntiViral Drug Accelerator \/ National Institutes of Health"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Q BioMed \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Q BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Columbia University \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Regeneron Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Columbia University \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Inapplicable"},{"orgOrder":0,"company":"Curia","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Curia \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"A2A Pharmaceuticals","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"A2A Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"A2A Pharmaceuticals \/ LAXAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"A2A Pharmaceuticals \/ LAXAI Life Sciences"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"State of North Dakota","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ImmunoPrecise \/ State of North Dakota","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ State of North Dakota"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Evonik","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Evonik \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Evonik \/ BARDA"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"University Hospital Institute","sponsor":"Pharnext","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University Hospital Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University Hospital Institute \/ Pharnext","highestDevelopmentStatusID":"4","companyTruncated":"University Hospital Institute \/ Pharnext"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Proteros","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Arbutus Biopharma \/ Proteros","highestDevelopmentStatusID":"2","companyTruncated":"Arbutus Biopharma \/ Proteros"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Defense Advanced Research Projects Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Inovio Pharmaceuticals \/ Defense Advanced Research Projects Agency","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Defense Advanced Research Projects Agency"},{"orgOrder":0,"company":"OntoChem","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OntoChem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"OntoChem \/ Anixa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"OntoChem \/ Anixa Biosciences"},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vopec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vopec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vopec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IDBiologics","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IDBiologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IDBiologics \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"2","companyTruncated":"IDBiologics \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"XBiotech","sponsor":"Biobridge Global","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"XBiotech \/ Biobridge Global","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Biobridge Global"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TFF Pharmaceuticals \/ Aptar Pharma","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Aptar Pharma"},{"orgOrder":0,"company":"iBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"iBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Inapplicable"},{"orgOrder":0,"company":"Macromoltek","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macromoltek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Macromoltek \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Macromoltek \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Southwest Research Institute","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southwest Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Southwest Research Institute \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Southwest Research Institute \/ Henry M. Jackson Foundation"},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vyripharm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vyripharm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PEEL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"PEEL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PEEL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Melbourne\u2019s Walter and Eliza Hall Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Melbourne\u2019s Walter and Eliza Hall Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Melbourne\u2019s Walter and Eliza Hall Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Melbourne\u2019s Walter and Eliza Hall Institute \/ Inapplicable"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Virginia Commonwealth University \/ Hoth Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Virginia Commonwealth University \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Adaptive Biotechnologies \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"Adaptive Biotechnologies \/ Amgen Inc"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kaiser Permanente Washington Health Research \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Kaiser Permanente Washington Health Research \/ Civica Rx"},{"orgOrder":0,"company":"Undisclosed","sponsor":"AIkido Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Undisclosed \/ AIkido Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ AIkido Pharm"},{"orgOrder":0,"company":"Verndari","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VaxiPatch COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dermal Patch","sponsorNew":"Verndari \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/ Inapplicable"},{"orgOrder":0,"company":"NuvOx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CAS 7632-00-0","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NuvOx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"NuvOx Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NuvOx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Baylx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BX-U001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ Inapplicable"},{"orgOrder":0,"company":"Amniotics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PulmoStem","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Amniotics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amniotics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amniotics \/ Inapplicable"},{"orgOrder":0,"company":"Amyris","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"hAd5 S+N","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Amyris","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amyris \/ ImmunityBio","highestDevelopmentStatusID":"7","companyTruncated":"Amyris \/ ImmunityBio"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Nant Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"hAd5 S+N","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunityBio \/ Nant Capital","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Nant Capital"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CM4620-IE","moa":"CRAC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"||CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DNA-Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaJet \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Inactivated Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Translate Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MRT5500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MRT5500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MUC1-SP-L","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxil Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PLX Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reparixin","moa":"IL-8 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Linear DNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takis Biotech \/ Applied DNA Sciences Inc","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Applied DNA Sciences Inc"},{"orgOrder":0,"company":"KM Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"KD-414","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KM Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"KM Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KM Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Tychan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Inapplicable"},{"orgOrder":0,"company":"Tychan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Virus Suppressing Factor","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuneMed, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneMed, Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneMed, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Messenger RNA Based COVID Vaccine","moa":"Undisclosed","graph1":"In